Identification and functional characterisation of novel APC/C interacting proteins by Sedgwick, Garry Gray
IDENTIFICATION AND FUNCTIONAL 
CHARACTERISATION 
OF NOVEL APC/C INTERACTING PROTEINS 
 
 
GARRY GRAY SEDGWICK 
 
 
A thesis submitted to the 
University of Birmingham 
for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
School of Cancer Sciences  
CRUK Institute for Cancer Studies  
The Medical School 
University of Birmingham 
 
April 2009 
 
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
 
        ABSTRACT  
 
The anaphase promoting complex /cyclosome  (APC/C) is a multi-protein E3 ubiquitin 
ligase complex that regulates cellular proliferation through its ability to target essential 
cell cycle regulators such as cyclin A, cyclin B, securin and S-phase kinase-associated 
protein 2 (SKP2) for proteasomal-dependent degradation. APC/C substrates and 
coactivators are aberrantly expressed in many cancers. It is thought that the APC/C can 
also regulate cellular proliferation by controlling p21 and cell division cycle 6 
homologue (CDC6)  transcription. It is therefore of great interest to study other cellular 
proteins that interact with the APC/C as these proteins may also be important in cell 
cycle regulation and hence may enhance our understanding of the molecular basis of 
cancer. Therefore, the aim of my study was to identify novel APC/C interacting proteins 
through mass spectrometric analysis of APC/C subunit 7 (APC7) immunoprecipitates 
and go on to examine the functional significance of these interactions. 
I identified six novel APC7 interacting proteins, and decided to focus on two of these 
interactions. Initially I examined the interaction between APC7 and transcriptional 
intermediary factor 1γ (TIF1γ), a transcriptional repressor previously reported to be 
aberrantly expressed in cancer. Data presented in this study demonstrate that the APC/C 
and TIF1γ cooperate to regulate mitotic progression. Notably TIF1γ displays in vivo 
interactions with APC/C subunits 1-8, the APC/C‟s mitotic coactivator CDC20 and 
mitotic substrate cyclin A. Moreover, TIF1γ depletion by RNAi arrests cells in a 
metaphase-like state characterised by elevated levels of APC/C substrates, cyclin A, 
cyclin B and CDC20. In support of a role for TIF1γ in regulating mitotic progression by 
directly targeting the APC/C, cells treated with TIF1γ-specific siRNA exhibit reduced 
APC/C E3 ubiquitin ligase activity. This work defines TIF1γ as a novel mitotic 
regulatory protein essential for APC/C function and suggests that loss of TIF1γ may 
compromise genomic integrity by allowing the mis-segregation of chromosomes. 
I also investigated the functional relationship between APC7 and the nuclear factor 
90/45 heterodimer (NF90/NF45), given that all of these proteins function as 
transcription factors. Results obtained demonstrate that APC5 and APC7 bind directly 
to NF90 in vitro and also form complexes with NF90 in vivo. It appears that APC/C 
interaction with NF90 is important in the regulation of interleukin-2 (IL-2) and tumour 
neucrosis factor (TNF) transcription, as exogenous APC5 and APC7 cooperate with 
NF90/NF45 to transactivate IL-2 and TNF promoter constructs. Lastly endogenous 
APC5 and APC7 bind to the IL-2 promoter in vivo while endogenous APC5 represses 
TNF transcription in vivo. Given that TNF and IL-2 stimulate cellular proliferation data 
presented here suggests that the APC/C might control cellular proliferation by 
regulating TNF and IL-2 transcription. 
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RB     retinoblastoma  
RBCC     RING finger, B-boxes, and a coiled-coil domain  
RET     rearranged during transfection  
RID     nuclear receptor interaction domain  
RING     really interesting new gene  
Rnasein    RNAse inhibitor  
RNA     ribonucleic acid  
RNAi     RNA interference  
RPMI-1640   Roswell Park Memorial Institute 1640 medium 
RSV     Rous sarcoma virus  
RT     room temperature  
RTS     Rubinstein Taybi syndrome  
RXR     retinoid X receptor  
SAC     spindle assembly checkpoint  
SCC1    sister chromatid cohesion 1  
SCF     skp cullin F-box  
SDS     sodium dodecyl sulfate 
SDS-PAGE    dodecyl sulphate-polyacrylamide gel electrophoresis 
SDW     sterile distilled water  
SKP    S phase kinase-associated protein  
SMAD    similar to Mothers against decapentaplegic homolog     
SNON    ski-related novel protein N 
SP-10    S-locus protein 10 
SRY-box2   sex determining region Y-box 2 
SUMO    small ubiquitin like modifier 
SWI/SNF    switch/sucrose nonfermentable  
TAP     transporter associated with antigen processing  
TBE     Tris, Boric acid and EDTA 
TBP     TATA-binding protein  
TBS     tris-buffered saline  
TBST     tris-buffered saline with Tween 20 
TCA     trichloroacetic acid  
TCR     T-cell receptor  
TE     tris EDTA 
TEMED    (N, N, N‟, N‟-tetramethyl-ethylenediamine) 
TGF-β    transforming growth factor-β  
TLS     translocated in liposarcoma  
TNF    tumour neucrosis factor  
TNFR    TNF receptor 
TPR     tetratrico peptide repeat  
TRIM    tripartite motif  
tRNA     transfer RNA 
TSS     TIF1 signature sequence  
UBC     ubiquitin-conjugating enzyme 
USP44    ubiquitin-specific protease 44  
VDR     vitamin D3 receptor  
WB    Western blotting 
XKID     Xenopus chromokinesin kid 
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1.1. Cancer  
Cancer is a disease that arises as a result of damage to the pathways that regulate 
cellular proliferation and death. Damage to these pathways is caused by genetic lesions 
that facilitate a gain in function of oncogenes and inactivation of tumour suppressors. 
There is a large amount of evidence to indicate that tumourigenesis is a multi-step 
process, requiring an accumulation of multiple mutations in order for a healthy cell to 
progress in to a malignant tumour (Vogelstein and Kinzler 1993; Hartwell and Kastan 
1994; Hahn and Weinberg 2002). Despite the fact that there are more than 100 distinct 
types of cancer, and a vast array of cancer cell genotypes, all human cancers display 
common phenotypes of self sufficiency in growth signalling, insensitivity to anti-growth 
signalling, the ability to evade apoptosis, the unlimited ability to replicate, and enhanced 
angiogenesis and metastasis (Hanahan and Weinberg 2000; Hahn and Weinberg 2002; 
Hahn and Weinberg 2002). 
 
1.1.1. Oncogenes  
Oncogenes are mutated derivatives of proto-oncogenes, which are involved in 
regulating proliferation, differentiation and apoptosis in normal cells. Oncogene 
activation occurs as a result of point mutations, chromosomal translocations and 
amplification of proto-oncogenes. Mutation of just one proto-oncogene allele produces 
a dominant gain in function, which contributes to uncontrolled cellular proliferation and 
tumour development (Land, Parada et al. 1983; Konopka, Watanabe et al. 1985; Bishop 
1987). Identification of the first oncogene began with work by Rous almost a century 
ago, which demonstrated that cancer could be triggered as a result of viral infection 
(Rous 1983). Subsequent study led to the identification of the transforming gene v-src 
from the Rous sarcoma virus (RSV) as the causative agent (Hanafusa, Halpern et al. 
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1977; Fung, Crittenden et al. 1983; Brickell 1992). v-src is generated as a result of viral 
recombination with the cellular (c)-src (Robinson 1982; Wyke 1983; Yaciuk and 
Shalloway 1986). c-src functions as a non receptor tyrosine kinase and transduces 
signals from plasma membrane receptors to the ras mitogen-activated protein kinase 
(MAPK) pathway in order to elicit cellular proliferation (Courtneidge 1994). Further 
studies have identified c-src as a bona fide oncogene, as increases in levels of its 
expression and kinase activity of its protein product have been observed in human 
cancers (Jacobs and Rubsamen 1983; Cartwright, Kamps et al. 1989; Budde, Ke et al. 
1994; Muthuswamy, Siegel et al. 1994; Mao, Irby et al. 1997) 
 
1.1.1.1. Ras
 
The ras
 
proto-oncogene
 
 was the first example of a naturally occurring mutation in a 
human cancer, and has since been shown to be mutated in 25% of all human tumours 
(Hanahan and Weinberg 2000). The ras protein family consists of Harvey [Ha]-ras, 
Kirsten [K]-ras and Neuroblastoma [N]-ras, all of which share a common intrinsic 
guanosine triphosphatase (GTPase) activity, allowing them to modulate cellular 
signalling cascades that stimulate cellular proliferation. Ras achieves this through 
various means such as activation of the raf pathway, which permits cells to enter G1, 
inactivating retinoblastoma (RB) in order to enable progression into S phase, and 
triggering the phosphoinositide 3-kinase (PI3-K) pathway to inhibit apoptosis(Coleman, 
Marshall et al. 2004). Mutations in ras that render the GTPase activity of ras 
constitutively active have been identified in lung (Hilbe, Dirnhofer et al. 2004; Huber 
and Stratakis 2004), colon (Westra, Plukker et al. 2004), breast and pancreatic cancers 
(D'Cruz, Gunther et al. 2001; Xiong 2004). 
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1.1.2. Tumour suppressors  
Tumour suppressors are proteins that generally act to repress cellular proliferation 
and/or enhance apoptosis, and are activated in response to cellular stresses such as DNA 
damage (Nelson and Kastan 1994), activation of oncogenes and hypoxia (Lowe and 
Ruley 1993; Graeber, Osmanian et al. 1996). Unlike oncogenes that are activated during 
tumourigenesis, tumour suppressors must be inactivated in order for cancer to develop. 
Using the prototypical tumour suppressor RB as a model, Knudson developed his „two 
hit hypothesis‟, which states that loss of both alleles must occur in order for inactivation 
of tumour suppressors to occur (Knudson 1971).  
 
1.1.2.1. p53 
p53 is a particularly significant example of a tumour suppressor as it is mutated in more 
than 50% of all human cancers (Soussi and Beroud 2001). These mutations 
predominantly affect p53‟s sequence specific DNA binding domain (Hainaut and 
Hollstein 2000), and therefore prevent p53 from activating transcription of genes 
required for G1 and G2 cell arrest, apoptosis and differentiation (Kastan, Zhan et al. 
1992; Agarwal, Agarwal et al. 1995; Aloni-Grinstein, Schwartz et al. 1995; Paules, 
Levedakou et al. 1995). Although many of the mutations that occur in p53 adhere to the 
Knudson „two hit hypothesis‟, it is unusual amongst tumour suppressors in that some 
p53 mutations produce a dominant negative effect, therefore mutation of just one p53 
allele can lead to inactivation of all cellular p53 and hence contribute to tumourigenesis. 
This is attributed to the fact that p53 is active only as a tetramer, therefore a mutation in 
just one p53 subunit is sufficient to affect activity of the entire p53 tetramer (Shaulian, 
Zauberman et al. 1992; Shaulian, Zauberman et al. 1993) (Halazonetis and Kandil 1993; 
Unger, Mietz et al. 1993). 
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1.1.2.2. CBP/p300 
The cyclic adenosine monophosphate (cAMP) response element (CRE) is found in the 
regulatory regions of many genes. Following production of cAMP the CRE is bound by 
the CRE binding protein (CREB), which then recruits the CREB binding protein (CBP), 
facilitating transcriptional activation (Chrivia, Kwok et al. 1993). CBP shares a number 
of functional domains with p300, which allow these proteins to function as 
transcriptional coactivators. Notably, CBP and p300 contain an acetyltransferase 
domain that allows these proteins to acetylate histone tails in order to produce a relaxed 
DNA conformation suitable for transcription. CBP and p300 are required for 
transcriptional activation of genes that stimulate cellular growth, proliferation, 
differentiation and apoptosis. (Goodman and Smolik 2000; Iyer, Ozdag et al. 2004). For 
instance, CBP/p300 can cooperate with p53 to activate transcription of the murine 
double minute 2 (MDM2), p21
CIP1
 and BCL2 –associated X (BAX) promoters in order 
to induce cell cycle arrest and apoptosis (Avantaggiati, Ogryzko et al. 1997; Gu, Shi et 
al. 1997; Lill, Grossman et al. 1997). Interestingly CBP/p300 can also regulate the DNA 
binding ability of p53 by directly acetylating p53 (Gu and Roeder 1997; Sakaguchi, 
Herrera et al. 1998; Dornan, Shimizu et al. 2003). 
There is mounting evidence to support a role for p300 and CBP as tumour suppressors, 
which is consistent with their ability to regulate transcription of genes involved in 
cellular growth, proliferation, differentiation and apoptosis. For instance chromosomal 
translocation of p300 and CBP is evident in cancer (Borrow, Stanton et al. 1996) (Giles, 
Dauwerse et al. 1997; Chaffanet, Gressin et al. 2000; Kitabayashi, Aikawa et al. 2001; 
Panagopoulos, Fioretos et al. 2001). Moreover CBP monoallelic inactivation is the 
genetic basis for Rubinstein Taybi syndrome (RTS), a disease characterised by 
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pleiotropic developmental abnormalities and an increased incidence of malignancies 
(Miller and Rubinstein 1995; Petrij, Giles et al. 1995).  
 
1.2. Gene expression  
Despite containing an identical genome, each individual cell within any multicellular 
organism can achieve specialisation by modulating the expression of a subset of its 
genes. Eukaryotic gene expression is a multistage process that begins with transcription 
of messenger ribonucleic acid (mRNA) and includes pre-mRNA processing, mRNA 
export, and culminates in the translation of mRNA into a functional protein product. 
 
1.2.1. RNA polymerase II dependent transcription 
Transcription is modulated by specific binding of transcriptional activators and 
repressors to their cognate DNA binding sequences within cellular gene promoters 
(Banerji, Rusconi et al. 1981; de Villiers and Schaffner 1981; Jones and Tjian 1985; 
Hiller, Hengstler et al. 1988). Transcriptional activators recruit coactivator proteins that 
include histone acetyl transferases (HATs) such as CBP/p300, and nucleosome 
remodelling complexes such as switch/sucrose nonfermentable (SWI/SNF). These 
coactivator proteins alter chromatin structure in order to allow access to RNA 
polymerase II and subsequent mRNA synthesis (Brown, Lechner et al. 2000; Gibbons 
2005). In contrast, access to DNA by RNA polymerase II can be prevented by binding 
of transcriptional repressors to cellular gene promoters. Transcriptional repressors 
generally function by recruiting corepressors such as histone deacetylases and DNA 
methylases in order to promote a closed DNA conformation that is therefore 
inaccessible to RNA polymerase II (Stallcup 2001; Hellebrekers, Griffioen et al. 2007). 
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RNA polymerase II is unable to recognise its target promoters directly, and therefore 
must associate with the general transcription factors (GTFs) TFIIB, D, E, F and H in 
order to form a preinitiation complex, and associate with the core promoter elements: 
the TATA box and the initiator sequence (Inr) (Weis and Reinberg 1992). The multi-
component factor TFIID binds directly to the TATA box via its TATA-binding protein 
(TBP) and also binds to TFIIB, which recruits RNA polymerase II to the promoter 
(Matsui, Segall et al. 1980; Li, Flanagan et al. 1994; Leuther, Bushnell et al. 1996; 
Cosma, Panizza et al. 2001). The intrinsic helicase activity of the multi subunit TFIIH 
unwinds DNA, while its kinase activity that is conferred by cyclin-dependent kinase 7 
(CDK7) initiates transcription by phosphorylating RNA polymerase II (Lu, Zawel et al. 
1992; Tirode, Busso et al. 1999; Seroz, Perez et al. 2000). An additional multi-
component protein factor known as mediator, is essential for RNA polymerase II 
dependent transcription in vivo, and bridges the interaction between transcriptional 
activators and the preinitiation complex (Flanagan, Kelleher et al. 1991; Thompson, 
Koleske et al. 1993; Kim, Bjorklund et al. 1994; Myers, Gustafsson et al. 1998). 
 
1.3. Transition through the cell cycle occurs in a cyclin-CDK 
dependent manner   
Cyclins are a group of proteins that regulate the orderly progression of cells through the 
cell cycle in conjunction with CDKs and are named on the basis of the cyclical periodic 
nature of their expression (see Fig 1.1 for a summary of cyclin-CDK activity throughout 
the cell cycle). They all share a common cyclin box that mediates their ability to bind, 
activate, and hence direct CDK activity (Minshull, Pines et al. 1989; Pines and Hunter 
1989; Kobayashi, Stewart et al. 1992; Lees and Harlow 1993). Activation of CDKs also 
requires their phosphorylation by the CDK activating kinase (CAK), which comprises  
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CDK7 and cyclin H (Solomon, Lee et al. 1992; Poon, Yamashita et al. 1993; Fisher and 
Morgan 1994; Matsuoka, Kato et al. 1994), and the removal of an inhibitory 
phosphorylation by CDC25 (cell division cycle) phosphatases. The activation of cyclin-
CDK complexes is regulated by CDC25A during the G1-S and G2-M transitions, 
whereas CDC25B and CDC25C function during the G2-M transition (Sadhu, Reed et al. 
1990; Millar, Blevitt et al. 1991; Honda, Ohba et al. 1993; Dunphy 1994; Strausfeld, 
Fernandez et al. 1994; Lammer, Wagerer et al. 1998; Donzelli, Squatrito et al. 2002; 
Mailand, Podtelejnikov et al. 2002). 
 
1.3.1. Cyclin D 
Entry into the cell cycle is stimulated by activation of proto-oncogenes such as ras and 
myc, which essentially enhance the formation of cyclin D-CDK4 and cyclin D-CDK6 
complexes (Matsushime, Ewen et al. 1992; Meyerson and Harlow 1994; Albanese, 
Johnson et al. 1995; Yu, Ciemerych et al. 2005). The activity of cyclin D-CDK4 or 
CDK6 complexes can be inhibited by members of the INK4 protein family of CDK 
inhibitors, which comprises p15
INK4B
, p16
INK4A
, p18
INK4C
 and p19
INK4D
 (Sherr 1996; 
Pavletich 1999). Cyclin D-CDK4/6 complexes predominantly function through 
phosphorylation of RB family proteins, thereby relieving repression of E2F responsive 
genes required for cell cycle progression, which notably includes cyclin E (Ohtani, 
DeGregori et al. 1995; Geng, Eaton et al. 1996; Harbour and Dean 2000; Classon and 
Harlow 2002). In addition to enhancing transcription of cyclin E, cyclin D-CDK4/6 
complexes further enhance the activity of cyclin E-CDK2 complexes by binding to and 
thus titrating out the CDK2 inhibitors p27
KIP1
 and p21
CIP1
 (Dulic, Lees et al. 1992; Koff, 
Giordano et al. 1992; el-Deiry, Tokino et al. 1993; Gu, Turck et al. 1993; Xiong, 
Hannon et al. 1993; Sherr and Roberts 1995). Significantly, binding of p16
INK4A
 to 
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cyclinD-CDK4/6 complexes has been demonstrated to induce dissociation of the CDK 
inhibitors p27
KIP1
 and p21
CIP1
, thereby enhancing G1 arrest by inhibiting the kinase 
activity of CDK2 (Jiang, Chou et al. 1998; McConnell, Gregory et al. 1999).  
 
1.3.2. Cyclin E 
Increasing levels of cyclin E during G1 result in formation of cyclin E-CDK2 
complexes that are required to negotiate the restriction point in G1, after which the cell 
is committed to proliferation (Ohtsubo and Roberts 1993; Ohtsubo, Theodoras et al. 
1995). It is thought that cyclin E-CDK2 stimulates G1 progression through activation of 
E2F dependent transcription by further enhancing RB family phosphorylation 
(Lundberg and Weinberg 1998; Harbour, Luo et al. 1999) and by directly 
phosphorylating E2F(Morris, Allen et al. 2000). Significantly, cyclin E-CDK2 is 
thought to mediate transcription of E2F responsive genes required for DNA synthesis, 
such as thymidine kinase (Chang, Huang et al. 1995), b-myb and cyclin A (DeGregori, 
Kowalik et al. 1995; Ohtani 1999). In addition, cyclin E-CDK2 organises the assembly 
of replication complexes containing CDC6 (Furstenthal, Kaiser et al. 2001; Coverley, 
Laman et al. 2002). Lastly cyclin E-CDK2 also initiates replication of centrosomes 
(Hinchcliffe, Li et al. 1999; Lacey, Jackson et al. 1999; Matsumoto, Hayashi et al. 
1999), which are required during mitosis in order to anchor bi-polar mitotic spindles 
and facilitate correct chromosomal segregation. Defects in chromosomal segregation 
can result in a change in the number of chromosomes in daughter cells, which is known 
as aneuploidy. Interestingly aneuploidy occurs in many solid tumours and can 
contribute to tumourigenesis as it can cause daughter cells to receive extra copies of 
oncogenes or lose tumour suppressors (D'Assoro, Lingle et al. 2002; Fukasawa 2005).  
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1.3.3. Cyclin A 
Cyclin A is expressed at the onset of S phase and through its association with CDK2 
directly activates DNA synthesis (Girard, Strausfeld et al. 1991; Bashir, Horlein et al. 
2000). Cyclin A-CDK2 complexes down regulate E2F transcription during S phase 
through phosphorylation of E2F‟s transcription binding partner DP-1 (dimerisation 
partner 1) (Krek, Xu et al. 1995). Cyclin A also forms a complex with CDK1 in G2, 
which may facilitate entry in to mitosis (Pagano, Pepperkok et al. 1992), as formation of 
cyclin A-CDK1 complexes might be important for nuclear envelope breakdown, 
chromosomal condensation and to stimulate nuclear import of cyclin B (Gong, 
Pomerening et al. 2007). The activity of cyclin A-CDK complexes can be inhibited by 
p27
KIP1
 and p21
CIP1
 or ablated as a result of cyclin A destruction. Cyclin A destruction 
occurs during nuclear envelope breakdown (NEBD) in response to ubiquitylation of 
cyclin A by the anaphase promoting complex/cyclosome (APC/C) (Dawson, Roth et al. 
1995; Sigrist, Jacobs et al. 1995; Sudakin, Ganoth et al. 1995; Furuno, den Elzen et al. 
1999; den Elzen and Pines 2001) (Sherr and Roberts 1999). 
 
1.3.4. Cyclin B 
Cyclin B transcription/translation is activated during late S phase and the protein exerts 
its effects by binding exclusively to CDK1 in vivo (Pines and Hunter 1989; Riabowol, 
Draetta et al. 1989). During early G2, cyclin B-CDK1 activity is inhibited by wee1 and 
myt1 kinases (Parker and Piwnica-Worms 1992; Mueller, Coleman et al. 1995). 
Removal of an inhibitory phosphate group from CDK1 by CDC25 phosphatases results 
in cyclin B-CDK1 activation and aids mitotic entry (Lammer, Wagerer et al. 1998; 
Mailand, Podtelejnikov et al. 2002) (Millar, Blevitt et al. 1991; Strausfeld, Fernandez et 
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al. 1994). Significantly, cyclin B-CDK1 stimulates nuclear lamin breakdown, through 
phosphorylation of lamin subunits and induces the dissociation of caldesmon from actin 
microfilaments, thereby permitting cell rounding (Dessev, Iovcheva-Dessev et al. 1991; 
Yamashiro, Chern et al. 2001). Also, consistent with its recruitment to chromatin, 
kinetochores and centrosomes during mitosis (Bentley, Normand et al. 2007; Chen, 
Zhang et al. 2008), cyclin B-CDK1 regulates a number of factors known to be 
associated with these structures. For instance cyclin B-CDK1 inhibits RNA poll II and 
III transcription by phosphorylating TFIIB (Hartl, Gottesfeld et al. 1993; Gottesfeld, 
Wolf et al. 1994; Leresche, Wolf et al. 1996). Furthermore cyclin B-CDK1 initiates 
centrosomal segregation by phosphorylating EG5, which is a kinesin-related motor 
protein required for bipolar spindle formation (Blangy, Lane et al. 1995; Mayer, Kapoor 
et al. 1999). Lastly, cyclin B-CDK1 initiates mitotic exit through activation of the 
APC/C (an E3 ubiquitin ligase) (Kraft, Herzog et al. 2003), which targets cyclin B and 
the inhibitor of sister chromatid separation, securin, for destruction (Dawson, Roth et al. 
1995; Sigrist, Jacobs et al. 1995; Sudakin, Ganoth et al. 1995; Cohen-Fix, Peters et al. 
1996; Kim, Fong et al. 2007). 
 
1.4. The ubiquitin-proteasome system 
Eukaryotic cells possess two major systems for protein degradation. The first to be 
characterised was the lysosomal system, which is chiefly concerned with the 
degradation of membrane associated proteins and extracellular proteins taken up by 
endocytosis. The predominant form of nonlysosomal protein degradation is mediated by 
the ubiquitin-proteasome system, which is responsible for >80% of cellular protein  
degradation (Lee and Goldberg 1998; Glickman and Ciechanover 2002; Dalton 2004) 
(refer to Fig 1.2 for an overview of the ubiquitin-proteasome pathway).  
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Protein degradation by the ubiquitin-proteasome pathway requires a protein to be post-
translationally modified by the attachment of a polyubiquitin chain so that it can be 
recognised and degraded by the 26S proteasome. Protein ubiquitylation is mediated by 
an enzymatic cascade that consists of an E1 ubiquitin activating enzyme, an E2 
ubiquitin conjugating enzyme (UBC) and an E3 ubiquitin ligase. Initially, the E1 binds 
to ubiquitin, and activates its C-terminal glycine residue through the formation of a 
high-energy thiol ester intermediate (E1~S~ubiquitin). Secondly the activated ubiquitin 
is transferred to an E2 enzyme. Lastly transfer of the ubiquitin from the E2 to a specific 
substrate is mediated by an E3 enzyme (Ciechanover and Schwartz 1998; Burger and 
Seth 2004). Formation of a polyubiquitin chain is mediated through attachment of 
additional ubiquitin molecules to any one of seven lysines within the ligated ubiquitin 
and may be enhanced by the presence of an E4 ubiquitin-elongation enzyme (Pickart 
2001; Kuhlbrodt, Mouysset et al. 2005). Attachment of Lys(11)-, Lys(29)- and Lys(48)-
linked polyubiquitin causes a protein to be targeted for degradation, whereas lysine (6)- 
or lysine (63)-linked polyubiquitin can regulate functions other than protein 
degradation, such as modulating protein activity or sub-cellular localisation (Hochrainer 
and Lipp 2007). Removal of ubiquitin from protein substrates is controlled by 
deubiquitinating enzymes (DUBs), providing a further layer of complexity in the 
regulation of protein proteolysis. DUBs also function to maintain cellular levels of free 
ubiquitin and remove liberated ubiquitin from the 26S proteasome (Nijman, Luna-
Vargas et al. 2005) 
The proteolytic component of the 26S proteasome is known as the 20S proteasome and 
has a barrel-like structure made up of two outer α-rings comprising seven α-type 
subunits, and two inner β-rings made up of seven β-type subunits. The proteolytic 
activity of the 20S proteasome is conferred by its β1, β2 and β5 subunits, which display 
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intrinsic energy independent chymotrypsin-, trypsin- and caspase-like activity 
respectively. Untimely degradation of proteins is prevented by constriction of the outer 
α rings of the 20S proteasome, which is relieved after binding of the 19S regulatory 
particle (RP, also called proteasome activator 700 (PA700)) to one or both ends of the 
20S proteasome to form the 26S proteasome (Groll, Bajorek et al. 2000; Heinemeyer, 
Ramos et al. 2004; Rechsteiner and Hill 2005). The 19S RP facilitates protein 
degradation by recognising ubiquitylated proteins, cleaving ubiquitin from its substrate 
and unfolding proteins in preparation for their degradation by the 20S proteasome 
(DeMartino 2005). Given its role in controlling protein stability, and hence activity, it is 
unsurprising therefore that the 26S proteasome has been implicated in numerous cellular 
processes such as cell cycle control, signal transduction, transcription, and programmed 
cell death (Weissman 1997; Hershko and Ciechanover 1998; Glickman and 
Ciechanover 2002)  
Formation of the proteasome variant known as the immunoproteasome is induced by 
Interferon-γ (IFN-γ) treatment (Tanaka 2009). The predominant function of the 
immunoproteasome is to produce antigenic peptides for presentation by the major 
histocompatibility complex I (MHC I) pathway (Khan, van den Broek et al. 2001; Teoh 
and Davies 2004), although a large number of antigens presented by the MHCI pathway 
are produced by the 26S proteasome (Tanaka 2009). The immunoproteasome differs 
from the 26S proteasome in that its 20S proteasome component (20Si) is thought to be 
bound and activated by the proteasome activator 28 (PA28, also known as the 11S 
regulator) a heteroheptamer consisting of PA28α and PA28β subunits (Preckel, Fung-
Leung et al. 1999; Rechsteiner, Realini et al. 2000; Yawata, Murata et al. 2001; Rivett 
and Hearn 2004). Also, the β1, β2 and β5 of the 20S proteasome, which confer 
proteolytic activity are replaced in the 20Si with distinct subunits known as β1i (LMP2),  
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β2i (MECL1), and β5i (LMP7). This results in increased chymotrypsin- and trypsin-like 
activity, which favour the production of peptides with C-terminal hydrophobic and 
basic amino acids. The resulting peptides are more suited to interaction with the peptide 
binding pockets of MHCI pathway molecules (Murata, Yashiroda et al. 2009; Tanaka 
2009). Immunoproteasomes are particularly enriched at the endoplasmic reticulum and 
are thought to be located in close proximity to TAP (transporter associated with antigen 
processing) to aid delivery of antigens to MHC class I molecules, which are found in 
the lumen of the endoplasmic reticulum (ER) (Brooks, Murray et al. 2000). 
Interestingly, aberrant immunoproteasome activity has been implicated in a number of 
diseases, such as multiple myeloma (Altun, Galardy et al. 2005) and also in diseases 
that are characterised by abnormal immune responses including rheumatoid arthritis and 
inflammatory bowel disease (Egerer, Martinez-Gamboa et al. 2006; Visekruna, Joeris et 
al. 2006; Fitzpatrick, Small et al. 2007). It is hoped that development of specific 
immunoproteasome inhibitors might be effective for treatment of these conditions.  
 
1.5. The APC/C 
The APC/C is a multi-component E3 ubiquitin ligase that coordinates temporal 
progression through the cell cycle, as a result of its ability to target cell cycle regulatory 
proteins for degradation. The APC/C regulates proteolysis by catalysing the formation 
of polyubiquitin chains on its substrates in order to promote their degradation by the 
26S proteasome. APC/C-mediated degradation inactivates effector proteins such as 
cyclin A and cyclin B, or inhibitory proteins such as securin and geminin (see Table 1.1 
for a list of APC/C substrates) (Peters 1999). In general APC/C substrates are defined 
by the presence of a D-box (minimal sequence is RXXL) or KEN-box (Glotzer, Murray 
et al. 1991; King, Glotzer et al. 1996; Pfleger and Kirschner 2000), although distinct  
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Table 1.1. Cell cycle related APC/C substrates (adapted from Acquaviva and Pines 
2006) 
 
 
 
* Post anaphase, not yet determined in vivo 
 
Protein Timing of destruction APC/C 
activator 
Function 
cyclin A Pro-metaphase CDC20 Mitotic regulator 
NEK2A Pro-metaphase CDC20 Centrosome regulator 
 
HOXC10 Pro-metaphase CDC20 Transcription factor 
cyclin B Metaphase CDC20 Mitotic regulator 
securin Metaphase CDC20 Separase inhibitor 
    
CDC20 Anaphase CDH1 APC/C activator 
CDH1 G1 CDH1 APC/C activator 
UBCH10 G0/G1  APC/C cofactor 
    
cyclin B3 Anaphase CDH1 Mitotic/meiotic reg 
 
regulator 
 
Regulator 
PLK1 Anaphase CDH1 Mitotic regulator 
aurora A Anaphase CDH1 Mitotic regulator 
aurora B Anaphase/telophase CDH1 Mitotic regulator 
survivin Anaphase* CDH1 Localises Aurora B 
    
ndc10 Anaphase* CDH1 Kinetochore 
component 
SLK1 Anaphase* CDH1 Spindle component 
ase1/prc1 Anaphase* CDH1 Spindle component 
KIP1 Anaphase* CDH1 Spindle motor 
anillin Anaphase* CDH1 Cytokinesis regulator 
ECT2 Anaphase* CDH1 Cytokinesis regulator 
    
geminin Anaphase* CDH1 DNA replication 
inhibitor 
    
hsl1 G1 CDH1 Swe1 inhibitor 
SKP2 G1 CDH1 SCF component 
CKS1 G1 CDH1 CDK cofactor 
SNON G1 CDH1 Inhibitor of TGF-β 
genes 
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destruction motifs have been identified in proteins such as chromosome instability 8p 
(CIN8p) (Hildebrandt and Hoyt 2001), aurora A (Littlepage and Ruderman 2002), 
origin recognition complex subunit 1 (ORC1) (Araki, Wharton et al. 2003), Xenopus 
chromokinesin kid (XKID) and spo13 (Castro, Vigneron et al. 2003) (Sullivan and 
Morgan 2007). A recent report reveals the existence of an additional substrate motif 
known as a TEK-box that is also found in ubiquitin and facilitates ubiquitin nucleation 
and subsequent chain elongation (Jin, Williamson et al. 2008). 
 
1.5.1. Factors required for APC/C ubiquitin ligase activity 
Amongst the E3 ubiquitin ligases the APC/C is extremely complex comprising at least 
11 subunits in vertebrates and 13 in yeast (see Table 1.2 for a summary of mammalian 
APC/C components and Fig 1.3 for a depiction of their organisation). However, APC/C 
ligase activity, albeit with greatly reduced substrate specificity, can be reconstituted in 
vitro in the presence of just APC2 and APC11 in conjunction with an E1 ubiquitin 
activating enzyme and an E2 ubiquitin conjugating enzyme (Gmachl, Gieffers et al. 
2000; Yoon, Feoktistova et al. 2002; Vodermaier, Gieffers et al. 2003). Significantly, 
APC2 contains a cullin domain and APC11 contains a really interesting new gene 
(RING) finger motif (Zachariae, Shevchenko et al. 1998; Gmachl, Gieffers et al. 2000), 
which are both commonly found in other E3 ubiquitin ligases such as SKP (S phase-
associated protein) cullin F-box (SCF) E3 ubiquitin ligases (Pickart 2001). It is thought 
that association of the cullin and RING-finger domains is important for recruitment of 
E2 enzymes (Gmachl, Gieffers et al. 2000; Tang, Li et al. 2001; Vodermaier, Gieffers et 
al. 2003). In order to catalyse substrate ubiquitylation in vivo the APC/C requires a 
universal E1 enzyme, and either one of the E2 enzymes UBCH4 or UBCH10, and must 
generally be bound by one of its coactivators CDC20 or CDC20-homologue protein 1  
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Table 1.2. Subunits and coactivators of the mammalian APC/C (adapted from van 
Leuken 2008 and Peters 1999).   
 
 
(CDH1) (Aristarkhov, Eytan et al. 1996; Yu, King et al. 1996; Peters 1999). The 
coactivators are thought to bind to APC/C subunits, which contain tetratrico peptide 
repeat (TPR) domains, through their C-boxes (DRF/YIPXR) and an IR dipeptide 
(Schwab, Neutzner et al. 2001; Passmore, McCormack et al. 2003; Vodermaier, 
Gieffers et al. 2003). It is thought that binding of CDH1 or CDC20 causes a 
conformational change in the APC/C that is associated with the activation of the 
APC/C‟s ligase activity (Dube, Herzog et al. 2005). In addition, CDC20 and CDH1 also 
contain a WD40 repeat, which is believed to mediate binding to substrate destruction 
motifs (Kraft, Vodermaier et al. 2005).  
 
 
Subunits Predicted size 
(KDa) 
Functional Aspects 
APC1 216 Mitotic phosphosites; scaffold? 
APC2 94 Cullin  
APC3/CDC27 92 TPR; mitotic phosphosites 
APC4 
 
92 Connector? 
APC5 85 Connector? 
APC6/CDC16 72 TPR; mitotic phosphosites 
APC7 63 TPR; mitotic phosphosites 
APC8/CDC23 69 TPR; mitotic phosphosites 
APC10 21 Processivity factor  
APC11 11 RING-E3 
APC13 9 Stability factor?  
CDC26 
Coactivators 
10 Stability factor? 
   
  
CDC20 55 WD40 repeats; substrate binding  
CDH1 55 WD40 repeats; substrate binding 
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1.5.2. Sequential formation of mitotic APC/C
CDC20
 and APC/C
CDH1
  
The APC/C is activated during mitosis and remains active until late G1, as a result of 
interaction with its coactivators CDC20 and CDH1, which function in a cell cycle 
dependent manner (see Fig 1.4 for an overview of APC/C activity and regulation during 
the cell cycle). Despite the fact that CDC20 is synthesised during S and G2 phases, it 
can only associate with, and activate, the APC/C efficiently after the APC/C has been 
phosphorylated by CDK1 on multiple subunits such as APC3 and APC1 in prophase 
(Kraft, Herzog et al. 2003). APC/C
CDC20
 complexes mediate degradation of cyclins A 
and B, and securin, therefore allowing sister chromatid separation, and subsequent 
mitotic exit (Dawson, Roth et al. 1995; Sigrist, Jacobs et al. 1995; Sudakin, Ganoth et 
al. 1995; Cohen-Fix, Peters et al. 1996). As a result of cyclin B degradation at the 
metaphase-anaphase transition CDK1 activity is ablated and can no longer maintain 
inhibitory phosphorylation of CDH1 (Jaspersen, Charles et al. 1999; Listovsky, Zor et 
al. 2000), allowing formation of APC/C
CDH1
 complexes that remain active until late G1 
(Fang, Yu et al. 1998; Kramer, Gieffers et al. 1998; Zachariae, 
Schwab et al. 1998; Jaspersen, Charles et al. 1999). Significantly, APC/C
CDH1
 facilitates 
mitotic exit by mediating degradation of proteins such as CDC20 (Prinz, Hwang et al. 
1998; Shirayama, Zachariae et al. 1998), Polo-like kinase 1 (PLK1) and the aurora 
kinases A and B (Shirayama, Zachariae et al. 1998; Littlepage and Ruderman 2002; 
Lindon and Pines 2004; Nguyen, Chinnappan et al. 2005). In addition 
APC/C
CDH1
enables prereplication complex (preRC) formation during M and early G1 
by targeting the replication licensing inhibitor geminin for degradation (McGarry and 
Kirschner 1998; Li and Blow 2005). 
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1.5.3. Chromosome segregation during mitosis requires cyclin B and securin 
degradation  
Prophase, prometaphase and metaphase constitute the early phases of mitosis and are 
chiefly concerned with bipolar chromosome attachment. Anaphase is characterised by 
the separation of sister chromatids, and the initiation of their migration to opposite poles 
of the cell, known as chromosome segregation. Untimely chromosome segregation and 
possible subsequent aneuploidy (Orr, Bousbaa et al. 2007), is prevented by a ring-like 
multisubunit complex called cohesin that persists at the centromere until anaphase 
(Gerton 2005; Losada and Hirano 2005). Cohesin maintains sister chromatid cohesion 
until the spindle assembly checkpoint (SAC) is inactivated. At which point the cohesin 
component, sister chromatid cohesion 1 (SCC1) is cleaved by separase allowing sister 
chromatids to migrate to opposite poles (Uhlmann, Lottspeich et al. 1999; Uhlmann, 
Wernic et al. 2000; Hauf, Waizenegger et al. 2001). Separase is rendered inactive prior 
to metaphase through binding of its inhibitor securin (also known as pituitary tumor 
transforming gene (PTTG)) and due to inhibitory phosphorylation by cyclin B-CDK1 
(Stemmann, Zou et al. 2001; Tfelt-Hansen, Kanuparthi et al. 2006). Therefore the 
metaphase-anaphase transition cannot occur until securin and cyclin B are degraded by 
the 26S proteasome in late metaphase as a result of their polyubiquitylation by 
APC/C
CDC20 
(see Fig 1.5 for an overview of APC/C dependent chromosome 
segregation) (Dawson, Roth et al. 1995; Sigrist, Jacobs et al. 1995; Sudakin, Ganoth et 
al. 1995; Cohen-Fix, Peters et al. 1996). 
 
1.5.4. Chromosome segregation is inhibited by the spindle checkpoint  
Given that APC/C
CDC20
 is activated during prophase, it is important to prevent the 
untimely cleavage of securin and cyclin B, in order to block early chromosome  
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segregation, and possible aneuploidy. Activation of the SAC prevents early 
chromosome separation by selectively inhibiting APC/C
CDC20
 dependent proteolysis of 
cyclin B and securin (den Elzen and Pines 2001; Geley, Kramer et al. 2001). The 
APC/C mediates degradation of NIMA (never in mitosis gene A)-related kinase 2 
(NEK2A), homeobox C10 (HOXC10) and cyclin A during early mitosis despite SAC 
activation. The mechanisms that allow this to occur are poorly understood. However, 
despite the fact that CDC20 activity is inhibited by the SAC, CDC20 is notably still 
required for activation of APC/C ligase activity towards these early mitotic, checkpoint 
independent substrates, suggesting the existence of multiple APC/C populations (den 
Elzen and Pines 2001; Geley, Kramer et al. 2001; Gabellini, Colaluca et al. 2003; 
Hayes, Kimata et al. 2006; Wolthuis, Clay-Farrace et al. 2008). 
The SAC is activated in the presence of misaligned chromosomes and unattached 
kinetochores, and is mediated by the mitotic checkpoint complex (MCC), which 
comprises mitotic arrest deficient 1(MAD1), CDC20, MAD2, budding uninhibited by 
benzimidazoles R1 (BUBR1) and BUB3 (Sudakin, Chan et al. 2001). Significantly, 
direct interactions between CDC20, MAD2 and BUBR1 account for the majority of 
APC/C inhibition in arrested cells (Fang, Yu et al. 1998; Hwang, Lau et al. 1998; Fang 
2002; Braunstein, Miniowitz et al. 2007). Interestingly, MAD2 and BUBR1 are thought 
to enforce the spindle checkpoint by catalysing CDC20 degradation, as they appear to 
mediate APC/C dependent ubiquitylation of CDC20 (Pan and Chen 2004; King, van der 
Sar et al. 2007; Nilsson, Yekezare et al. 2008; Ge, Skaar et al. 2009). In contrast two 
other studies reveal that the APC/C can also promote SAC inactivation, as 
ubiquitylation of CDC20 by the APC/C actually prevents interaction between CDC20 
and MAD2. Consistent with this, depletion of the ubiquitin specific protease 44 
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 (USP44) that antagonises CDC20 ubiquitylation in vivo results in SAC failure (Reddy, 
Rape et al. 2007) (Stegmeier, Rape et al. 2007). 
Aurora B also plays a key role in regulating the spindle checkpoint, as it aids 
recruitment of MCC components to the kinetochore and promotes MCC activation and 
correct chromosome alignment by severing microtubules that are not attached to 
kinetochores properly (Tanaka, Rachidi et al. 2002; Ditchfield, Johnson et al. 2003; 
Hauf, Cole et al. 2003). 
 
1.5.5. Regulation of the APC/C during interphase  
During G1, PC/C
CDH1
 inhibits CDK activity and therefore prevents early passage into S 
phase; indeed ablation of CDH1 expression leads to an enrichment of cells in S phase 
(Sudo, Ota et al. 2001; Bashir, Dorrello et al. 2004; Wei, Ayad et al. 2004). APC/C
CDH1
 
prevents early S phase entry by targeting the F-box protein SKP2 for destruction, which 
results in elevated levels of the CDK inhibitor p27
KIP1
 (Bashir, Dorrello et al. 2004; 
Wei, Ayad et al. 2004). In addition APC/C
CDH1
 also inhibits CDK activity by 
maintaining cyclin A instability during G1 (Hsu, Reimann et al. 2002; Havens, Ho et al. 
2006).  
APC/C
CDH1
 activity is inhibited during late G1 and S phases through mechanisms that 
are intricately linked to cyclin-CDK activity. During late G1 when all APC/C
CDH1
 
substrates have been degraded, liberated APC/C
CDH1
 negatively regulates its own ability 
to ubiquitylate substrates by targeting the E2 UBCH10 for degradation (Yamanaka, 
Hatakeyama et al. 2000; Rape and Kirschner 2004). Cyclin A-CDK accumulation 
further enforces the inactivation of APC/C
CDH1
 by mediating phosphorylation of CDH1, 
which prevents association between the APC/C and CDH1 (Lukas, Sorensen et al. 
1999; Rape and Kirschner 2004). E2F-dependent transcription at the G1-S transition, 
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presumably mediated by cyclin E-CDK2 complexes, results in expression of the early 
mitotic inhibitor 1 (EMI1), which also inhibits the formation of the APC/C
CDH1
 complex 
during S and G2 phases (Hsu, Reimann et al. 2002). In addition, inhibition of 
APC/C
CDH1
 activity is further enforced during S phase and G2 by the E3 ubiquitin ligase 
SCF
Roc1
, which targets CDH1 for degradation (Benmaamar and Pagano 2005). This 
multifaceted approach to APC/C
CDH1 
inhibition enables the accumulation of the 
APC/C
CDH1
 substrate CDC20 during S and G2 phases. However, untimely formation of 
APC/C
CDC20
 complexes is also inhibited by EMI1 during this period (Reimann, Freed et 
al. 2001), therefore preventing the premature destruction of APC/C substrates. 
Complete inhibition of APC/C activity is maintained until EMI1 is targeted for 
degradation by the E3 ubiquitin ligase SCF
h-TRCP
, as a result of PLK1 and CDK1 
dependent phosphorylation of EMI1. Indeed stabilisation of EMI1 or ablation of SCF
h-
TRCP
 activity prevents activation of APC/C
CDC20
 and arrests cells in prometaphase 
(Guardavaccaro, Kudo et al. 2003; Margottin-Goguet, Hsu et al. 2003; Hansen, Loktev 
et al. 2004).  
 
1.5.6. APC/C
CDH1 
regulates DNA replication licensing and initiation  
Formation of prereplication complexes (preRCs) often referred to as replication 
licensing, requires that CDC6 and chromatin licensing and DNA replication factor 1 
(CDT1) cooperate with the origin of replication complex (ORC) to load 
minichromosome maintenance (MCM) factors 2–7 on to origins of replication 
(Machida, Hamlin et al. 2005). During S phase preRC formation and subsequent 
rereplication at freshly liberated origins of replication is prevented through APC/C
CDH1
 
inhibition, which allows accumulation of the APC/C substrates and licensing inhibitors 
cyclin A and geminin. Cyclin A-CDK2 complexes prevent preRC formation by 
28 
 
stimulating nuclear export of CDC6 and by promoting degradation of CDT1. Geminin 
prevents preRC formation by inhibiting interaction between CDT1 and MCM 
complexes (Sivaprasad, Machida et al. 2007). It is not until anaphase when APC/C
CDH1
 
is reactivated that geminin is degraded and replication licensing can occur (see Fig 1.6 
for an overview of APC/C dependent preRC formation) (McGarry and Kirschner 1998; 
Li and Blow 2005).  
  
1.5.7. APC/C
CDH1
 induces quiescence   
Most study of the APC/C has so far been directed towards understanding its role in 
promoting cellular proliferation, however APC/C
CDH1 
also carries out important 
functions during the induction and maintenance of quiescence or G0. This was first 
suggested by the presence of APC/C
CDH1
 in differentiated mouse and human brain 
sections, while CDC20 expression, which is required for cellular division was absent 
(Gieffers, Peters et al. 1999). More recently APC/C
CDH1 
has been found to be active
 
during G0 in neurons where it maintains cyclin B instability, and therefore prevents re-
entry into G1 and subsequent apoptosis (Almeida, Bolanos et al. 2005). A number of 
neurodegenerative diseases such as Alzheimer‟s are characterised by stimulation of N-
methyl-D-aspartate receptors (NMDARs) (Parameshwaran, Dhanasekaran et al. 2008) 
(Fan and Raymond 2007), which are thought to enhance cyclin B1 accumulation by 
stimulating CDH1 phosphorylation, therefore rendering the APC/C inactive, resulting in 
neuronal apoptosis and neurodegeneration (Maestre, Delgado-Esteban et al. 2008). The 
APC/C is also required to maintain quiescence in murine hepatocyte cells, as 
conditional inactivation of APC2 forces them to re-enter the cell cycle and go on to 
arrest in metaphase, which ultimately results in liver failure (Wirth, Ricci et al. 2004). 
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1.5.7.1. APC/C
CDH1 
initiates
 
quiescence in response to TGF-β signalling 
Activation of transforming growth factor-β (TGF-β) receptors following binding by 
TGF-β results in phosphorylation and hence activation of the protein similar to mothers 
against decapentaplegic homolog 2 (SMAD2) and SMAD3 (also known as receptor-
SMADs (R-SMADs)). Phosphorylated SMAD2 and SMAD3 then associate with 
SMAD4 and translocate into the nucleus where they regulate a program of transcription 
that is generally considered to inhibit cellular proliferation and induce differentiation 
(Attisano and Wrana 2000; Massague, Seoane et al. 2005). Interestingly, TGF-β 
treatment also promotes interaction between APC/C
CDH1
 and SMAD3, which is 
important for degradation of ski-related novel protein N (SNON) and subsequent 
induction of quiescence (Wan, Liu et al. 2001). Degradation of the transcriptional 
repressor SNON enhances transcription of the CDK inhibitors p15
INK4B
 and p21
CIP1
, and 
as a result promotes quiescence (Wu, Glickstein et al. 2007). It appears that APC/C
CDH1
 
can also transduce TGF-β signals by stimulating degradation of the human enhancer of 
filamentation 1 (HEF1), as HEF1 interacts with CDH1, SMAD3 and APC10 while 
SMAD3 has previously been shown to mediate HEF1 degradation in response to TGF-β 
(Nourry, Maksumova et al. 2004). It is thought that HEF1 is targeted for degradation by 
APC/C
CDH1
 as it has a role in attenuating SMAD3 gene responses (Liu, Elia et al. 2000). 
 
1.5.7.2. Interaction between APC/C
CDH1
 and RB is important for quiescence 
RB prevents cell cycle progression by repressing transcription of E2F-responsive genes 
that are important for cellular proliferation (Classon and Harlow 2002). However, RB 
can also mediate cell cycle exit, differentiation and senescence independently of its 
capacity to inhibit transcription. It achieves this by enhancing the degradation of the F-
box protein SKP2, and as a result promotes the accumulation of the SKP2 substrate, and 
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CDK inhibitor p27
KIP1
 (Alexander and Hinds 2001; Ji, Jiang et al. 2004; Thomas, 
Johnson et al. 2004). Interestingly,
 
a recent study by Binne and Dyson (2007) reveals 
that RB mediates SKP2 degradation by recruiting APC/C
CDH1
. Significant observations 
made by the authors demonstrate that APC/C subunits associate with RB during cell 
cycle exit, that RB precipitates APC/C ligase activity and that knockdown of CDH1 
significantly attenuates the ability of RB to induce cell cycle-arrest. (Binne, Classon et 
al. 2007). 
 
1.5.7.3. APC/C
CDH1 
couples axon growth
 
and quiescence 
The APC/C regulates axon growth, as knockdown of CDH1 expression or over-
expression of APC/C inhibitors such as EMI1 increases the rate and final length of axon 
growth (Konishi, Stegmuller et al. 2004). It appears that the ability of the APC/C to 
limit axonal growth is coupled to its capacity to induce a G0 state. For instance, 
APC/C
CDH1
 dependent degradation of SNON is not only required for cell cycle exit, but 
also occurs in quiescent neuronal cells in response to basal TGF-β stimulation in order 
to prevent axon growth (Stegmuller, Konishi et al. 2006; Stegmuller, Huynh et al. 
2008). In addition, APC/C dependent degradation of the inhibitor of differentiation 2 
(ID2) is also required for inhibition of axonal growth (Lasorella, Stegmuller et al. 
2006). Deregulation of ID2 expression can prevent quiescence while eptopic expression 
of ID2 can stimulate quiescent cells to re-enter the cell cycle (Lasorella, Boldrini et al. 
2002; Kowanetz, Valcourt et al. 2004; Baghdoyan, Lamartine et al. 2005; Chaudhary, 
Sadler-Riggleman et al. 2005). These findings may be of particular importance for 
treatment of spinal injuries, as localised inactivation of CDH1 in damaged neuronal 
tissue may be sufficient to force neurons back into their growth phase. 
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1.5.7.4. APC/C
CDH1 
controls differentiation
  
In addition to its role in regulating cell cycle exit and cell growth, the APC/C also 
appears to control differentiation. For instance, inactivation of CDH1 inhibits lens 
differentiation, which is characterised by a reduction in the levels of the CDK inhibitors 
p21
CIP1
 and p15
INK4B
 (Wu, Glickstein et al. 2007), suggesting that CDH1 facilitates 
differentiation by stimulating cell cycle exit, and not by directly regulating 
differentiation. However the APC/C does appear to regulate differentiation 
independently of cell cycle effects in Drosophila, as inactivation of the APC2 
homologue morula (Mr) and various APC/C subunits in C. elegans doesn‟t force cells 
to re-enter G1, but does result in an increase in the number of glutamate receptors in the 
post synaptic neuron (Juo and Kaplan 2004; van Roessel, Elliott et al. 2004). Its seems 
likely that the APC/C may regulate glutamate receptor recycling by direct 
monoubiquitylation, as monoubiquitylation has been shown to be important for 
endocytosis and recycling of plasma membrane receptors while APC/C inactivation 
increases the number of glutamate receptors (Hicke 2001) (Juo and Kaplan 2004).  
 
1.5.8. The APC/C functions in concert with CBP and p300  
Work from our lab demonstrates that the transcriptional coactivators CBP and p300 
associate with the APC/C in vivo, and that CBP and p300 display a direct interaction 
with the E1A homology domains of APC5 and APC7 in vitro. These interactions are 
important for the APC/C‟s novel function as a transcriptional regulator, as APC5 and 
APC7 stimulate CBP auto-acetylation, and therefore enhance the ability of CBP to 
acetylate histone H4 and hence stimulate transcription. In light of this it seems likely 
that APC5 and APC7 may also modulate p300‟s function as a transcriptional regulator 
in a similar fashion. 
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A number of observations also from our lab suggest that the APC/C may regulate the 
G1-S transition by modulating transcription of a panel of genes in conjunction with 
p300. Significantly, APC5 and APC7 enhance p21
CIP1 
transcription in response to 
ionising radiation (IR) and also display a physiological interaction with the p21
CIP1 
promoter. This implies that the APC/C can inactivate CDK activity by enhancing 
expression of p21
CIP1
 in response to DNA damage and hence arrest cells in G1. 
Moreover APC5 and APC7 may also be able to regulate E2F dependent progression 
into S phase, which is suggested by the ability of APC5 and APC7 to potentiate E2F-1 
dependent transcription of the CDC6 promoter. Lastly, ablation of p300 expression 
results in an enrichment of cells in G1, suggesting that deregulation of APC/C-p300 
target genes might interfere with processes required for G1 progression. 
Work from our lab also demonstrates that CBP, in contrast to p300, mediates 
polyubiquitylation of the APC/C‟s early mitotic substrates and therefore is important for 
progression into anaphase. Specifically, CBP immunocomplexes are capable of 
polyubiquitylating cyclin B in vitro, and are therefore associated with APC/C E3 
ubiquitin ligase activity. Moreover, ablation of CBP expression results in the 
stabilisation of cyclin B and other APC/C substrates in vivo, while also causing a 
substantial delay in mitotic progression. These observations could be attributed to the 
ability of CBP to function as an E4 ubiquitin-elongation enzyme (Grossman, Deato et 
al. 2003), which may enhance the formation of polyubiquitin chains upon APC/C 
substrates. Alternatively, there are many instances in which CBP has been demonstrated 
to alter protein function by direct acetylation (Yang 2004), suggesting the intriguing 
possibility that CBP might contribute to activation of APC/C
CDC20
 ubiquitin ligase 
activity by directly acetylating APC/C subunits.  
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1.5.9. The role of the APC/C during tumourigenesis 
Aberrant chromosomal segregation can often give rise to aneuploidy, which is 
commonly observed in malignant tumours (Castedo and Kroemer 2004). Given that 
deregulation of the APC/C can give rise to incorrect chromosomal segregation, it is 
somewhat surprising that there are few reports of altered APC/C subunit expression in 
human tumours. These include deleterious mutations in APC6 and APC8 identified in 
colon cancers and reduced APC7 expression in breast cancer (Wang, Moyret-Lalle et al. 
2003; Park, Choi et al. 2005). However, there is mounting evidence to suggest that the 
majority of APC/C pathway deregulation during tumourigenesis occurs due to mutation 
of APC/C regulatory molecules and over-expression of APC/C substrates. For instance, 
a recent report shows that the APC/C coactivators CDC20 and CDH1 are over-
expressed in a number of malignancies (Singhal, Amin et al. 2003; Lehman, Tibshirani 
et al. 2007; Kidokoro, Tanikawa et al. 2008). Interestingly, an absence of CDH1 
expression correlates with accumulation of SKP2 and a decrease in the level of p27
KIP1
 
in breast, colon, and rectal cancers (Fujita, Liu et al. 2008; Fujita, Liu et al. 2008). 
Over-expression of securin has also been observed in tumours originating from pituitary 
(Pei and Melmed 1997), thyroid (Heaney, Nelson et al. 2001) ovary (Puri, Tousson et 
al. 2001), breast and central nervous system tissues (Solbach, Roller et al. 2004; 
Chamaon, Kirches et al. 2005). Securin over-expression in tumours and in cell lines 
results in an increase in aneuploidy and genomic instability (Mu, Oba et al. 2003; Yu, 
Lu et al. 2003; Kim, Pemberton et al. 2005; Kim, Ying et al. 2007). Over-expression of 
securin is believed to contribute to tumourigenesis by preventing chromosome 
segregation, resulting in asymmetrical cytokinesis and subsequent aneuploidy (Yu, Lu 
et al. 2003). Somewhat paradoxically, inactivation of securin has also been implicated 
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in aneuploidy, as it appears that securin is also required for separase activation 
(Jallepalli, Waizenegger et al. 2001).  
The APC/C regulator and substrate PLK1, is also over expressed in many cancers such 
as melanoma and non-small-cell lung cancer (Wolf, Elez et al. 1997) (Strebhardt, 
Kneisel et al. 2000). Significantly cells in which PLK1 is over expressed display defects 
in cytokinesis, which manifests as potentially tumourigenic multi-nuclei (Mundt, 
Golsteyn et al. 1997). Given that PLK1 mediates degradation of the APC/C inhibitor 
EMI1, it is tempting to speculate that PLK1 over-expression may result in premature 
EMI1 destruction and hence contribute to early activation of APC/C
CDC20
, which could 
result in aberrant chromosome separation and aneuploidy (Hansen, Loktev et al. 2004).  
 
1.5.10. Substrate recruitment requires cooperation between the APC/C and its 
coactivators  
Classically, substrate binding to the APC/C was believed to be entirely mediated 
through the APC/C‟s coactivators CDC20 and CDH1; indeed substrate binding to the 
APC/C is directly proportional to the amount of coactivator present (Passmore and 
Barford 2005). However, current opinion favours the view that substrate binding is a 
cooperative process, requiring interaction between substrate and both the APC/C and 
either CDC20 or CDH1. In support of this notion, it is thought that the APC/C subunit 
APC10 can also mediate substrate interaction, as ablation of its expression prevents 
stable binding of the APC/C to its substrates (Passmore, McCormack et al. 2003). In 
addition the APC/C binds to the D-box of cyclin B in the absence of CDC20 and CDH1 
(Yamano, Gannon et al. 2004), and securin in the absence of CDC20 (Eytan, Moshe et 
al. 2006). However a notable exception to this rule is provided by the mitotic kinase 
NEK2A, which can bind to the APC/C completely independently of CDC20 via an MR 
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dipeptide, although association of CDC20 with the APC/C is still required for NEK2A 
degradation (Hayes, Kimata et al. 2006).  
 
1.5.11. Regulation of APC/C activity by factors intrinsic to the substrate 
In addition to direct regulation of the APC/C and its coactivators by factors such as 
phosphorylation, degradation, and binding of inhibitors, it appears that the ability of the 
APC/C to mediate protein ubiquitylation is also regulated by factors that are intrinsic to 
the substrate. For instance, APC/C
CDC20 
recognises substrates that contain two D-boxes, 
whereas APC/C
CDH1
 preferentially recognises substrates that contain a D-box and a 
KEN box (Pfleger and Kirschner 2000; Burton, Tsakraklides et al. 2005). 
The ordering of substrate degradation is thought to be determined by the rate at which a 
substrate can be ubiquitylated. For instance, CDC20, PLK1 and aurora A are 
preferentially multi-ubiquitylated in vitro in a manner that corresponds to the order of 
their degradation in vivo (Lindon and Pines 2004). It is thought that this is dependent on 
whether substrates are polyubiquitylated in a processive single event or distributively 
over multiple rounds of APC/C binding. As a result of this distributive substrates would 
have a longer half life due to the prolonged period of time that they are exposed to 
DUBs and competition by processive substrates. It has been suggested that the fashion 
in which a substrate is modified may be attributed to the affinity of the APC/C for its 
destruction motifs or the density of its lysine residues (Rape, Reddy et al. 2006). 
Substrate modification can also be regulated by spatial separation of the APC/C and its 
substrates. For example in Drosophila melanogaster embryos only a small fraction of 
the total cellular pool of cyclin B is associated with the mitotic spindles and is 
accessible to the APC/C, while the majority found in the cytoplasm remains stable 
(Clute and Pines 1999). Also, maintenance of yeast fin1 phosphorylation by CDK1 until 
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metaphase prevents its association with the spindle and hence the APC/C, while its 
dephosphorylation by CDC14 causes it to migrate to spindle poles where it is degraded 
by the APC/C (Woodbury and Morgan 2007). 
Substrate phosphorylation has also been demonstrated to directly inhibit ubiquitylation 
of substrates. For example, CDC6 is no longer targeted for degradation by the APC/C 
after its G1 phosphorylation by cyclin E-CDK2 on residues that lie adjacent to its D-box 
(Mailand and Diffley 2005).  
 
1.6. Cytokines 
Cytokines are a large group of secreted proteins and glycoproteins that allow inter-
cellular communication between haemopoietic and non-haemopoietic cells. They are 
secreted in response to a wide range of stimuli which include infection, inflammation, 
invasion, injury, irradiation and other cytokines. The list of cytokines is constantly 
evolving with more than 191 identified to date (Tracey and Cerami 1993; Peters 1996; 
Tayal and Kalra 2008). Each cytokine exerts its effects by binding to its cognate cell 
surface receptors, which then activate various cellular signalling cascades (Tracey and 
Cerami 1993; Peters 1996; Tayal and Kalra 2008). 
 
1.6.1. TNF 
The cytokine tumour necrosis factor (TNF) was originally identified on the basis of its 
ability to promote tumour regression and has more recently been demonstrated to 
stimulate destruction of tumour vasculature (Old 1988; Weichselbaum, Kufe et al. 
2002). However, subsequent studies have also defined TNF as a tumour promoter 
(Rosen, Goldberg et al. 1991; Suganuma, Okabe et al. 1999; Rivas, Carnevale et al. 
2007). For instance, TNF can enhance proliferation of human papilloma virus (HPV) 
38 
 
infected carcinoma cells, as it enhances CDK activity through up regulation of cyclin A 
and cyclin B, and down regulation of p21
CIP1
 and p27
KIP1
. Other TNF functions include 
lymphocyte and leukocyte activation and migration, inflammation, fever, apoptosis 
(Tracey, Lowry et al. 1988; Fiers 1991; Vassalli 1992; Vandenabeele, Declercq et al. 
1995).
 
 
1.6.1.1. TNF transcription  
Levels of TNF are tightly regulated at the level of transcription through binding of sub-
sets of transcription factors to the TNF promoter in a cell type and stimulus dependent 
manner (Falvo, Uglialoro et al. 2000). TNF transcription can be initiated by a diverse 
range of factors such as lipopolysaccharide (Economou, Rhoades et al. 1989), PMA 
(phorbol 12-myristate 13-acetate) treatment (Hensel, Mannel et al. 1987; Richards, 
Dennert et al. 1989) and T-cell receptor (TCR) ligation (Sung, Bjorndahl et al. 1988). 
The TNF promoter is activated by transcription factors such as activator protein-1 (AP-
1) (Rhoades, Golub et al. 1992), nuclear factor kappa B (NF-κB), (Yao, Mackman et al. 
1997), Ets1 (Kramer, Wiegmann et al. 1995), and nuclear factor of activated T-cells 1 
(NFAT1) (Oum, Han et al. 2002). In addition, CBP and p300 appear to fulfil important 
roles as activators of the TNF promoter. For example, the TNF promoter contains a 
cyclic-AMP response element (CRE), which is required for induction of TNF 
transcription (Tsai, Jain et al. 1996).  
 
1.6.2. IL-2 
Activation of TCRs or ligation of cytokine receptors such as the IL-2 receptor (IL2-R) 
results in IL-2 secretion and expression of IL-2 receptors (Lenardo, Chan et al. 1999). 
The predominant function of IL-2 is to stimulate proliferation of CD4+ and CD8+ T-
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cells, and to provide protection from apoptosis (Miyazaki, Liu et al. 1995). 
Interestingly, mice deficient in IL-2 signalling display auto-immunity (Schorle, 
Holtschke et al. 1991; Sadlack, Merz et al. 1993), which is currently attributed to their 
inability to produce T regulatory cells (Treg), which are important for recognising self 
reactive T-cells (Almeida, Legrand et al. 2002).  
 
1.6.2.1. IL-2 transcription  
The region that extends -300bp from the start site in the IL-2 promoter is sufficient for 
maximal activation of IL-2 transcription (Jain, Loh et al. 1995), and is activated by 
transcription factors such as octamer-1 (oct-1) (Kamps, Corcoran et al. 1990; Hentsch, 
Mouzaki et al. 1992), NF-κB, AP-1 (Brabletz, Pietrowski et al. 1991; Jain, McCaffrey et 
al. 1992), NFAT1 (Shaw, Utz et al. 1988) and CREB (Solomou, Juang et al. 2001; 
Solomou, Juang et al. 2001). 
Transcriptional regulation of the IL-2 promoter is partially dependent on its antigen 
receptor response element-2 (ARRE-2) (a model for activation of the IL-2 promoter 
from the ARRE-2 is displayed in Fig 1.7). The ARRE-2 is prebound by a transcriptional 
regulatory complex that functions as a repressor in resting T-cells and undergoes 
expansion into a transcriptional activator after T-cell activation (Shaw, Utz et al. 1988; 
Randak, Brabletz et al. 1990). It is thought that the ARRE-2 transcriptional regulatory 
complex induces IL-2 transcription following recruitment of NFAT1, which undergoes 
nuclear translocation in response to dephosphorylation by the calcium dependent 
phosphatase calcineurin following T-cell activation (Flanagan, Corthesy et al. 1991; 
McCaffrey, Luo et al. 1993; McCaffrey, Perrino et al. 1993). T-cell activation also 
results in protein kinase C (PKC) dependent upregulation of fos and jun, which dimerise 
and associate with the AP-1 binding site in the 3‟ region of the ARRE-2, therefore  
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stabilising the interaction between the ARRE-2 and NFAT1 (Jain, McCaffrey et al. 
1992; Boise, Petryniak et al. 1993; Northrop, Ullman et al. 1993). 
A number of observations suggest that the ARRE-2 transcriptional regulatory complex 
may also contain nuclear factor 90 (NF90) and its binding partner nuclear factor 45 
(NF45). For instance NF90/NF45 display similar properties to NFAT1 such as the 
ability to bind to the ARRE-2, activate the IL-2 promoter upon T-cell stimulation and 
sensitivity to the NFAT1 transcriptional inhibitors FK506 and cyclosporin A (CsA) 
(Flanagan, Corthesy et al. 1991; Corthesy and Kao 1994; Kao, Chen et al. 1994; Aoki, 
Zhao et al. 1998). Recent work reveals that NF90 is associated with the IL-2 promoter 
in vivo and that targeted disruption of NF90 in mice results in severe T-cell 
lymphocytopenia and an impairment of ARRE-2 driven IL2 transcription (Shi, Godfrey 
et al. 2007; Shi, Qiu et al. 2007). In addition Ku70 and Ku80 display a capacity to bind 
to the ARRE-2 element in vitro, while Ku70 and Ku80 cooperate with NF90/NF45 to 
regulate the IL-2 promoter in vitro (Aoki, Zhao et al. 1998; Ting, Kao et al. 1998). 
Significantly Ku70 and NF90 demonstrate dynamic binding to the IL2 promoter in vivo 
in response to PMA and ionomycin stimulation; in this instance a reduction of Ku70 
binding and concomitant increase in binding of NF90 to the IL-2 promoter correlates 
with activation of IL2 transcription, therefore suggesting that Ku70 functions to repress 
ARRE-2 dependent transcription in unstimulated cells (Shi, Qiu et al. 2007). 
 
1.7. NF90/NF45  
Nuclear factor 90 (NF90) and its binding partner nuclear factor 45 (NF45) were 
originally identified due to their ability to bind to, and regulate transcription from the 
antigen receptor response element-2 (ARRE-2) found within the interleukin-2 promoter 
(IL-2) (Corthesy and Kao 1994). Subsequent work revealed that NF90/NF45 also 
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regulate transcription from the proliferating cell nuclear antigen (PCNA) promoter and 
the S-locus protein 10 (SP-10) promoter in vitro (Reichman, Parrott et al. 2003; 
Ranpura, Deshmukh et al. 2007). NF90/NF45 also mediate gene expression by 
regulating splicing (Saunders, Perkins et al. 2001; Zhou, Licklider et al. 2002; Leung, 
Andersen et al. 2003), mRNA export, mRNA stabilisation (Shim, Lim et al. 2002; Shi, 
Zhao et al. 2005), and translation (Ting, Kao et al. 1998; Xu and Grabowski 1999). 
Recent work also demonstrates that NF90/NF45 is important for mitotic exit and may 
regulate DNA synthesis (Guan, Altan-Bonnet et al. 2008).  
 
1.7.1. Structural features of NF90/NF45 
NF90 and NF45 display homology in their dsRBM (double stranded RNA binding 
motif)-and zinc finger associated motif (DZF), which has been proposed to mediate 
their DNA binding activity (Shi, Zhao et al. 2005), while NF45 has limited similarity to 
the prokaryotic transcription factor σ-54 and to human DNA topoisomerase I (Gralla 
1991; Merino, Madden et al. 1993).  
 
1.7.2. The NF90 family 
The NF90 family comprises five proteins that are generated by differential splicing of 
the interleukin enhancer binding factor 3 (ILF3) locus, giving rise to proteins with an 
apparent molecular mass of 90KDa and 110KDa (see Fig 1.8 for an overview of NF90 
family structure). These proteins are essentially identical apart from some minor 
polymorphisms and the addition of a C-terminal GQSY-rich region in NF110, which 
mediates binding to the splicing factors survival motor neuron (SMN) and translocated 
in liposarcoma (TLS) (Duchange, Pidoux et al. 2000; Saunders, Perkins et al. 2001; 
Reichman, Parrott et al. 2003). Interestingly the GQSY-rich region enhances  
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the ability of NF110 to activate the PCNA promoter in vitro, which may be due to the 
enhanced DNA binding conferred by the GQSY-rich region (Reichman, Parrott et al. 
2003). Members of the NF90 family all contain dsRBMs that allow them to bind to 
mRNA, small dsRNA regulatory molecules such as small NF90-associated RNA 
(SNAR) and adenovirus VA RNAII (Liao, Kobayashi et al. 1998; Langland, Kao et al. 
1999; Parrott and Mathews 2007). NF90 family proteins may also be capable of binding 
to RNA through a RGG motif (Patel, Vestal et al. 1999). The dsRBMs of NF90 
facilitate binding to other proteins of the dsRBM family such as protein kinase R (PKR) 
and adenosine deaminase acting on RNA (ADAR1), by utilising dsRNA molecules as 
binding intermediates to bridge the interaction (Parker, Fierro-Monti et al. 2001; Nie, 
Ding et al. 2005). The dsRBMs found in NF90 family proteins appear to be important 
for transcription, as mutation of the dsRBMs, so that they cannot bind dsRNA, results in 
a reduction in the transcriptional activity of NF90 family members (Reichman and 
Mathews 2003). 
 
1.7.3. NF90/NF45 and post transcriptional RNA regulation  
The presence of dsRBMs and an RGG motif might be important for the ability of NF90 
to regulate pre-mRNA and mRNA processing. Indeed NF90/NF45 might play an 
important role in splicing, as they have been identified as components of the 
splicesosome in proteomic studies (Zhou, Licklider et al. 2002; Leung, Andersen et al. 
2003), while NF110 binds to the splicing factor TLS and associates with spliced RNA 
(Saunders, Perkins et al. 2001). In addition to its putative role in splicing, NF90 also 
regulates mRNA stability and nuclear export. For example, NF90 binds to IL-2 mRNA 
and facilitates its nuclear export and stabilisation (Shim, Lim et al. 2002). Moreover 
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NF90 mediates cell cycle exit and differentiation through binding to, and stabilization 
of, p27
KIP1
 and myoD mRNA (Shi, Zhao et al. 2005).  
The initial observation that NF90 interacts with the elongation initiation factor 2 
subunits alpha, beta, and gamma suggested that NF90 also functions in translation 
(Ting, Kao et al. 1998). Subsequent work defined NF90 as a bona fide translation factor 
as it was shown to inhibit acid beta-glucosidase translation in liver (Xu and Grabowski 
1999). A recent study by Vumbaca et al. 2008 also demonstrates that NF90 is required 
to load vascular endothelial growth factor (VEGF) mRNA onto polyribosomes 
(Vumbaca, Phoenix et al. 2008). 
 
1.8. The TRIM/RBBC family 
The TRIM/RBCC family is composed of at least 66 proteins to date, which all share a 
common N-terminal region that is composed of a RING finger, B-boxes, and a coiled-
coil domain (RBCC), also known as a tripartite motif (TRIM) (Nisole, Stoye et al. 
2005). Its most notable member promyelocytic leukaemia (PML), is required for 
formation of PML nuclear bodies (PML-NBs), which are involved in a number of 
diverse cellular processes, including cellular senescence, apoptosis and DNA repair (Le, 
Yang et al. 1996; Wang, Delva et al. 1998; Wang, Ruggero et al. 1998) (Mirzoeva and 
Petrini 2001; Carbone, Pearson et al. 2002). In acute promyelocytic leukemia (APL) the 
N-terminal region of PML that encompasses the TRIM/RBCC domain, which is 
essential for PML nuclear body formation, fuses with the retinoic acid receptor (RAR) 
(de The, Lavau et al. 1991) (Pandolfi, Grignani et al. 1991; Fagioli, Alcalay et al. 1998), 
precluding PML body formation and negating its growth suppressive properties 
(Grignani, Ferrucci et al. 1993; Rogaia, Grignani et al. 1995). Interestingly, there are a 
number of other observations that demonstrate the importance of the TRIM/RBCC 
46 
 
motif in the regulation of cellular growth. Specifically, the N-terminal TRIM/RBCC of 
transcriptional intermediary factor 1 alpha (TIF1α) and TIF1γ are fused to the RET 
receptor tyrosine kinase domain in papillary thyroid carcinomas (PTC) (Klugbauer and 
Rabes 1999). Moreover, the TRIM/RBCC domain is essential for targeting of TIF1α 
into PML-associated tracks during adenovirus infection. It has been proposed that the 
adenovirus protein E3ORF3, sequesters TIF1α into PML-associated tracks in order to 
modulate its function as a regulator of hormone induced growth suppression, therefore 
creating an environment that is permissive to viral replication (Yondola and Hearing 
2007).  
  
1.8.1. The transcriptional intermediary factor 1 (TIF1) family 
The TIF1 family of proteins α, β, γ and δ exhibit ~30% identity at the amino acid level, 
while TIF1 and TIF1 exhibit the highest degree of identity at 50% (see Fig 4.1 for a 
linear depiction of TIF1)(Venturini, You et al. 1999; Yan, Dolle et al. 2004). The TIF1 
proteins display identical arrangement of their TRIM/RBCC domains, TIF1 signature 
sequence (TSS), plant homeobox domain (PHD) and bromodomains, suggesting that 
they share common functions. It has been demonstrated that the PHD domain of TIF1β 
is required for TIF1β SUMOylation (Mascle, Germain-Desprez et al. 2007). Indeed the 
PHD domain is structurally similar to the PML RING finger (Capili, Schultz et al. 
2001), which is suggested to function as an E3 SUMO ligase (Quimby, Yong-Gonzalez 
et al. 2006). The bromodomain of TIF1α is required for binding to nucleosomes in vitro 
(Remboutsika, Yamamoto et al. 2002), indicating that it may be necessary for the TIF1 
family to regulate transcription in vivo. 
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1.8.1.1. The TIF1 family regulates transcription 
TIF1, TIF1β and TIF1γ have all been demonstrated to function as transcriptional 
repressors when tethered to DNA, and this function is thought to be dependent on their 
TSS motif (Le Douarin, Nielsen et al. 1996; Moosmann, Georgiev et al. 1996; 
Venturini, You et al. 1999). TIF1β associates with the Krüppel associated box (KRAB) 
domain of human zinc finger proteins (Friedman, Fredericks et al. 1996; Kim, Chen et 
al. 1996), a motif that is one of the most widely distributed transcriptional repression 
domains, suggesting that TIF1β functions as a universal co-repressor. Moreover, TIF1α, 
TIF1β and TIF1δ all interact with heterochromatin protein 1 (HP1) subunits that are 
located on transcriptionally inactive heterochromatin (Le Douarin, Nielsen et al. 1996; 
Khetchoumian, Teletin et al. 2004). Furthermore TIF1α can bind to and regulate the 
AF-2 transcription activation domain of retinoid X (RXR), retinoic acid (RAR), vitamin 
D3 (VDR), estrogen (ER), and progesterone (PR) nuclear receptors (Le Douarin, 
Nielsen et al. 1996; vom Baur, Zechel et al. 1996; Beckstead, Ortiz et al. 2001). 
However, despite the ability of TIF1β and TIF1γ to heterodimerise with TIF1 (Peng, 
Feldman et al. 2002; Germain-Desprez, Bazinet et al. 2003; Teyssier, Ou et al. 2006), 
studies have, as yet, been unable to demonstrate that these interactions are important for 
the ability of TIF1 to regulate nuclear receptor function (Le Douarin, Nielsen et al. 
1997; Venturini, You et al. 1999).  
 
1.8.2. TIF1γ regulates cellular proliferation, differentiation and contributes to 
tumourigenesis  
TIF1γ was first proposed to regulate cellular proliferation and differentiation, as a result 
of its fusion to the rearranged during transfection (RET) receptor tyrosine-kinase
 
domain in papillary thyroid carcinomas (PTC) (Klugbauer and Rabes 1999). More 
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recent work in zebra fish concludes that the TIF1γ ortholog mon is required for 
differentiation of erythroid progenitor cells and posterior mesenchymal cells (Ransom, 
Bahary et al. 2004). In addition to this, work by He and colleagues (2006) reveals that 
TIF1γ mediates differentiation of hematopoietic, mesenchymal, and epithelial cells in 
response to TGF-β signalling. TGF-β is generally considered to inhibit cellular 
proliferation and induce differentiation via SMAD 2/3-SMAD4 dependent transcription 
(Attisano and Wrana 2000; Massague, Seoane et al. 2005) However, He et al. (2006) 
show that TGF-β signalling also induces complex formation between activated SMAD 
2/3 and TIF1γ. Significantly, knockdown of TIF1γ impedes differentiation of CD34+ 
haematopoietic progenitors, but has no effect on the growth-inhibitory action of TGF-β, 
which is shown to be mediated by SMAD4 (He, Dorn et al. 2006). 
Ectodermin, the Xenopus homologue of TIF1γ mediates ectoderm formation during 
embryogenesis. Importantly, ectodermin expression is highly enriched at the blastula 
animal pole, an ectoderm precursor, where it functions to attenuate the mesoderm 
inducing activity of TGF-β during embryogenesis. Indeed injection of ectodermin 
mRNA into developing Xenopus embryos enhances the expression of the ectoderm 
marker SRY (sex determining region Y)-box 2 while also reducing levels of the 
prospective mesoderm markers mix1 and mixer. In this instance ectodermin appears to 
inhibit TGF-β signalling by functioning as a ubiquitin ligase for the TGF-β signal 
transducer SMAD4, as ectodermin knock down reduced the amount of hemagglutinin 
(HA)-ubiquitin SMAD4 conjugates while ectodermin over-expression decreases the 
levels of SMAD4 and increases the formation of HA-ubiquitin SMAD4 conjugates 
(Dupont, Zacchigna et al. 2005). It is thought that ectodermin‟s RING domain is 
important for its ubiquitin ligase activity, as mutation of RING domain residues that 
have previously been shown to inhibit interaction between SMAD ubiquitination 
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regulatory factor 1 (SMURF1) and the ubiquitination machinery (Zhu, Kavsak et al. 
1999), appears to impair ectodermin function. This is demonstrated by over-expression 
of an ectoderm RING domain mutant, which in contrast to the wild type (wt) protein, is 
unable to enhance the formation of HA-ubiquitin SMAD4 conjugates (Dupont, 
Zacchigna et al. 2005). Also injection of mRNA encoding the ectodermin RING mutant 
into developing embryos fails to inhibit mesoderm formation, whereas injection of wt 
ectodermin prevents mesoderm induction (Dupont, Zacchigna et al. 2005). 
Work by Dupont and Piccolo (2005) also reveals that TIF1γ enhances cellular 
proliferation in adult cells by interfering with the TGF-β-SMAD4 antiproliferative axis. 
For instance treatment with TIF1γ siRNA enhances the ability of TGF-β and activin, a 
member of the TGF-β super family, to induce growth arrest. Consistent with this, TIF1γ 
knockdown cells treated with activin display increased expression of p21
CIP1
, which 
crucially mediates the antiproliferative effects of TGF-β (Nicolas and Hill 2003).  
In accordance with its role in enhancing proliferation, aberrant TIF1γ expression 
appears to contribute to tumourigenesis. For instance TIF1γ expression is enriched in 
the nuclei of the proliferating crypt regions of normal colon samples, whereas staining 
of colonic adenomas and adenocarcinomas reveals that TIF1γ becomes 
noncompartmentalized and over expressed. It is thought that TIF1γ promotes 
tumourigenesis by attenuating the TGF-β response in tumour cells, as C32 colorectal 
cancer cells become more sensitive to TGF-β growth arrest following TIF1γ depletion. 
It appears that TIF1γ inhibits growth arrest in these cells through SMAD4 degradation, 
as TIF1γ depletion in SMAD4 null tumour lines has no effect on cell growth (Dupont, 
Zacchigna et al. 2005). 
Although work by He et al. (2006) and Dupont et al. (2005) shares common ground in 
that both studies demonstrate that TIF1γ is involved in regulating TGF-β signalling, the 
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authors differ in the actual mechanism by which TIF1γ achieves this. Dupont et al. 
(2005) argue that TIF1γ attenuates the TGF-β response by targeting SMAD4 for 
degradation. In contrast He et al (2006) dispute that TIF1γ is a SMAD4 ubiquitin ligase, 
as they were unable to demonstrate TIF1γ as an ubiquitin ligase, and maintain that 
TIF1γ doesn‟t actually bind to SMAD4, but instead competes with SMAD4 for binding 
to SMAD2/3 in order to mediate differentiation. Whether one of these models 
dominates remains to seen. 
 
1.9. Aims  
The APC/C is a large multicompoment E3 ubiquitin ligase that mediates cell growth, 
quiescence and progression through mitosis. The APC/C controls the cell cycle through 
its ability to post-translationally modify important cell cycle regulators with 
polyubiquitin chains, resulting in their proteasomal-dependent degradation (Kanayama, 
Tamura et al. 1992; Sudakin, Ganoth et al. 1995; Peters 2002; Skaar and Pagano 2008). 
However, the precise function of individual APC/C subunits remains unclear. Thus in 
order to further explore the subtleties of APC/C regulation and discern the functions of 
individual APC/C subunits the aim of the first part of my study was to identify novel 
APC7 interacting proteins by mass spectrometery. APC7 was chosen due to the 
availability an excellent antibody generated for a previous project in our laboratory and 
also because APC7 is found only in vertebrates (Han, Kim et al. 2008), suggesting 
additional APC/C functions in vertebrates. The second aim of my project was to 
determine the functional role of novel APC7 interacting proteins. 
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2.1. Molecular biology techniques  
2.1.1. Bacterial strains    
     
      Strain                                                              Genotype 
 
BL21-codon Plus (DE3)-RIL              E. coli B Fˉ ompT hsdS (rвˉ mвˉ) dcm
+
 Tet
r
 gal λ  
(Stratagene)                                          (DE3) endA Hte [argU ileY leuW Cam
r
]
 
DH5α                                                   
 
DH5α                                                  supE44, ΔlacU169 (80 lacZΔM15) hsdR17 recA1     
(Invitrogen)                                         end A1 gyrA96 thi-1 rellA1  
 
2.1.2. Media     
Luria Broth (LB): 10g/L bactotryptone (Difco), 5g/L bacto-yeast extract (Difco) and 
10g/L NaCl (pH 7.2), and was sterilised prior to use.  
LB-agar plates: LB was supplemented with 1.5% agar and sterilised. Prior to pouring 
ampicillin was added to a concentration of 100µg/ml.   
 
2.1.3. Antibiotics 
              Ampicillin was made up as a stock solution of 100mg/ml in sterile distilled 
water (SDW); filter sterilised through a 0.2µm filter and stored at 4
o
C.  
 
2.1.4. Enzymes         
              All enzymes were obtained from Roche unless otherwise stated. ABI PRISM
® 
 
BigDye™ Terminator v 3.0 Cycle Sequencing Ready Reaction kit with ampli Taq DNA 
Polymerase was purchased from Applied Biosystems, Perkin Elmer.
   
53 
 
 
2.1.5. Oligonucleotides      
Oligonucleotides were custom synthesised by Alta Biosciences Ltd, The University of 
Birmingham. 
 
2.1.6. Measuring DNA concentration 
DNA was diluted 50 fold in SDW and 50μl was added to a quartz micro-cuvette. The 
absorbance was measured using an Eppendorf photometer at wave lengths of 260 and 
280nm 
 
2.1.7. Transformation of Bacteria 
Transformation of DNA constructs into BL21 and DH5α competent cells was 
performed as follows (DNA constructs are displayed in Table 2.2). The cells were 
initially thawed on ice and 25μl aliquots were then combined with approximately 50ng 
of DNA, and mixed with gentle pipetting. Following incubation on ice for 30 minutes 
samples were heat shocked at 42
o
C for 1 minute and cooled on ice for 5 minutes. After 
addition of 250μl of LB, the transformation mixture was incubated at 37oC for 1 hour at 
220rpm in a shaking incubator.  Cells were then pelleted at 13000rpm for 1 minute, 
resuspended in 100μl of LB broth and spread onto L-agar plates containing ampicillin. 
After drying, the plates were incubated over night at 37
o
C and analysed the next 
morning. 
 
2.1.8. Small scale preparation of DNA 
Plasmid DNA was extracted using a Qiagen miniprep kit as per the instructions supplied 
by the manufacturer. Briefly, a single colony containing the desired plasmid was used to 
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inoculate 5mls of LB broth supplemented with 100µg/ml of ampicillin, and incubated 
overnight at 37
o
C with shaking. Following centrifugation at 3000rpm, cell pellets were 
re-suspended in 250μl of P1 buffer and transferred to a 1.5ml microfuge tube. Cells 
were then lysed for 5 minutes after addition of 250μl P2 buffer. The lysis reaction was 
neutralised by 350μl of buffer N3. After centrifugation at 13000rpm for 10 minutes the 
supernatant was transferred into QIAprep column and adsorbed by centrifugation at 
13000rpm for 1 minute. Following washing with of 750μl of buffer PE and 
centrifugation, the DNA was eluted into a fresh sterilised 1.5ml microfuge tube by 
addition of 50μl of sterilised distilled water (SDW) to the column and subsequent 
centrifugation. The DNA solution was then stored at -20
o
C. 
 
2.1.9. Large scale preparation of DNA 
DNA was purified using a Genelute HP plasmid maxiprep kit (Sigma) following the 
protocol supplied. In short, 10ml of LB containing 100μg/ml of ampicillin was 
inoculated with a single colony of bacteria containing the desired plasmid, and left at 
37
o
C for 9 hours at 220rpm in a shaking incubator. The culture was then used to 
inoculate a 250ml flask of LB containing 100μg/ml of ampicillin, and grown over night 
as per the initial culture. The following morning the cells were pelleted at 6000rpm for 
10 minutes at 4
o
C, and resuspended in 12mls of resuspension solution and lysed by 
mixing with 12mls of lysis solution. The solution was allowed to clear for 3-5 minutes 
and the reaction was stopped by addition of 8mls of neutralisation solution. The 
resulting cell lysis suspension was immediately combined with 9mls of binding solution 
and added to the barrel of a filter syringe and left to stand for 5 minutes. Meanwhile a 
binding column was primed for adsorption of DNA by addition of 12ml of binding 
solution and centrifugation at 3000 x g for 2 minutes. The contents of the syringe filter 
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were then added to the binding column and centrifuged at 3000 x g for 2 minutes. 
Following washing with wash solutions 1 and then 2, DNA was collected by addition of 
3mls of elution solution to the binding column and centrifugation. The DNA was then 
precipitated with 0.7 volumes of room temperature isopropanol and 0.1 volumes of 3M 
Sodium Acetate pH 5.5 at 13000 x g for 30 minutes at 4
 o
C. DNA pellets were washed 
in 70% ethanol, centrifuged as above for 10 minutes, air dried, resuspended in 100-
200μl of SDW and stored at -20 oC.  
 
2.1.10. PCR of gene sequences flanked by restriction sites 
10-100ng of template DNA was mixed with 25pmol of the appropriate forward and 
reverse primers containing the desired restriction sites (see Table 2.1), 5µl of 10X 
buffer, 1µl of  dNTPs (10mM), 1µl of pfu DNA polymerase (2.5 U/µl) (Promega) and 
SDW up to total volume of 50µl. DNA polymerase was added to sample reactions after 
5minutes at 95
o
C in thermal cycler. The reaction solutions were mixed and placed in the 
thermal cycler (GeneAmp PCR Systems 9600) and subjected to the following 
conditions: 1 cycle of 95
o
C for 5 minutes, 55
o
C for 2 minutes, 72
o
C for 2 minutes; 15-
30 cycles of 95
o
C for 1 minute, 55
o
C for 30 seconds, 72
o
C for 1minute/Kb; and 1 cycle 
of 72
o
C for 7 minutes. The resulting DNA products were resolved by agarose gel 
electrophoresis and purified using a Qiagen gel extraction kit as detailed below. 
 
2.1.11. Real time PCR 
16-HBE cells were treated with the appropriate siRNAs as described in section 2.3.2. 3 
days later the cells were either mock treated or stimulated for 2.5 hours with 20ng/ml of 
PMA and 2µM ionomycin in DMEM-HEPES-supplemented with 8% FCS. Next, total 
RNA was purified using an RNAeasy kit (Qiagen) as per the manufacturers instructions. 
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Following elution in 30µl of RNase free water any remaining DNA was digested by 
addition of 3 µl of 10X DNA digestion buffer and 1µl of DNase (Ambion) followed by 
incubation at 37
o
C for 20 minutes. The reaction was quenched by addition of 3µl of 
inactivating reagent (Ambion) and RNA was repurified using an RNAeasy kit (Qiagen) 
following the manufacturers instructions. 
cDNA synthesis was performed using the Promega IMProm-II reverse transcription 
system. Each reaction contained 400ng of RNA template, 4µl of 5X reaction buffer, 
0.5mM dNTPs, 20units of recombinant RNase inhibitor, 1µl of reverse transcriptase, 
1µl of random primer and was made up to 20µl with nuclease free water. The reverse 
transcription reaction was then transferred to a thermal cycler (GeneAmp PCR Systems 
9600) and subjected to a temperature of 25
o
C for 5 minutes followed by incubation at 
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 o
C for 1 hour. The reverse transcriptase was then inactivated at 70
 o
C for 15 minutes 
in preparation for realtime-PCR (RT-PCR). 
The RT-PCR was carried out using 10ng of cDNA and 0.4µM of TNF primers or 2.5ng 
of cDNA and 0.1µM β-actin primers as a normalising control, and 14ul of mastermix 
made up to 20 µl with nuclease free water. Alternatively, a no template control reaction 
was carried out with each primer set. A standard curved was generated using 1ng, 0.5ng, 
0.2ng, 0.05ng and 0.01ng of mock treated control cell cDNA with either 0.4µM TNF 
primers or 0.1µM β-actin primers and 14ul of mastermix again made up to 20µl with 
nuclease free water. Each reaction was carried out in triplicate. The reactions were then 
transferred to an ABI PRisim 7700 sequence detection system and cycled at the 
following conditions: 95
 o
C for 10 minutes, and 40 cycles of 95
 o
C for 15 seconds and 
60
 o
C for 1 minute.  
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Table 2.1 Primers for generating restriction sites flanking coding regions 
 
 
 
 
Gene Primer Sequence  
NF45 Forward 
Reverse 
5‟GTCATGAATTCATGAGGGGTGACAGAGGCCGTGGT 3‟ 
5‟ATTGCCTCGAGTTAGGCTCCAGTCTTTCCCTTGGG 3‟ 
NF90 Forward 
Reverse 
5‟GTCATGAATTCATGCGTCCAATGCGAATTTTTGTGA 3‟ 
5‟GTCATGAATTCTCATGTAGCCTCCATGGTTGGCGCC 3‟ 
NF90 Fragment 1 Forward 
Reverse 
5‟GTCATGAATTCATGCGTCCAATGCGAATTTTTGTGA 3‟ 
5‟GTTACGCGGCCGCATAGGTGGTGCTTGGTGGGATCTG 3‟ 
NF90 Fragment 2 Forward 
Reverse 
5‟GTCATGAATTCGCCATTACGCCCATGAAACGCCCA 3‟ 
5‟GTTACGCGGCCGCTACCACTGGGGCAGGGGCCACCAC 3‟ 
NF90 Fragment 3 Forward 
Reverse 
5‟GTCATGAATTCGAAGCTGTCTCCACCCCTAGTGCG 3‟ 
5‟GTTACGCGGCCGCTCATGTAGCCTCCATGGTTGGCGC 3‟ 
NF90 dsRBM1 Forward 
Reverse 
5‟GTCATGAATTCGCTATGAATGCCCTGATGCGGTTGA 3‟ 
5‟GTTACGCGGCCGCCATGTCCTGTAACACCTTAACGGCC 3‟ 
NF90 dsRBM2 
 
Forward 
Reverse 
5‟GTCATGAATTCAAGAACCCAGTCATGGAGCTGAACG 3‟  
5‟GTTACGCGGCCGCCTTTTCTAGGGCAGCAAGAGCAGCG 3‟ 
TIF1γ Fragment 1 Forward 
Reverse 
5‟GTCATGGATCCATGGCGGAAAACAAAGGCGGCGGC 3‟ 
5‟ATTGCCTCGAGCTGTCTTTCCTTTGTAACATTCTC 3‟ 
TIF1γ Fragment 2 Forward 
Reverse 
5‟GAAATGGATTCATGAAGTTACTACAGCAGCAGAAT 3‟ 
5‟ATTGCCTCGAGCTGATCAGATTTGAAACTAAGACT 3‟ 
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2.1.12. Cloning  
2.1.12.1. Generation of DNA coding regions flanked by restriction sites 
To facilitate cloning, gene sequences with 5‟ and 3‟ flanking restriction sites were 
generated by PCR as described above. Alternatively, coding sequences were excised 
from a vector by restriction enzyme digest for subcloning. 
 
2.1.12.2. Restriction digest  
The digest was carried out for 3 hours at 37
o
C with the appropriate restriction enzymes, 
in a volume of 50μl that contained 500ng-2μg of DNA, 5μl of 10x buffer, and 25 units 
of each restriction enzyme. DNA was then gel purified as detailed below.                       
 
2.1.12.3. Ligation 
The gene of interest was cloned in to pcDNA 3.1 for in vitro transcription/translation 
(IVT) and in vivo over-expression or pGEX 4T-1 in order to generate GST-fusion 
proteins (see Table 2.2 for all constructs made for this study). Ligation reactions were 
incubated at 16
 oC overnight and contained 3μl of 10X buffer, 1 unit of T4 DNA ligase, 
500ng-2μg of digested insert, and 20ng of vector cut with complementary restriction 
enzymes, made up to a total volume of 30μl with SDW. The following day the reactions 
were heated at 65
o
C for 15 minutes then placed on ice for 5 minutes, mixed with 25μl of 
DH5α cells, and transformed as previously described. DNA from the resulting bacterial 
colonies was purified using a Qiagen miniprep kit and sequenced.  
 
2.1.13. Agarose gel Electrophoresis  
Analysis of DNA was performed on agarose gels prepared with 50ml of TBE (100mM 
Tris,100mM boric Acid, 2mM EDTA, pH 8.3), 1% w/v agarose and ethidium bromide 
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was added to a final concentration of 0.5µg/ml. Samples were diluted 1/6 with 6X gel 
buffer [30%v/v of glycerol, 0.25% w/v of bromophenol blue and 0.25% w/v of xylene 
cyanol FF in SDW] and then loaded. Gel electrophoresis was performed in 1X TBE at 
60V for approximately 40 minutes, depending on the size of the DNA to be analysed. 
DNA was visualised by exposure to UV light. 
 
2.1.14. Gel extraction of DNA 
In order to purify DNA generated by PCR or subjected to digestion with restriction 
enzymes, samples were first resolved by agarose gel electrophoresis. The DNA of 
interest was excised and the DNA was purified using QIAquick Gel extraction kit 
(Qiagen) as per the manufactures instructions. 
 
2.1.15. Sequencing  
Sequencing reactions were carried out in order to validate the DNA sequence of coding 
regions generated by PCR. Each reaction was carried out using a kit obtained from ABI 
and consisted of: 1µl of terminator ready reaction mix (Big Dye™ terminator V3.0), 
4µl of 5X buffer, 200ng-500ng of DNA, 5pmol of primer and made up to 20µl with 
SDW (see Table 2.3 for primers used). Reactions were placed in a thermal cycler 
(GeneAmp PCR Systems 9600) for the sequencing reaction. A total of 25 cycles were 
performed using the following conditions: 96
o
C for 10 seconds, 50
o
C for 5 seconds, and 
60
o
C for 4 minutes. The PCR products were precipitated by adding 80µl of 75% v/v 
isopropanol for 30 minutes at room temperature (RT) and pelleted at 13000rpm for 20 
minutes in a centrifuge. The pellet was then rinsed with 200µl of 75% v/v isopropanol 
and centrifuged for a further 5 minutes. The residual isopropanol was removed by air 
drying at a temperature of 90
 o
C. Following addition of 10µl of formamide the mixture 
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was heated for 5 minutes at 95
o
C, quenched on ice, and briefly centrifuged before 
loading on the ABI Prism 337 Automated DNA sequencer (PE Applied Biosystems). 
Sequences were analysed using the NCBI nucleotide-nucleotide BLAST analysis 
obtained online at http://www.ncbi/nlm/nih.org. 
 
Table 2.2. Gene expression constructs used in this study  
Gene Vector Application Source 
NF45 
(aa 1-390) 
pGEX 4T-1 
pcDNA 3.1 
GST-fusion protein production 
In vivo over-expression 
PCR from cDNA 
NF90 
(aa 1-671) 
pGEX 4T-1 
pcDNA 3.1 
GST-fusion protein production 
In vivo over-expression 
PCR from cDNA 
NF90 Fragment 1 
(aa 1-366) 
pGEX 4T-1 GST-fusion protein production PCR from cDNA 
NF90 Fragment 2 
(aa 367-501) 
pGEX 4T-1 GST-fusion protein production PCR from cDNA 
NF90 Fragment 3 
(aa 502-671) 
pGEX 4T-1 GST-fusion protein production PCR from cDNA 
NF90 dsRBM1 
(aa 403-466) 
pGEX 4T-1 GST-fusion protein production PCR from cDNA 
    NF90 dsRBM2 
      (aa 531-592) 
pGEX 4T-1 GST-fusion protein production PCR from cDNA 
TIF1γ Fragment 1 
(aa 1-392) 
pGEX 4T-1 GST-fusion protein production PCR from cDNA 
TIF1γ Fragment 2 
(aa 393-800) 
pGEX 4T-1 GST-fusion protein production PCR from cDNA 
APC5 
(aa 1-755) 
pcDNA 3.1 In vivo over-expression and IVT Dr A Turnell 
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Table 2.3. Primers utilised for sequencing  
 
 
 
2.1.16. Production and purification of GST fusion proteins 
pGEX 4T-1 expression constructs containing the coding sequence of interest down 
stream of a region that encodes glutathione S-transferase (as displayed in Table 2.2), 
were transformed into BL21 cells and plated out as previously described. The following 
day two colonies were used in order to inoculate 20mls of LB broth containing 
100µg/ml of ampicillin, the starter culture was incubated overnight at 37
o
C with shaking 
at 200rpm. This was then used to inoculate 500mls of LB medium in the presence of 
100g/ml ampicillin and grown at 37ºC for 2.5 hours with shaking at 200rpm. Once the 
bacteria had reached an appropriate density (A600 = 0.6-0.8), the culture was cooled to 
30
o
C and incubated for further 3 hours in the presence of 0.02% w/v isopropyl β-D-1-
APC7 
(aa 1-565) 
pcDNA 3.1 In vivo over-expression and IVT Dr A Turnell 
ΔAPC7 
(aa 1-146-433-565) 
pcDNA 3.1 In vivo over-expression Dr A Turnell 
Primer Sequence 
     pcDNA3 forward 5‟ACTCACTATAGGGAGACCCAAGC 3‟ 
     pcDNA3 reverse 5‟GCAACTAGAAGACACAGTCGAGG 3‟ 
pGEX4T1 forward 5‟GGGCTGGCAAGCCACGTTTGGTG 3‟ 
pGEX4T1 reverse 5‟CCGGGAGCTGCATGTGTCAGAGG 3‟ 
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thiogalactopyranoside (IPTG) (Sigma). The bacterial cells were then pelleted at 
6000rpm for 10 minutes at 4
o
C and stored at -80
o
C.  
In order to purify the GST-fusion proteins, the bacterial cell pellet was lysed in 20mls of 
lysis buffer containing 1X PBS, 1mM EDTA (pH 8) and 1% v/v Triton X-100. The 
lysate was then sonicated 3 times on ice for 45 seconds, at two minute intervals. The 
lysate was then centrifuge for 20 minutes at 20000rpm at 4
o
C, the resulting supernatant 
was transferred to a fresh tube and centrifuged again as before. The supernatant was 
then mixed with 2mls of a solution containing 1:1 lysis buffer and glutathione-agarose 
beads, and rotated at 4
o
C for 2 hours. The beads were then centrifuged at 3000rpm and 
washed in lysis buffer 3 times and twice with wash buffer (1X PBS and 1mM EDTA 
pH 8.0). In order to elute the GST-fusion proteins, the glutathione-agarose beads were 
incubated with 2ml of 20mM glutathione and 50mM Tris solution pH 8.0 again at 4
o
C 
for 2 hours with rotation. Following centrifugation the supernatant containing eluted 
GST-fusion protein was transferred to dialysis tubing, which was previously hydrated in 
a warm solution of 3% NaHCO3, 2mM EDTA pH 8.0 for 20 minutes to chelate metal 
ions. This was followed by overnight dialysis at 4
o
C in 2L of 25mM Tris pH 8.0, 
100mM NaCl, 1mM dithiothreitol (DTT) (Sigma) and 10% v/v glycerol. The dialysed 
GST-fusion protein was transferred to a new tube and its protein concentration was 
determined by Bradford assay and quantified against a standard curve. The purity of the 
proteins was assessed by SDS-PAGE electrophoresis and Coomassie blue staining. The 
protein was stored in aliquots at −80oC.  
 
2.1.17. In vitro transcription/translation (IVT)   
Eukaryotic in vitro translation was carried out using a Promega TNT T7/SP6 coupled 
rabbit reticulocyte or wheat germ lysate system as per the manufacturer‟s instructions. 
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Briefly the reaction consisted of 25µl reticulocyte or wheat germ lysate, 2µl reaction 
buffer, 1µl T7 or SP6 RNA polymerase, 1µl of 1mM amino acid mixture minus 
methionine, 2µl of [35S]-methionine (1000Ci/mmol at 10mCi/ml; Amersham 
Biosciences). 0.5µl RNasin ribonuclease inhibitor (40U/µl), 1µg DNA template and 
nuclease free water to a final volume of 50µl. The reaction was incubated at 30
o
C for 90 
minutes, centrifuged and then stored at -80
o
C.  
 
2.1.18. Luciferase reporter gene assays 
Typically, 0.5-2µg of the relevant DNA constructs were transfected into HCT116 cells 
using Lipofectamine 2000 according to manufacturer‟s instructions (see Table 2.2 for 
the expression constructs used). The total amount of DNA added was kept equal by 
adding „empty‟ pcDNA3.1 vector to all transfected cells. After 48 hours the cells were 
washed twice in cold saline and lysed in 400µl of lysis reagent for 30 minutes at RT. 
Cell debris was then pelleted by centrifugation at 13000rpm for 5 minutes. 20µl 
samples, of equivalent protein concentration, were mixed with 100µl of luciferase assay 
reagent. Light emission was measured immediately using a Berthold luminometer. Cell 
lysis and luciferase reagents were purchased from Promega.  
 
2.2. Tissue culture techniques 
2.2.1. Tissue culture media and solutions  
All tissue culture reagents were presterilised and purchased from Invitrogen unless 
otherwise stated. All reagents were stored at 4
o
C and pre-warmed to 37
o
C unless 
otherwise specified. Cell lines were maintained in Roswell Park Memorial Institute 
1640 medium (RPMI-1640), or Dulbecco‟s Modified Eagle‟s HEPES buffered Medium 
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(DMEM-HEPES) supplemented with 2mM L-glutamine. Before use, all media were 
supplemented with 8% foetal calf serum (FCS) unless otherwise stated.  
 
2.2.2. Maintenance of cell cultures     
Cells were grown in humidified incubators in a 95% air and 5% carbon dioxide 
environment at 37
o
C. Adherent cell lines were maintained in DMEM-HEPES. To 
subculture adherent cells, medium was removed when cells reached confluency, and the 
cells were then washed twice in PBS. 1ml of trypsin solution was added to the cells, 
which were then incubated at 37
o
C as necessary. Detachment of the adherent cells was 
confirmed by microscopy, after which cells were washed with media containing FCS to 
inactivate the trypsin and centrifuged for 4 minutes at 1400 rpm. The cells were re-
suspended in DMEM-HEPES complete media and re-plated to the required density. 
Suspension cells were grown in 75cm
2
 tissue culture flasks and were subcultured by 
removing 50% of the cell culture volume and mixing 1:1 with RPMI-1640.  
 
2.2.3. Cell lines  
The cells used in this study, are summarized in Table 2.4 
 
Table 2.4. Human cell lines used in this study 
Name Description ATCC number 
HCT116 Colon carcinoma cell line expressing wt p53 CCL -247 
16HBE Bronchial epithelial cells expressing SV40 large T-
antigen 
Gift from Dr C Stellato 
A549 Small cell lung carcinoma cell line CCL -185 
Jurkat T- Thymus cells expressing SV40 large T-antigen TIB-152 
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cells 
HeLa Cervical carcinoma cell line expressing  human 
papilloma virus (HPV-18) 
CCL-2.2 
 
 
2.2.4. Cryopreservation of cells 
Cells were trypsinised, pelleted by centrifugation at 1400 rpm for 4 minutes. Each 
confluent plate was divided into 5 aliquots and each aliquot re-suspended in 1ml of cold 
DMEM-HEPES complete with 10% v/v dimethyl-sulphoxide (DMSO). The cells were 
stored in sterile ampoules, and placed in the neck of liquid nitrogen containers or in 
freezing boxes at −80oC over night, allowing cooling at a controlled rate of 1oC/minute. 
The ampoules were then transferred to liquid nitrogen storage tanks.  
 
2.2.5. Recovery of cells from liquid nitrogen  
To recover cells from nitrogen, cell suspensions were thawed quickly in a 37
o
C 
waterbath followed by immediate dropwise transfer to a centrifuge tube containing 
10ml of culture medium. The cells were then pelleted at 1400rpm and re-suspended in 
the appropriate fresh culture medium and re-plated and incubated at 37
o
C.  
 
2.2.6. Nocodazole release  
A549 cells were grown to 90% confluence and incubated at 37
o
C overnight with 
DMEM-HEPES supplemented with 8% FCS and nocodazole at a concentration of 
1µg/ml. Mitotic cells were then harvested by shakeoff and washed twice in DMEM-
HEPES containing 8%FCS. After resuspension in DMEM-HEPES containing 8%FCS 
the cells were then plated out and harvested at the appropriate time.  
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2.3. Cell Biology Techniques  
 
2.3.1. Transient transfection of mammalian cells using Lipofectamine 2000 
Twenty four hours prior to transfection HCT116 cells were plated onto a 6cm tissue 
culture dish and incubated at 37ºC in a CO2 incubator until the cells were 90% 
confluent. Transfection solution was prepared by incubating 10 µl of Lipofectamine 
2000 transfection reagent (Invitrogen) with 90µl of serum-free DMEM-HEPES, for five 
minutes at room temperature. 1-2µg of plasmid DNA was diluted into 100µl of serum 
free DMEM-HEPES medium. Then the transfection reagent and DNA mixture were 
combined, mixed gently and incubated at room temperature for 30 minutes to allow 
DNA-liposome complexes to form. Meanwhile, cultured cells were washed with 2mls 
of DMEM-HEPES. For each transfection, 3.8mls of DMEM-HEPES containing 8% 
FCS was added into the transfection mixture and overlaid onto the rinsed cells. The 
cells were then incubated with the transfection mixture at 37ºC. Transfected cells were 
harvested at appropriate time after transfection and assayed for protein expression or 
reporter gene activity. The DNA plasmids used for transfection in this study are listed in 
Table 2.2. 
 
2.3.2. Transient down regulation of gene expression by small interfering RNAs  
Purified, annealed double stranded 21-mer RNA oligonucleotides, with dTdT overhangs 
were custom synthesised by Ambion and predesigned non-silencing control siRNA was 
also purchased from Ambion (all siRNAs used are displayed in Table 2.5). 8µl of the 
desired siRNA (40μM) was mixed with 20µl of Oligofectamine (Invitrogen) in 972µl of 
Optimem medium and left for 30 minutes. 1ml of the siRNA solution was added to 
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HeLa cells grown to 35% confluence on 6cm tissue culture dishes and washed twice 
with 4mls of Optimem medium. The following day 3mls of DMEM-HEPES 
supplemented with 12% FCS was added to each dish. Cells were typically harvested 60 
hours post transfection.   
 
Table 2.5. siRNAs used in this study 
 
2.3.3. Flow cytometric analysis  
Flow cytometry was used to asses the cell cycle distribution of HeLa cells transfected 
with non-silencing and TIF1γ-specific siRNA, which are displayed in Table 2.5. Cells 
were harvested by trypsinisation 72 hours after transfection, washed twice with ice- cold 
PBS and resuspended in 3ml of PBS. Cells were fixed by adding 7mls of ice-cold 
ethanol whilst vortexing to avoid cell clumping and stored at -20 ºC. 
On the day of analysis cells were pelleted at 1600rpm for 5 minutes and washed in PBS 
twice, permeabilised in ice cold PBS with 0.25% Triton X-100 for 15 minutes. After 
washing with 10mls of PBS with 1% BSA, cells were incubated with 100μl 1% w/v 
BSA containing an anti-phosphohistone H3 (Ser10) polyclonal antibody for 1.5 hours at 
room temperature. Samples were then washed twice with 1ml of 1% w/v BSA in PBS 
and resuspended in 100μl 1% w/v BSA in PBS containing fluorescein isothiocyanate 
Target protein siRNA Sense sequence 
Non-silencing Negative Control #1 siRNA Proprietary  
NF45 NF45 5‟GCACCUGAUGAAACUUCCUtt 3‟ 
NF90 NF90 5‟CGGGAAGAUAUCACACAGAtt 3‟ 
TIF1γ TIF1γ_1 5‟CCUGCAUCUAGAAAGUGAAtt 3‟ 
TIF1γ TIF1γ_2 5‟GCGACUGAUUACUUUCCAGtt 3‟ 
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(FITC)-conjugated-anti-Rabbit antibody, and left in a light resistant container for 30 
minutes (antibody dilutions used for this procedure are displayed in Table 2.6). After 
washing with 1ml of PBS with 1% w/v BSA and then 1ml of PBS, cells were 
resuspended in 1 ml of PBS containing propidium iodide (25μg/ml) and 0.1mg/ml of 
RNAse A, and left at RT in a light resistant container for a further 30 minutes. Cell 
cycle analysis was carried out using a Coulter XL-MCL flow cytometer (Beckman-
Coulter).  
 
2.4. Protein chemistry techniques 
2.4.1. Preparation of cultured adherent cell samples for protein analysis by 
Western blot analysis  
Tissue culture medium was removed and cells were washed twice in 5ml of cold 0.9% 
saline. Cells were lysed in buffer containing 9M urea, 50mM Tris (pH 7.3) and 0.15M 
β-mercaptoethanol. After incubation at 4oC for 15 minutes with gently rocking, cells 
were detached from the tissue culture dish with a plastic scraper. Harvested cells were 
sonicated for 10sec on ice and clarified by centrifugation at 13000 rpm for 20 minutes at 
4
o
C. The supernatant was transferred to a fresh centrifuge tube for protein determination 
or storage at −80ºC. 
 
2.4.2. Protein determination by Bradford assay 
A small volume (2-10µl) of the protein sample was carefully diluted and mixed with 
1ml of Bradford reagent (BioRad). After 15 minutes the absorbance was measured in a 
spectrophotometer at λ 595 nm against the distilled water blank. Protein concentrations 
were determined by comparison with a standard calibration curve prepared from known 
quantities of bovine serum albumin (0-10µg). 
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2.4.3. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)     
Immunoprecipitates, GST pull-down samples or 50µg of whole cell lysates were 
electrophoresed on 12% polyacrylamide gels that included ultra pure Biorad acrylamide 
solution (30% w/v acrylamide, 0.8% N, N-bis acrylamide), 0.1M Tris,0.1M bicine (N, 
N-bis [2-hydroxy-ethyl-glycine]) pH 8.3, 0.1% w/v SDS and 0.3% v/v TEMED (N, N, 
N‟, N‟-tetramethyl-ethylenediamine) in a total volume of 50ml. After the addition of 
300µl of 10% ammonium persulfate solution (APS), the gel was poured into the 
apparatus (Hoefer) and left to polymerise. A well-forming comb was inserted into the 
gel before polymerisation occurred. Once the gel had set the comb was removed, the 
wells rinsed with distilled water and immersed in running buffer (0.1M bicine, 0.1M 
Tris pH 8.3, 0.1% w/v SDS). Samples were diluted in an equal volume of Laemmli 
sample buffer (25% v/v glycerol, 62.5mM Tris pH 6.8, 5% β-mercaptoethanol, 2% w/v 
SDS and 0.01% w/v bromophenol blue), boiled for 5minutes and applied to the gel. Pre-
stained molecular weight markers were also applied to the gel. The samples were 
typically electrophoresed overnight, at 12mA in running buffer.  
 
2.4.4. Staining of polyacrylamide gels 
After electrophoresis, gels were stained in 0.1% w/v Coomassie brilliant blue R-250 
(Sigma) in methanol/glacial acetic acid/water (3:1:6 v/v) on a shaker for 20 minutes at 
room temperature, and subsequently destained in methanol/glacial acetic acid/water ( 
3:1:6 v/v) as required. 
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2.4.5. Staining of proteins on nitrocellulose membranes 
 To evaluate even loading and efficient transfer of proteins after electroblotting, 
nitrocellulose filters were stained with Ponceau S stain (0.1% w/v Ponceau S (Sigma) 
and 3% v/v trichloroacetic acid (TCA)) for a few minutes. After visualization of protein 
bands, the dye on the membrane was washed off with distilled water and the proteins on 
it were subjected to immunoblot analysis. 
 
2.4.6. Detection of radioactive proteins on gels 
Following electrophoresis, gels were stained with Coomassie blue as previously 
described. The gel was then soaked in the Amplify™ reagent (Amersham Bioscience) 
for 2 hours with agitation. Amplify™ reduces exposure times for gels containing [35S]-
labelled samples. The gel was dried under vacuum at 80ºC for 1 hour and exposed for 
autoradiography at −20ºC. 
 
2.4.7. GST-pulldown 
The binding capacity of [
35
S]-labelled APC5 and APC7 for GST-NF45, GST-NF90 and 
various GST-NF90 fragments was assayed by GST-pulldown. Typically, 20µg of GST-
fusion protein was incubated with 20µl of [
35
S]-labelled protein on ice for 1 hour. 
Volumes were then equalised by addition of low salt buffer (50mM Tris pH 7.4, 0.15M 
NaCl and 1% NP-40), and protein complexes were isolated by incubation with 20µl 
glutathione-agarose beads for 1 hour with rotation at 4
o
C. Beads were then washed with 
1ml of low salt buffer 3 times. GST-protein complexes were then eluted with 80µl of 
buffer containing 20mM glutathione and 50mM Tris pH 8.0. Lastly the eluate was 
mixed with Laemmli sample buffer and boiled for 5 minutes in preparation for SDS-
PAGE.  
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2.4.7.1. Treatment of GST-pulldowns with RNase V1  
Prior to elution as described above, glutathione-agarose beads were washed twice with 
RNase V1 digestion buffer (Ambion) and resuspended in the 30 µl of the same buffer 
containing 6U of RNase V1 (Ambion). The samples were then incubated at 37°C for 25 
minutes and the glutathione-agarose beads containing the still bound proteins were 
centrifuged and washed twice in 500µl of low salt buffer.     
 
2.4.8. In-gel digestion of proteins for analysis by mass spectrometry 
Following Coomassie staining, protein bands of interest were excised with a sterile 
scalpel and placed in a sterile 1.5ml microfuge tube and washed twice in 400µl of wash 
solution 1 (50% v/v acetonitrile and 50mM ammonium bicarbonate) for 45 minutes at 
37
o
C on a shaker. After removal of the wash buffer the gel slices were dried in a DNA-
Mini vacuum centrifuge for 30 minutes. The gel slice was then treated with 250µl of 
reduction solution (10% v/v acetonitrile, 50mM ammonium bicarbonate and 50mM 
DTT) at 56
o
C in a water bath for 1 hour. The supernatant was then removed and 
replaced with alkylating solution (10% v/v acetonitrile, 50mM ammonium bicarbonate 
and 200mM iodoacetamide) and left for 30 minutes at room temperature in total 
darkness. After 3 washes with 500µl of wash buffer 2 (10% v/v acetonitrile and 40mM 
ammonium bicarbonate) at room temperature for 15 minutes, the gel slice was dried in 
DNA-Mini vacuum centrifuge for 1hour. In order to digest any fixed proteins the gel 
slice was re-hydrated with 20µl of 12.5µg/ml modified trypsin (Sigma) in wash buffer 2 
at room temperature for 1 hour. In order to immerse the gel slice, a further 20µl of wash 
buffer 2 was added and the sample was incubated overnight with shaking at 37
o
C. The 
next day the supernatant was removed and stored in a 1.5ml eppendorf tube. The gel 
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slice was then twice incubated with 25µl of 50% acetonitrile and 0.1% formic acid for 
30 minutes at 37
o
C with shaking. Following centrifugation the supernatant was removed 
and pooled with the tryptic supernatant from the previous step and stored at -20
o
C until 
mass spectrometric analysis.  
 
2.5. Immunological techniques   
 
2.5.1. Antibodies 
 All antibodies utilised in this study, including their application, dilution, species and 
source are displayed in Table 2.6. 
 
 
Table 2.6. Antibodies used in this study   
 
Antibody Antigen Application Dilution Species Source 
TIF178 TIF1γ WB 1:500 Rabbit Made in 
conjunction 
with 
Eurogentec 
TIF198 TIF1γ WB 
IP 
1:500 
1:10 
Rabbit Made in 
conjunction 
with 
Eurogentec 
αNF45 NF45 WB 
IP 
1:1000 
1:25 
Rabbit Prof P Kao 
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αNF90 NF90 WB 
IP 
1:1000 
1:25 
Rabbit Prof P Kao 
DRBP76 NF90 ChIP 1:20 Mouse BD 
Transduction 
Labs 
AF3.1 
 
APC3 IF 
IP 
1:500 
1:25 
Mouse CRUK 
#4 APC5 WB 
IP 
ChIP 
1:2000 
1:25 
1:160 
Mouse Dr A Turnell 
#33 APC5 ChIP 1:160 Mouse Dr A Turnell 
197 APC7 WB 
IP 
ChIP 
1:1000 
1:25 
1:160 
Rabbit Dr A Turnell 
198 APC7 ChIP 1:160 Rabbit Dr A Turnell 
B-5-1-2 α-
Tubulin 
IF 1:5000 Mouse Sigma 
Phospho-
histone H3 
(ser10) 
Phospho-
histone 
H3 
(ser10) 
IF 
FACs 
1:1000 
1:100 
Rabbit Cell 
signalling 
Anti-Mouse-
HRP 
Mouse 
IgG 
WB 1:1000 Goat 
DAKO 
Anti-Rabbit- 
HRP 
Rabbit 
IgG 
WB 1:2000 Swine 
DAKO 
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Alexa 
fluor® 488 
anti-Rabbit 
Rabbit 
IgG 
FACs 1:50 Donkey 
Invitrogen 
Alexa 
fluor® 546 
anti-Rabbit 
Rabbit 
IgG 
IF 1:1000 Goat 
Invitrogen 
Alexa 
fluor® 488 
anti-Mouse 
Mouse 
IgG 
IF 1:1000 Goat 
Invitrogen 
Anti-FLAG 
M2 
FLAG WB 1:1000 Mouse 
Sigma 
 
2.5.2. Western blotting   
Following electrophoresis, cell lysates were electrophoretically transferred to a 
nitrocellulose membrane. A blotting cassette was set up containing a piece of 
nitrocellulose membrane pre-soaked in blotting buffer (0.05M Tris, 0.19M glycine and 
20% v/v methanol). The membrane was placed onto a sheet of 3MM Whatman filter 
paper on a blotting pad and then the gel was placed onto nitrocellulose membrane. The 
gel was then overlaid with another sheet of pre-soaked 3MM Whatman filter paper and 
a second blotting pad. The blotting cassette was placed in a Hoefer transblot 
electrophoresis apparatus that was filled with blotting buffer with the nitrocellulose 
facing the anode. Blotting was carried out for 6-7 hours at 34 volts. After transfer, the 
membrane was stained with Ponceau S stain as previously described, in order to 
visualise the transferred proteins. The membrane was then washed for 10 minutes in 
Tris-buffered saline with Tween 20 (TBS-T) (0.1% v/v Tween™ 20, 8g/L Sodium 
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Chloride and 0.02M Tris pH 7.6) to remove the Ponceau S stain. The nitrocellulose 
membrane was incubated on an orbital shaker for 1 hour at room temperature in 
blocking agent (5% w/v skimmed dried milk, in PBS) to block non-specific binding 
sites. Primary antibodies were diluted in TBS-T with 5% w/v skimmed milk, and added 
to the blots in polythene bags, which were heat sealed and incubated for 2 hours at room 
temperature or overnight at 4ºC on a rocking platform. The membrane was rinsed and 
washed with 3 X 10 minute washes in TBS-T. Blots were then incubated with the 
appropriate secondary antibody conjugated to horseradish peroxidise, which was diluted 
in TBS-T with 5% w/v skimmed milk and incubated for 2h at room temperature with 
gentle agitation. After a further five 15 minute washes in TBS-T the antigen-antibody 
complex was visualised using the enhanced chemiluminescence (ECL) detection 
reagent (Amersham). The membranes were soaked in 1:1 mixture of ECL detection 
solution for one minute. The membranes were wrapped, protein side up, in a Saran wrap 
sheet and exposed to X-ray film for an appropriate period of time. Exposure times, 
ranging from a few seconds to 5 minutes were used, depending on the protein being 
detected or primary antibody.  
 
2.5.3. Immunoprecipitation  
Cells were lysed for 15 minutes at 4
o
C in 0.5mls of immunoprecipitation (IP) buffer 
containing 50mM Tris pH 7.4, 0.825M NaCl and 1% v/v NP-40. Alternatively cells 
were lysed in NETN buffer (50mM Tris [pH 7.5], 150mM NaCl, 0.5mM EDTA,
 
and 
0.5% v/v NP40). Cell lysates were centrifuged at 35,000 rpm for 20 minutes at 4
o
C. 
Protein complexes were then immunoprecipitated by adding an appropriate antibody, 
typically 20µg, and mixed by rotation for two hours at 4
o
C. The resulting protein-
antibody complexes were then mixed for a further hour with 20µl of packed protein G 
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agarose beads (Sigma). Immunocomplexes bound to the beads were then spun and 
washed three times with 1ml of the relevant IP buffer, prior to resuspending in Laemmli 
sample buffer and boiling for 5 minutes in preparation for SDS-PAGE.  
 
2.5.4. Immunofluorescence 
Cells were grown on 12-well glass slides to densities of around 1-2 x 10
4
cells/well. 
Slides were washed twice in PBS, fixed in 4% w/v paraformaldehyde in PBS for 8 
minutes and washed again in PBS. Acetone extraction was then carried out for 15 
minutes at -20
o
C. Cells were rehydrated in PBS and blocked in 10% FCS in PBS for 1 
hour. Primary antibodies were diluted to the appropriate concentration in 0.1% FCS in 
PBS, and were incubated with the cells for 2 hours. Cells were then incubated with 
secondary antibody diluted in 0.1% FCS in PBS for 1 hour in a light shielded container. 
Slides were then washed three times in PBS, before being mounted in Vectashield 
Mounting Medium (Vector Laboratories) containing 4‟,6-diamidino-2-phenylindole 
(DAPI), and protected with glass coverslips. Cells were viewed on a Zeiss Axioskop 
microscope, and z-Layer images (0.2-µm horizontal sections) were recorded with 
Openlab v3.0.9 Biovision software package (Improvision). Single, equivalent z-layers 
were merged to show colocalisation. 
 
2.5.5. Analysis of the mitotic distribution by immunofluorescence microscopy 
following RNAi  
Two days post siRNA treatment as previously described, cells were trypsinised and 
plated on to poly-L-Lysine treated 12 well slides so that they reached a density of 
around 1-2 x 10
4
cells/well the following day, at which point slides were fixed in 100% 
methanol at -20
o
C for 8 minutes. Following fixation slides were washed in PBS three 
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times and blocked in 10% FCS in PBS for 1 hour. Slides were then washed in PBS and 
each well was incubated with α-tubulin and phospho-histone H3 antibodies in 50µl of 
PBS containing 2% FCS for 1 hour. Next, the slides were washed with PBS three times; 
each well was then incubated with 50µl of 2% FCS in PBS containing the appropriate 
secondary antibodies for 1 hour in a light proof container. Slides were then washed 
three times in PBS, before being mounted in Vectashield Mounting Medium (Vector 
Laboratories) containing DAPI, and protected with glass coverslips. Cells were viewed 
on a Nikon eclipse E600 and images were processed with the associated software.         
 
2.5.6. Chromatin immunoprecipitation (ChIP)     
In order to identify factors that bind to the IL-2 promoter in Jurkat T-cells, ChIP assays 
were performed as follows. Four million Jurkat T-cells in RPMI-1640 were either mock 
treated or stimulated with 20ng/ml of PMA and 2µM ionomycin for 6 hours at 37
o
C. 
DNA was then crosslinked to any associated proteins by addition of 1% w/v 
formaldehyde and incubation at 37
 o
C for 10 minutes. The cells were then pelleted at 
1000rpm, washed twice in PBS, resuspended in 400μl of lysis buffer (50mM HEPES 
pH7.5, 140mM NaCl, 1% v/v Triton X-100 and 1mM EDTA) and left on ice for 4 
hours. Lysates were sonicated 3 times on ice at 1 minute intervals in order to shear the 
DNA to approximately 500 base pairs. Addition of 100units of EcoRI and HindIII, and 
45µl of 10X NEB buffer 2 and overnight incubation at 37
o
C completed DNA 
fragmentation. Next 30µl was removed from each sample for use as an input control and 
stored at -20
 o
C. Lysates were centrifuged at 2500rpm for 1 minute and pre-cleared with 
20µl of protein A-Sepharose for 2 hours at 4
o
C with rotation. After centrifugation at 
2500rpm for 1 minute the supernatant was removed and incubated overnight with the 
appropriate antibodies at 4
o
C with rotation (see Table 2.6). The following day  
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immunocomplexes were precipitated by addition of 60µl of protein A-Sepharose and 
rotation at 4
o
C overnight. Beads were then washed with 500µl wash buffer 1 
(50mMTris pH7.5, 500mM NaCl, 0.1%NP-40), 500µl wash buffer 2(50mMTris 
pH7.5, 0.1% NP-40) and 500µl TE buffer (20mM Tris pH8.0, 1mM EDTA). 
Protein-DNA complexes were eluted overnight at 65
o
C in 200 µl of extraction buffer 
(1%SDS in TE), and incubated with 100µg of proteinase K at 50
o
C for 1 hour. The 
DNA was recovered with a Qiagen PCR purification Kit as per the manufacturers 
instructions and eluted in 50µl of water. DNA was isolated form the input sample by 
mixing 30µl of the DNA solution with 80µl of extraction buffer and heating overnight 
at 65
o
C, incubating with 50µg of proteinase K at 50
o
C for 1 hour and recovered with a 
Qiagen PCR purification Kit and eluted in 30µl of water.  
PCR was carried out using FastStart Taq DNA polymerase and primers for 
amplification of the IL-2 promoter, which are displayed in Table 2.7. Briefly 8µl of 
DNA derived from ChIP was added to a reaction mix containing 2.5 µl of 10X PCR 
reaction buffer containing MgCl2, 0.5 µl of dNTPs (10mM), 1µl of 5pmol/µl of forward 
and reverse primers, 5µl of GC-rich solution, 0.2µl of FastStart Taq DNA polymerase 
and 8.8µl of SDW. Cycling conditions were as follows: initial denaturation at 95
 o
C for 
4minutes, followed by 35 cycles of denaturation at 95
 o
C for 30s, annealing at 59
o
C for 
30s, and extension at 72
 o
C for 45s, and a final extension at 72
 o
C for 7 minutes. PCR 
products were visualised by running the entire reaction volume on an agarose gel 
containing ethidium bromide.  
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Table 2.7. IL-2 promoter primers used for PCR analysis of immunoprecipitated 
chromatin 
 
2.5.7. Ubiquitylation assay 
A549 cells were washed in cold saline twice, lysed in APC/C lysis buffer (20mM Tris 
pH 7.5, 100mM NaCl, 20mM β-glycerophosphate, 5mM MgCl2, 1mM NaF, 0.2% NP-
40, 10% glycerol, 0.5mM DTT) for 20mins and centrifuged at 35,000 rpm for 20 
minutes at 4
o
C. Lysates were then incubated with 20µg of anti-APC3 antibody for 2 
hours with rotation at 4
o
C. The resulting protein-antibody complexes were then mixed 
for a further hour with 20µl of packed protein G agarose beads (Sigma). 
Immunocomplexes bound to the beads were then spun and washed three times with 1ml 
of APC/C lysis buffer. The ligase reaction was carried in a total of 10µl, containing 4µl 
of protein G agarose beads (Sigma) with bound APC3 and 50mM Tris (pH 7.5), 2mM 
MgCl2, 2mM ATP, 15mM creatine phosphate, 350U/ml of creatine phosphokinase, 
15μg/ml ubiquitin aldehyde, 80μg/ml rabbit E1 (Biomol), 50μgml of E2 enzymes 
UBC4, UBC5 and UBCH10, and either [35S]-cyclin A or [35S]-cyclin B. The reactions 
were incubated at 37
 o
C for 30 minutes before addition of Laemmli sample buffer and 
then boiled for 5 minutes in preparation for SDS-PAGE.  
Promoter Primer Sequence 
IL-2 Forward   
Reverse 
–317 5‟GAGTTACTTTTGTATCCCCACCCCC 3‟–292 
   33
 5‟CCTGTACATTGTGGCAGGAGTTGAGG 3‟58 
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2.6. Statistical tests  
A two tailed T-test was used to determine the statistical significance of all bar charts in 
this manuscript. The T-test is used to determine whether the difference between two 
means is significant. The test equation is displayed below; x-bar, mean. 
σ
d, the standard 
deviation of the difference between the means. 
 
T= x-bar
1
-x-bar
2 
                     σ
d 
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CHAPTER 3 
 
 
 
 
 
MASS SPECTROMETRIC ANALYSIS OF APC7 
IMMUNOPRECIPITATES 
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3.1. Introduction 
The APC/C is a multi-component E3 ubiquitin ligase that mediates ubiquitylation of 
proteins in order to elicit their degradation by the 26S proteasome (Kanayama, Tamura 
et al. 1992; Sudakin, Ganoth et al. 1995). The APC/C coordinates temporal progression 
through the cell cycle in conjunction with its coactivators CDC20 and CDH1 (van 
Leuken, Clijsters et al. 2008) (refer to section 1.5 for an overview of the APC/C).  
Although the mechanisms underlying APC/C action are largely understood, little is 
known about how APC/C activity is modulated or how individual subunits contribute to 
APC/C function. Therefore, I decided to identify novel APC7 binding proteins using a 
mass spectrometry approach, in the hope that further study of APC7 and its binding 
partners may give new insight into the subtleties of APC/C regulation and function. 
 
3.2. Results 
 
3.2.1. Mass spectrometric determination APC7 immunoprecipitates 
In order to determine novel APC7 binding proteins by mass spectrometric analysis, I 
initially performed an IP from A549 cells using an anti-APC7 polyclonal antibody. The 
APC7 antibody was generated using full length APC7. Given that this APC7 polyclonal 
antibody should recognise multiple APC7 epitopes it seems likely that this antibody is 
capable of immunoprecipitating all APC7 interacting proteins. Bound proteins were 
eluted, separated by SDS-PAGE and protein bands were detected by Coomassie R250 
blue staining (Fig. 3.1). Individual protein bands were then excised and digested with 
modified trypsin. The resulting peptides were separated by high-performance liquid 
chromatography (HPLC) and analysed using an electrospray ioniser (ESI) coupled to 
tandem array mass spectrometery (MS/MS). It should be noted that mass spectrometric  
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data, like other methods of identifying protein-protein interactions is not entirely 
definitive and therefore any novel interactions identified must be corroborated by more 
traditional means such as co-IP and/or GST-pulldown. The results presented in this 
chapter were obtained over a number of separate experiments and a great deal of work 
went into the optimisation of the protocol as the departmental mass spectrometry 
facility was at this time in its infancy. In particular a number of gel staining methods 
were examined and steps to minimise false positives generated by non-specific binding 
were also investigated. 
 
3.2.2. Detection of known APC7 binding proteins by mass spectrometric analysis 
The initial objective was to demonstrate the efficacy of the mass spectrometer by 
identifying peptides from APC7, and other APC/C components and interacting proteins. 
The data obtained confirmed the presence of six APC7 peptides (Fig. 3.2) and resulted 
in detection of five peptides from APC8 (Fig. 3.3), three peptides from APC6 (Fig. 3.4), 
and five peptides from APC3 (Fig 3.5). Also four peptides were detected from the E2 
ubiquitin conjugating enzyme UBCH10, a protein that is essential for the E3 ubiquitin 
ligase function of the APC/C (Hershko, Ganoth et al. 1994). Taken together these 
results provide overwhelming evidence to support the validity of this technique and its 
potential to identify novel APC7-interacting proteins.  
 
3.2.3. Detection of novel APC7 binding proteins by mass spectrometric analysis 
Interestingly peptides from six proteins previously unknown to bind to APC7 were also 
detected (Table 3.1 summarises the data obtained in this chapter), however the mass 
spectrometer generally identified fewer peptides from these novel interacting proteins 
when compared to known APC7 binding proteins. This may suggest that these novel  
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Table 3.1. Summary of APC7 interacting proteins identified by mass spectrometric 
analysis 
 
 
 
 
 
 
APC/C components and 
known interacting proteins 
Number of peptides Coverage of protein 
APC7 6 8% 
APC3 5 5.8% 
APC6 3 5.6% 
APC8 5 9% 
UBCH0 4 23.5% 
Novel APC7 interacting 
proteins  
  
NF45 3 9.5% 
TIF1 2 3.3% 
eEF1A 2 4.3% 
CEP290 2 1% 
Ku70 3 8% 
TLS 3 7.4% 
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APC7 interacting proteins are present in sub-stoichiometric amounts, binding to only a 
fraction of the total cellular pool of APC7.  
 
3.2.3.1. Detection of Nuclear Factor 45 (NF45) peptides in APC7 
immunoprecipitates by mass spectrometric analysis 
Mass spectrometric analysis of APC7 immunoprecipitates resulted in the identification 
of three peptides from NF45 (Fig. 3.7). NF45 is always found in vivo as a heterodimer 
with members of the NF90 family. Both proteins were originally identified on the basis 
of their ability to bind to the antigen receptor response element-2 (ARRE-2) in the 
proximal IL-2 promoter in T-cells. Subsequent experiments defined NF90/NF45 as 
essential components of the ARRE-2 regulatory complex (Corthesy and Kao 1994; Kao, 
Chen et al. 1994), which activates IL-2 transcription in response to ligation of the T-cell 
receptor or treatment with stimuli such as PMA and ionomycin. NF90/NF45 also 
functions in translation (Xu, Busald et al. 2000), post-transcriptional mRNA 
stabilization and export (Shim, Lim et al. 2002; Shi, Zhao et al. 2005). 
 
3.2.3.2. Detection of transcriptional intermediary factor 1 gamma (TIF1) peptides 
in APC7 immunoprecipitates by mass spectrometric analysis 
Two peptides were identified from TIF1 (Fig. 3.8), which is part of a family that is 
defined by the presence of an N-terminal TRIM/RBCC domain (Reymond, Meroni et 
al. 2001). This is composed of a RING finger, two B-boxes, and a coiled-coil domain 
(RBCC), and is also known as a tripartite motif (TRIM). The coiled coil region 
mediates TIF1 homo-oligomerisation, hetero-oligomerisation with TIF1α and is 
thought to be important for targeting proteins to discrete cellular compartments (Peng, 
Feldman et al. 2002). The RING domain functions as a Smad4 E3 ubiquitin ligase 
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(Dupont, Zacchigna et al. 2005). There is evidence to suggest that TIF1 functions as a 
transcriptional repressor (Venturini, You et al. 1999), which may be important for the 
ability of TIF1 to mediate erythroid differentiation and embryonic development 
(Ransom, Bahary et al. 2004; Dupont, Zacchigna et al. 2005). A more detailed analysis 
of TIF1 function can be found in section 1.8. 
 
3.2.3.3. Detection of eukaryotic elongation factor 1A (eEF1A) peptides in APC7 
immunoprecipitates by mass spectrometric analysis 
My study also resulted in the identification of two peptides from eEF1A (Fig. 3.9). It 
has been demonstrated that eEF1A is required for the recruitment of aminoacyl-tRNA 
to the elongating ribosome, quality control of freshly synthesised proteins (Hotokezaka, 
Tobben et al. 2002) and promoting degradation of defective proteins by the proteasome 
(Chuang, Chen et al. 2005). There is also evidence to suggest that eEF1A interacts with 
the actin cytoskeleton and this may be important for its function in translation (Gross 
and Kinzy 2007). Given that eEF1A is highly homologous to a centrosomal protein in 
sea urchin eggs (Kuriyama, Savereide et al. 1990; Owen, DeRosier et al. 1992), it seems 
likely that eEF1A may also contribute to spindle pole function during mitosis.     
 
3.2.3.4. Detection of centrosomal protein 290kDa (CEP290) peptides in APC7 
immunoprecipitates by mass spectrometric analysis 
Interaction between APC7 and CEP290 is suggested by the identification of two 
CEP290 peptides in APC7 immunoprecipitates (Fig. 3.10). Very little is known about 
the functions of CEP290, although it has been demonstrated as a centrosomal 
component (Sayer, Otto et al. 2006) and is also localised to the connecting cilium of 
retinal photoreceptors, an interaction that is important for retinal maintenance (Chang, 
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Khanna et al. 2006). Analysis of the amino acid sequence of CEP290 revealed the 
presence of 13 putative coiled-coil domains, an ATP/GTP binding site motif A 
(phosphate-binding loop or P-loop) that facilitates binding of motor proteins to DNA, a 
nuclear localisation signal and an acidic coiled-coil found in centrosomal proteins and 
required for microtubule organization. Interestingly these motifs are also present, but 
arranged differently, in centromere protein F (CENP-F), a protein that is important for 
chromosome segregation (Zhou, Wang et al. 2005). CEP290 also appears to function as 
a transcription factor, as it activates activating transcription factor 4 (ATF4) dependent 
transcription, and may antagonize the ability of CENP-F to inhibit activation of 
transcription by ATF4 (Sayer, Otto et al. 2006).  
 
3.2.3.5. Detection of Ku70 peptides in APC7 immunoprecipitates by mass 
spectrometric analysis 
Mass spectrometric analysis of APC7 immunoprecipitates also resulted in the detection 
of three peptides from Ku70 (Fig3.11), a component of the Ku heterodimer that also 
contains Ku80. It has been demonstrated that Ku is the regulatory subunit of DNA 
protein kinase (DNA-PK), which also comprises a catalytic subunit DNA-PKcs (Carter, 
Vancurova et al. 1990; Collis, DeWeese et al. 2005). DNA-PK is crucial for repairing 
double strand breaks (DSBs) by non-homologous DNA-end-joining (NHEJ) and also 
functions during V(D)J recombination (Chen, Peterson et al. 1996; Errami, Smider et al. 
1996). Intriguingly, DNA-PK also regulates the IL-2 promoter in cooperation with 
NF90/NF45 (Aoki, Zhao et al. 1998; Shi, Qiu et al. 2007). In addition Ku functions 
independently of DNA-PK in order to prevent chromosomal instability, by regulating 
telomere maintenance (Bailey, Meyne et al. 1999; Samper, Goytisolo et al. 2000). Ku 
also regulates the initiation of DNA replication (Novac, Matheos et al. 2001), 
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transcription, and protein expression by regulating internal ribosome entry site (IRES) 
dependent translation (Kuhn, Stefanovsky et al. 1993; Silvera, Koloteva-Levine et al. 
2006).  
 
3.2.3.6. Detection of translocated in liposarcoma (TLS) peptides in APC7 
immunoprecipitates by mass spectrometric analysis 
A total of three peptides were identified from TLS (Fig 3.12). This protein was first 
identified as an oncogenic fusion protein that contains the N-terminal half of TLS with 
full length CCAAT enhancer binding homologous protein (CHOP) (Crozat, Aman et al. 
1993), and subsequently with the C-terminal half of v-ets erythroblastosis virus E26 
oncogene homolog (ERG) (Ichikawa, Shimizu et al. 1994). However the peptides 
identified in this study originate from the C-terminal portion of TLS that is absent in the 
TLS oncogenic fusions, suggesting that APC7 may bind to wild type protein. TLS is 
identical to the heterogeneous ribonucleoprotein P2 (hnRNP P2), and as such can bind 
to RNA, regulate RNA splicing and may also be involved in mRNA export (Calvio, 
Neubauer et al. 1995). TLS is also thought to function as a transcription factor, as it can 
enhance nuclear factor kappa B (NFκB) mediated transactivation (Uranishi, Tetsuka et 
al. 2001). Lastly TLS mediates binding of homologous DNA (Baechtold, Kuroda et al. 
1999) and TLS-deficient mice show an increased sensitivity to ionizing radiation due to 
chromosome pairing defects (Kuroda, Sok et al. 2000). 
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3.3. Discussion 
Prior to this study, the only known APC7 binding proteins were other APC/C 
components and the transcriptional coactivators CBP and p300 (Peters 2002; Turnell, 
Stewart et al. 2005; Skaar and Pagano 2008). Work in this chapter provides evidence to 
suggest that APC7 also interacts with NF45, TIF1γ, eEF1A, CEP290, Ku70 and TLS. 
These observations present many implications for both APC7 and APC/C function. 
As APC7 has previously been demonstrated to potentiate CBP/p300 dependent 
transcription (Turnell, Stewart et al. 2005), it is therefore somewhat unsurprising that 
five out of six of the novel APC7-interacting proteins have been demonstrated to 
function as transcription factors. The putative interaction between APC7 and NF45 
suggests that APC7 and the APC/C holoenzmye may interact with the ARRE-2 
transcription complex and hence may regulate IL-2 transcription in response to T-cell 
receptor activation (Corthesy and Kao 1994; Kao, Chen et al. 1994). Data presented in 
this chapter suggests that APC7 interacts with Ku70, which also regulates IL-2 
transcription in conjunction with NF90/NF45 (Aoki, Zhao et al. 1998; Shi, Qiu et al. 
2007). A role for APC7 in transcription is also implied due to interactions with TLS, 
TIF1γ and CEP290. 
Identification of NF45, TLS, Ku70 and eEF1A as APC7 interacting proteins suggests 
that APC7 is involved at multiple stages of RNA processing. This is implied by the 
observations that NF90/NF45 regulates post-transcriptional mRNA stabilization and 
controls mRNA export (Shim, Lim et al. 2002; Gwizdek, Ossareh-Nazari et al. 2003; 
Shi, Zhao et al. 2005), while TLS is also thought to be involved in pre-mRNA splicing 
and mRNA export (Calvio, Neubauer et al. 1995). Moreover NF90/NF45, Ku70 and 
eEF1A are all involved in regulating translation (Kuhn, Stefanovsky et al. 1993; Xu, 
Busald et al. 2000; Hotokezaka, Tobben et al. 2002; Silvera, Koloteva-Levine et al. 
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2006), therefore it seems likely that APC7 or possibly the entire APC/C may also be 
involved in this process (Xu, Busald et al. 2000; Hotokezaka, Tobben et al. 2002; 
Silvera, Koloteva-Levine et al. 2006). Indeed there is already evidence to suggest that 
APC5 functions to regulate translation (Koloteva-Levine, Pinchasi et al. 2004), and it 
seems likely therefore that this may be in conjunction with APC7.  
A number of the novel APC7 protein interactions identified in this chapter suggest that 
APC7 might be involved in the maintenance of genomic integrity. Firstly DNA-PK is 
crucial for DSB repair (Carter, Vancurova et al. 1990; Collis, DeWeese et al. 2005), 
while its regulatory component Ku is required for telomere maintenance (Bailey, Meyne 
et al. 1999; Samper, Goytisolo et al. 2000). Secondly TLS knockout mice show an 
increased sensitivity to IR that may be related to the ability of TLS to mediate binding 
of homologous DNA, which is an important step in homologous recombination 
(Kuroda, Sok et al. 2000). NF45/NF90 may also function in the maintenance of 
genomic integrity as suggested by interaction with DNA-PK (Ting, Kao et al. 1998). 
Interaction between APC7 and Ku70 also provides evidence to suggest that the APC/C 
may cooperate with Ku in order to initiate chromosome replication (Novac, Matheos et 
al. 2001).  
The APC/C is localised to centrosomes where it stimulates degradation of proteins such 
as cyclin B and ninein-like protein (NLP), in order to facilitate centrosomal maturation 
(Tugendreich, Tomkiel et al. 1995; Casenghi, Meraldi et al. 2003; Wang and Zhan 
2007). In accordance with this my study presents evidence to support the notion that 
APC7 is required for correct centrosome function. This is suggested by interaction 
between APC7 and the centrosomal component CEP290, and also as a result of 
interaction with eEF1A, which is highly homologous to a centrosomal protein in sea 
urchin embryos and is also capable of interacting with actin (Kuriyama, Savereide et al. 
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1990; Owen, DeRosier et al. 1992), and may therefore mediate mitotic spindle 
formation.  
The interaction between APC7 and TIF1, suggests that APC7 and TIF1 might 
cooperate to regulate transcription or that TIF1 may be important for ubiquitylation of 
APC/C substrates, by functioning as substrate adaptor or due to its ability to function as 
an E3 ubiquitin ligase (Venturini, You et al. 1999; Dupont, Zacchigna et al. 2005). 
Taken together the results in this chapter suggest a role for APC7 in isolation or as a 
component of the APC/C holoenzyme in transcription, post-transcriptional RNA 
processing, centrosome function, initiation of DNA replication and also imply that the 
APC/C may be involved in maintenance of genome integrity. Interestingly, a number of 
the novel APC7 binding proteins identified in this chapter have previously been 
demonstrated to bind and function together. For instance, the NF90 homologue NF110, 
which may bind to APC7 as a result of its interaction with NF45, has previously been 
shown to bind to TLS (Saunders, Perkins et al. 2001). In addition DNA-PK interacts 
with NF90/NF45 (Ting, Kao et al. 1998), therefore suggesting that these proteins may 
form a multi-component complex with APC7, and further validates the efficacy of the 
data obtained.  
Work presented in chapters four and five focuses on validating the interactions between 
TIF1γ-APC7 and NF45-APC7, and also on determining the functional significance of 
the interactions. 
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CHAPTER 4 
 
 
 
 
TIF1γ COOPERATES WITH THE APC/C TO 
REGULATE 
TRANSITION THROUGH MITOSIS 
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4.1. Introduction 
TIF1 is a member of the TRIM/RBCC family and was originally identified and 
characterised as a transcription factor due to its homology with TIF1α (Venturini, You 
et al. 1999). Subsequent work demonstrated that TIF1 is fused to the RET receptor 
tyrosine-kinase
 
domain in papillary thyroid carcinomas (PTC) (Klugbauer and Rabes 
1999), suggesting that TIF1 regulates cellular proliferation and differentiation. In 
accordance with this finding, TIF1 has more recently been demonstrated as a Smad4 
ubiquitin ligase, important for enhancing proliferation in postnatal cells and regulating 
embryogenesis after TGF- treatment (Dupont, Zacchigna et al. 2005). Moreover TIF1 
also binds to R-SMADs in response to TGF- signalling in order to mediate erythroid 
differentiation (He, Dorn et al. 2006).  
In the previous chapter I presented evidence to suggest that APC7 interacts with TIF1, 
eEF1A, CEP290, Ku70, and TLS. However mass spectrometric analysis is only one 
method of identifying protein-protein interactions, therefore in this chapter my objective 
was to confirm the interaction between APC7 and TIF1γ, and go on to determine the 
functional significance. I decided to focus on the TIF1γ-APC7 interaction, due to 
TIF1γs role in human cancer (Klugbauer and Rabes 1999; Venturini, You et al. 1999). 
 
4.2. Results 
4.2.1. Generation of GSTTIF1 fusion proteins  
In order to confirm the interaction between TIF1 and APC7 identified by mass 
spectrometry in the previous chapter (Fig 3.8), it was essential to perform a 
coimmunoprecipitation Western blot between TIF1 and APC7. Given the lack of a 
commercial TIF1 antibody, it was necessary to generate one. I therefore constructed 
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two fragments that encompassed the Nterminal and the central regions of TIF1 (Fig 
4.1 C), using full length TIF1 cDNA, and inserted them into pGEX4T1. After 
validating DNA sequences, BL21 RIL E. coli were transformed with the appropriate 
pGEX constructs and the fusion proteins were expressed and purified. Expression was 
validated by Coomassie staining following SDSPAGE (Fig 4.2). Given that the 
GSTTIF1F1 fusion protein showed higher levels of expression relative to 
GSTTIF1F2 (Fig 4.2), I decided to use GSTTIF1F1 in order to generate 
polyclonal antibodies using a commercial supplier (Eurogentec). 
 
4.2.2. Generation of TIF1 antibody and validation of its specificity 
In order to test the efficacy and specificity of the antibodies TIF198 and TIF178 that 
were generated for this study, I performed Western blot analysis of whole cell extracts 
from the indicated cell lines (Fig 4.3A and 4.4) using these antibodies. Interestingly, 
both antibodies detected multiple bands of varying molecular weights. This may be due 
to the existence of multiple TIF1 splice products (Venturini, You et al. 1999). The 
TIF178 antibody predominantly recognises a protein band that runs below the 45K 
molecular weight marker and fails to recognise any bands with the same nominal size of 
180K as TIF1 (Fig 4.4), and was therefore not suitable for further evaluation. In 
contrast the TIF198 antibody recognises a band that has a nominal size of 180k and 
also a number of weakly expressed sub 180K bands (Fig 4.3A). In order to determine 
whether these corresponded to TIF1, I assayed the ability of the TIF198 antibody to 
recognise the putative TIF1 bands, after knockdown of TIF1 using two distinct 
siRNAs in HeLa cells. 72 hours after siRNAmediated knockdown, cells were 
harvested and lysed in urea buffer, proteins were then analysed by Western blot. 
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Significantly both siRNAs knocked down expression of the 180k band to a high degree, 
indicating that this band corresponds to TIF1. All but one of the multiple sub 180k 
bands recognised by the TIF198 antibody also displayed reduced expression after 
treatment with TIF1 siRNA, indicating that they may be TIF1 degradation products or 
hitherto unknown TIF1 splice variants (Fig 4.3B). The only band recognised by the 
TIF198 antibody that doesn‟t exhibit reduced expression following treatment with 
TIF1 siRNA, runs midway between the 66K and 77k molecular weight markers, and 
may therefore represent a related protein such as another TRIM/RBCC family member. 
In light of this I decided to determine whether the bands recognised by the TIF198 
antibody resembled the expression pattern of various FLAG-TIF1 constructs in 293 
cells. Results obtained reveal the existence of a TIF1 cDNA expression product that 
runs between 66k and 77k (Fig 4.5) suggesting that the band of similar size that is 
recognise by the TIF198 antibody might correspond to a TIF1 splice variant that is 
insensitive to the TIF1 siRNAs utilised in this study 
  
4.2.3. Binding of the APC/C to TIF1 in vivo 
To confirm that the APC/C and TIF1 interact I performed immunoprecipitation from 
A549s using various APC/C subunit antibodies and the TIF1 polyclonal antibody 
TIF198. Proteins were then eluted, separated by SDS-PAGE and detected by Western 
blotting with the indicated antibodies (Fig 4.6A and B). As anticipated, TIF1 forms 
complexes with APC/C subunits 1-8 in vivo. 
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4.2.4. TIF1 isn’t an APC/C substrate in vitro 
Analysis of TIF1‟s protein sequence revealed the presence of three putative destruction 
boxes (Fig 4.1). Taken together with TIF1‟s interaction with the APC/C this suggested 
that TIF1 is ubiquitylated by the APC/C. In order to examine this possibility active 
APC/C complexes were immunoprecipitated with an anti-APC3 antibody, and added to 
a ubiquitin ligase reaction mix containing L-α-[35S]-methionine-labelled cyclin B or 
TIF1. As anticipated APC3 and its associated APC/C holoenzyme was able to 
polyubiquitylate cyclin B (Fig 4.7A), therefore demonstrating the efficacy of this assay. 
However APC3 immunoprecipitates were not capable of ubiquitylating TIF1 (Fig 
4.7B). 
 
4.2.5. CDH1 maintains TIF1 stability in vivo  
To further explore the possibility that TIF1 degradation is mediated by the APC/C I 
transfected HeLas with an siRNA against the APC/C coactivator CDH1. 72 hours later 
cells were lysed in urea buffer and analysed by Western blotting to determine the effect 
of CDH1 knockdown on TIF1 stability. Interestingly reduction of CDH1 levels results 
in reduced expression of TIF1 (Fig 4.8), therefore suggesting that APC/CCDH1 may 
prevent TIF1 degradation by targeting a TIF1 ubiquitin ligase for destruction. 
 
4.2.6. Binding of TIF1 to APC/C substrates and coactivators in vivo 
Given that TIF1 interacts with the APC/C and is not itself an APC/C substrate it 
seemed likely that TIF1 may therefore regulate the APC/C‟s function as a ubiquitin  
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ligase during mitosis. In order to further explore this possibility, I decided to determine 
whether TIF1 could interact with the APC/C‟s mitotic coactivator CDC20, and the 
APC/C‟s mitotic substrates cyclin A and cyclin B. To do this I carried out 
immunoprecipitations from HeLa cells using the anti-TIF1 polyclonal antibody 
TIF198. Precipitated proteins were eluted, separated by PAGE and Western blotted 
with the indicated antibodies (Fig 4.9A-C). These studies reveal that TIF1 is associated 
with CDC20 and cyclin A, but not cyclin B in vivo. 
 
4.2.7. TIF1 displays a band shift during mitosis 
Results from our lab demonstrate that CBP and mediator of DNA damage checkpoint 
protein 1 (MDC1), which function in concert with the APC/C during early mitosis 
display a band shift after treatment with the mitotic spindle poison nocodazole, 
suggesting that they might be phosphorylated either during mitosis or following 
activation of the SAC and therefore indicates that they have important functions during 
mitosis. Given that the results described above strongly suggest that TIF1 is important 
for the function of the APC/C during early mitosis, I decided to examine whether TIF1 
also displays a similar band shift following nocodazole treatment. Interestingly TIF1 
undergoes a band shift after nocodazole treatment (Fig 4.10), indicating that TIF1 is 
either phosphorylated in response to the SAC or constitutively phosphorylated during 
mitosis. Therefore data in this section further strengthens a role for TIF1 during 
mitosis.      
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4.2.8. TIF1 is required for degradation of mitotic APC/C substrates 
Previous work in this section details interactions between TIF1 and the APC/C, 
CDC20 or cyclin A and also mitotic band shift of TIF1, suggesting that TIF1 might be 
required for the degradation of the APC/C‟s mitotic substrates. To test this possibility I  
transfected HeLa cells with TIF1_1 and TIF1_2 siRNAs. 72 hours later the cells were 
harvested and lysed in urea buffer, proteins were then analysed by Western blot. 
Ablation of TIF1 expression correlated with stabilisation of the APC/C substrates 
cyclin A, cyclin B, PLK1 and CDC20 when compared to the non-silencing control (Fig 
4.11). Results in this section suggest that TIF1 might regulate ubiquitylation and hence 
degradation of APC/C substrates in vivo. 
 
4.2.9 TIF1 enhances APC/C ligase activity 
The ability of TIF1 to interact with APC7, CDC20 and cyclin A in vivo, coupled to the 
observation that TIF1 mediates degradation of the APC/C‟s mitotic substrates, 
suggests that TIF1 might regulate the APC/C‟s E3 ubiquitin ligase activity. In order to 
investigate this possibility, I took advantage of the observation that immunoprecipitated 
APC/C complexes are capable of polyubiquitylating cyclin A and cyclin B in the 
presence of E1 and E2 enzymes in vitro (King, Peters et al. 1995; Geley, Kramer et al. 
2001). Initially I performed TIF1 knockdown in HeLa cells with TIF1_1 and TIF1_2 
siRNAs. 72 hours later I performed immunoprecipitation with an anti-APC3 antibody. 
Precipitated immune-complexes were then added to a ubiquitin ligase reaction mix 
containing rabbit E1, human E2 enzymes (UBCH10, UBCH5 and UBCH4), and L-α-
[
35
S]-methionine-labelled cyclin A or cyclin B substrates. Samples were then separated  
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by SDS-PAGE and subjected to fluorography and autoradiography. Interestingly 
ablation of TIF1 expression partially inhibited the ability of APC3 immunoprecipitates 
to polyubiquitylate cyclin A (Fig 4.12A) and cyclin B (Fig 4.12B), suggesting that 
TIF1 regulates APC/C ligase activity.  
 
4.2.10. TIF1 is not associated with APC/C E3 ubiquitin ligase activity in vitro  
Results above reveal that TIF1 regulates APC/C ligase activity, therefore to confirm 
whether TIF1 is directly associated with APC/C ligase activity, I performed 
immunoprecipitations from A549 cells using the TIF198 polyclonal antibody, and an 
anti-APC3 antibody. Precipitated immune-complexes were then added to a ubiquitin 
ligase reaction mix as in section 4.2.9, again containing L-α-[35S]-methionine-labelled 
cyclin A or cyclin B substrates. Samples were then separated by SDS-PAGE and 
subjected to fluorography and autoradiography. As expected, complexes that were 
immunoprecipitated with an anti-APC3 monoclonal antibody were capable of 
polyubiquitylating cyclin A (Fig 5.7A; page 161) and cyclin B (Fig 5.7B; page 161). In 
contrast immune complexes associated with TIF1 were unable to catalyse mono or 
polyubiquitylation of cyclin A and cyclin B (Fig 5.7A and B; page 161 ) and hence 
suggests that TIF1 might not be associated with APC/C ubiquitin ligase activity. 
 
4.2.11. TIF1 mediates passage through mitosis 
Despite the inability of TIF1 to precipitate APC/C ligase activity, the fact remains that 
TIF1 is capable of interacting with the APC/C and mediating degradation of APC/C 
substrates in vivo, indicating that TIF1 regulates mitotic progression. In order to test 
this assumption HeLa cells were harvested 72 hours after transfection with TIF1_1 and  
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TIF1_2 siRNAs. Cells were then stained with propidium iodide and anti-phospho-
histone H3 antibody, and the mitotic index was assessed by flow cytometry. 
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Significantly, treatment with both TIF1 siRNAs increased the proportion of cells in 
mitosis when compared to the non-silencing control (Fig 4.13); TIF1_1 siRNA 
treatment caused the number of mitotic cells to increase by approximately 10 fold (Fig 
4.13B); the TIF1_2 siRNA also enlarged the mitotic population by approximately 4 
fold (Fig 4.13C). The mitotic index taken from three independent experiments is also 
displayed in the form of bar chart (Fig 4.13D). The extent of TIF1 knockdown was 
assessed by Western blot (Fig 4.13E). In summary data in this section establishes that 
TIF1 is required for mitotic progression in vivo. 
 
4.2.12. TIF1 is required for the metaphase-anaphase transition 
Work above (section 4.2.11) demonstrates that TIF1 is important for mitotic 
progression, therefore in order to elucidate the role of TIF1 in mitotic progression I 
examined the mitotic distribution after TIF1 knockdown. To do this I transfected HeLa 
cells with TIF1_1 and TIF1_2 siRNAs. Cells were then trypsinised and plated out 
onto poly-L-lysine treated 12 well slides 48 hours later. The cells were grown on slides 
for a further 24 hours and fixed in ice-cold methanol and stained with anti-α-tubulin and 
anti-phospho-histone H3 antibodies. The relative mitotic distribution was then 
quantified using the criteria set out in Fig 4.14. Interestingly, TIF1 knockdown 
increased the number of metaphase-like cells, which are characterised by the presence 
of mitotic spindles and an inability to form a metaphase plate (Fig 4.15A), and were 
therefore counted as metaphase cells. After TIF1 knockdown (Fig 4.15C) there was a 
large increase in the number of metaphase cells when compared to the non-silencing 
control, which was accompanied by a complementary reduction in anaphase and 
telophase cells (Fig. 4.15B). Taken together these results demonstrate that the increase 
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in the mitotic index of TIF1 knockdown cells (section 4.2.11) can be attributed to an 
inability to progress into anaphase. 
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4.3. Discussion  
Co-immunopricipitation experiments in this chapter demonstrate the existence of in vivo 
protein complexes comprising TIF1 and APC/C subunits 1-8, which is consistent with 
mass spectrometry data from chapter 3 detailing interaction between APC7 and TIF1. 
In addition TIF1 also interacts with the APC/C‟s mitotic coactivator CDC20 and 
substrate cyclin A, suggesting that TIF1 is required for the activity of mitotic APC/C. 
Consistent with these observations I also demonstrate that TIF1 regulates the 
polyubiquitylation and degradation of a number of the APC/C‟s mitotic substrates, and 
also regulates passage through mitosis by facilitating entry into anaphase.  
The TIF198 antibody that was used for TIF1 immunoprecipitation and Western 
blotting was generated using GSTTIF1F1. This decision was taken due to higher 
levels of expression in comparison to GSTTIF1F2, which was predominantly 
composed of GST (Fig 4.2). The TIF198 antibody is specific to TIF1, as it recognises 
a protein with the same nominal size of 180K as TIF1 (Fig 4.3A) that is knocked down 
after treatment with two distinct TIF1 siRNAs (Fig 4.3B). In addition, the TIF198 
antibody recognises a number of sub 180K bands (Fig 4.3A), all but one of which 
display reduced expression following TIF1 knockdown (Fig4.3B), suggesting that they 
correspond to TIF1 breakdown products or splice variants. It is likely that these sub 
180K bands are products of alternative TIF1 splicing, as expression of a FLAG-tagged 
„intronless‟ cDNA in 293 cells gives rise to a similar pattern of bands (Fig 4.5), which 
might arise due to the presence of alternative start sites within the cDNA. The only 
protein band recognised by the TIF198 antibody that doesn‟t display reduced intensity 
following treatment with TIF1 siRNAs runs midway between the 66k and 77k 
molecular weight markers, and may therefore correspond to a TIF1 splice variant that 
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doesn‟t contain complementary sequence to the siRNAs used. Alternatively, this band 
might correspond to a protein that is homologous to TIF1, such as another 
TRIM/RBCC family member, which all have a similar architecture within their 
TRIM/RBBC domains (Nisole, Stoye et al. 2005). In particular PML splice variants 
with a molecular weight of ~66Kda have been described (de The, Lavau et al. 1991; 
Fagioli, Alcalay et al. 1992). Although, I have been unable to successfully 
coimmunoprecipitate APC7 and PML from asynchronous cells (data not shown).  
A number of observations from this chapter strongly imply that TIF1 mediates mitotic 
progression by regulating the function of the APC/C. For instance, TIF1 interacts with 
the APC/C‟s early mitotic coactivator CDC20 and early mitotic substrate cyclin A in 
vivo (Fig 4.9B and C). In addition, TIF1 interacts with a higher molecular weight form 
of APC7 in vivo (Fig 4.6B), which may correspond to a phosphorylated form of APC7 
that has previously been identified during mitosis (Kraft, Herzog et al. 2003). TIF1 
fails to immunoprecipitate cyclin B (Fig 4.9A) suggesting that any potential interaction 
between these two proteins is extremely transient, or that only a very small percentage 
of the total cellular pool of these proteins is bound together. Alternatively, the inability 
of TIF1 to interact with cyclin B suggests that TIF1 doesn‟t regulate the ability of the 
APC/C to target cyclin B for degradation. If this is the case, TIF1 may only be 
associated with an APC/C sub-pool that mediates degradation of cyclin A, and possibly 
other early mitotic substrates such as NEK2A and HOXC10, which unlike cyclin B are 
not stabilised during early mitosis as a result of SAC activation (den Elzen and Pines 
2001; Geley, Kramer et al. 2001; Gabellini, Colaluca et al. 2003; Hayes, Kimata et al. 
2006).  
Further evidence to support a role for TIF1 as a mitotic APC/C regulatory protein is 
provided by the ability of TIF1 to enhance polyubiquitylation of cyclins A and B in 
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vitro (Fig 4.12) and mediate degradation of the APC/C substrates cyclin A, cyclin B, 
CDC20 and Plk1 in vivo (Fig 4.11). In addition to, and consistent with, the ability of 
TIF1 to associate with the APC/C and regulate the stability of APC/C mitotic 
substrates, it appears that TIF1 regulates transition through mitosis, as ablation of 
TIF1 expression with two distinct siRNAs (Fig 4.13E) causes an increase in the mitotic 
index when compared to a non-silencing control (Fig 4.13A-C). 
Given that TIF1 knockdown prevents degradation of cyclin A and cyclin B (Fig 4.11), 
and that TIF1 only binds to cyclin A (Fig 4.9B) it seems likely that TIF1 knockdown 
might stabilise cyclin B indirectly, and possibly also CDC20 and PLK1, by directly 
regulating cyclin A degradation. Significantly over-expression of wt cyclin A has 
previously been shown to delay chromosome alignment while TIF1 knockdown 
increases the number of cells arrested in metaphase with unaligned chromosomes (Fig 
4.15A and B) (den Elzen and Pines 2001), further suggesting that TIF1 regulates cyclin 
A degradation. Chromosome alignment is a prerequisite for SAC inactivation and 
subsequent degradation of cyclin B (Geley, Kramer et al. 2001), and would therefore 
explain the ability of TIF1 knockdown to stabilise cyclin B indirectly. A delay in the 
metaphase-anaphase transition due to cyclin B stabilisation would also prevent the 
degradation of CDC20 and PLK1, which occurs during anaphase (Acquaviva and Pines 
2006), again demonstrating that TIF1 knockdown could indirectly stabilise mitotic 
APC/C substrates purely as a result of a failure to degrade cyclin A. 
Despite the fact that TIF1 enhances the ability of the APC/C to polyubiquitylate its 
substrates in vitro (Fig 4.12) and regulates APC/C substrate stability in vivo (Fig 4.11), 
the TIF198 antibody failed to immunoprecipitate APC/C ligase activity (Fig 5.7A and 
B). Notably, work from our laboratory demonstrates that a number of antibodies against 
various APC/C subunits fail to precipitate APC/C ligase activity (A Turnell, personal 
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communication), suggesting that the inability of the TIF198 antibody to precipitate 
APC/C ligase activity could merely be due to the antibody being unsuitable for this 
application. Given that TIF1 enhances APC/C ligase activity (Fig 4.12) it seems likely 
that the ability of TIF1 to function as a RING dependent E3 ubiquitin ligase may be 
important for APC/C ligase activity (Dupont, Zacchigna et al. 2005). Indeed TIF1 can 
modify SMAD4 activity through monoubiquitylation (Dupont, Mamidi et al. 2009), 
indicating that TIF1 might also regulate APC/C ligase activity by monoubiquitylating 
APC/C subunits. Alternatively the RING domain of TIF1 may directly enhance the 
polyubiquitylation of APC/C substrates. 
Following CDH1 knockdown TIF1 expression is reduced (Fig 4.8), indicating that the 
APC/C might indirectly regulate TIF1 stability by controlling the accumulation of a 
TIF1 E3 ubiquitin ligase. However CDH1 knockdown has previously been 
demonstrated to result in premature entry into S-phase due to cyclin A and SKP2 
accumulation (Sudo, Ota et al. 2001; Hsu, Reimann et al. 2002; Bashir, Dorrello et al. 
2004; Wei, Ayad et al. 2004; Havens, Ho et al. 2006). Therefore the observed reduction 
in TIF1 expression could be due to the possibility that TIF1 levels are reduced in S 
phase.  
A recent report demonstrates that APC1 is targeted to PML bodies after expression of 
apoptin (Heilman, Teodoro et al. 2006), suggesting that the APC/C may be recruited to 
PML bodies in the absence of this viral protein. The observation that the TRIM/RBCC 
motif of TIF1α in isolation and as part of the intact protein, is required for recruitment 
into PML associated tracks that form after adenovirus infection (Yondola and Hearing 
2007), coupled to the ability of TIF1α to hetero-oligomerise with PML (Zhong, Delva et 
al. 1999), indicates that TIF1α may be a component of PML-NBs in the absence of viral 
infection. This also suggests that other TIF1 family members could also be components 
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of PML-NBs, given that the TRIM/RBCC motif within members of the TIF1 family 
display up to 70% identity (Venturini, You et al. 1999). 
If TIF1 is a component of PML-NBs it may be important for recruitment of APC/C 
components into these structures, indeed, unpublished observations from our lab reveal 
that APC/C components are present in PML bodies in the absence of viral infection. In 
addition it has been suggested that SUMOylation actually occurs in PML-NBs, 
therefore APC/C components may undergo SUMOylation in these structures. If this 
were the case, TIF1 may have the potential to function as an E3 SUMO ligase for the 
APC/C, which is suggested by the presence of a RING finger domain and a PHD 
domain in TIF1, both of which been have been proposed as SUMO E3 ligases (Capili, 
Schultz et al. 2001; Quimby, Yong-Gonzalez et al. 2006; Mascle, Germain-Desprez et 
al. 2007).The possibility that TIF1 functions as a SUMO ligase suggests that TIF1 
may regulate transition through mitosis by via SUMOylation of APC/C subunits. This is 
given credence by the requirement for the SUMO E1 UBC9 in yeast, for degradation of 
APC/C mitotic substrates (Dieckhoff, Bolte et al. 2004). 
Given the ability of the TIF1 family proteins (Le Douarin, Nielsen et al. 1996; 
Moosmann, Georgiev et al. 1996; vom Baur, Zechel et al. 1996; Venturini, You et al. 
1999; Beckstead, Ortiz et al. 2001) and the APC/C to function in transcription (Turnell, 
Stewart et al. 2005), the interaction between the APC/C and TIF1 (Fig 4.6A and B) 
might be also be important for regulation of transcription. TIF1 may function as a 
cofactor in APC/C dependent transcription, recruiting repressive complexes via its TSS 
motif. Interestingly TIF1γ contains two putative LXCXE RB binding motifs (Fig 4.1B), 
and as such may facilitate binding of the APC/C to RB (Binne, Classon et al. 2007). 
Alternatively the presence of a bromodomain in TIF1 and the inferred capacity for 
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chromatin binding, might also allow recruitment of APC/C complexes and its associated 
transcription factors such as CBP/p300 to DNA (Turnell, Stewart et al. 2005). 
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CHAPTER 5 
 
 
 
 
THE APC/C COOPERATES WITH NF90/NF45 TO 
REGULATE CYTOKINE TRANSCRIPTION 
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5.1. Introduction 
NF90 and its binding partner NF45 facilitate gene expression by regulating transcription 
(Flanagan, Corthesy et al. 1991; Corthesy and Kao 1994; Kao, Chen et al. 1994; Aoki, 
Zhao et al. 1998; Reichman, Parrott et al. 2003; Ranpura, Deshmukh et al. 2007; Shi, 
Godfrey et al. 2007; Shi, Qiu et al. 2007), mRNA processing and translation(Ting, Kao 
et al. 1998; Xu and Grabowski 1999; Saunders, Perkins et al. 2001; Shim, Lim et al. 
2002; Zhou, Licklider et al. 2002; Leung, Andersen et al. 2003; Shi, Zhao et al. 2005). 
The majority of study directed towards NF90 and NF45 has been concerned with their 
ability to activate IL-2 transcription from the IL-2 promoter ARRE-2 (Corthesy and 
Kao 1994; Kao, Chen et al. 1994; Aoki, Zhao et al. 1998; Shi, Godfrey et al. 2007; Shi, 
Qiu et al. 2007). NF90 and NF45 are thought to be components of the ARRE-2 
transcriptional regulatory complex, which functions as a constitutive repressor. The 
ARRE-2 regulatory complex also undergoes conversion into an IL-2 transcriptional 
activator following events such as PMA and ionomycin stimulation or TCR ligation, 
which stimulate the nuclear translocation and subsequent recruitment of NFAT1 to the 
ARRE-2 transcriptional regulatory complex (Shaw, Utz et al. 1988; Randak, Brabletz et 
al. 1990). Notably, NFAT1 has also been implicated in transcription of a number of 
other cytokine promoters such as TNF and GMCSF (Cockerill, Shannon et al. 1993; 
Oum, Han et al. 2002), suggesting that NF90/NF45 might also regulate transcription of 
these genes. 
In chapter three I presented mass spectrometric evidence of an interaction between 
APC7 and a number of other proteins including the proposed ARRE-2 transcriptional 
regulatory complex component NF45. However, mass spectrometric analysis is only 
one method of identifying protein-protein interactions, therefore in this chapter my 
objective was to confirm the validity of the interaction between NF45 and APC7, and 
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also NF45‟s binding partner NF90, I choose to focus on the interaction between NF45 
and APC7 due to NF45‟s well defined role in transcription, which might relate to 
APC7‟s ability to regulate transcription (Turnell, Stewart et al. 2005). I was also 
fortunate to obtain some excellent reagents that were sourced from collaboration with 
Professor Peter Kao (Stanford). Details of my findings are presented in this chapter. 
 
5.2. Results 
5.2.1. Binding of the APC/C to NF45 and NF90 in vivo 
To confirm the interaction between APC7 and NF45, which was identified by mass 
spectrometry in chapter 3 (Fig 3.7), I performed coimmunoprecipitation and Western 
blotting analysis from A549 cells using an antibody that specifically recognises NF45. 
Also, given that NF45 is generally present with its binding partner NF90, I decided to 
perform a coimmunoprecipitation using an antibody that specifically recognises NF90. 
Precipitated proteins were then eluted, separated by SDS-PAGE and subsequently 
Western blotted for APC5 (Fig 5.1A) and APC7 (Fig 5.1B). As anticipated APC5 forms 
complexes with NF90 (Fig 5.1A), while APC7 associates with NF45 and NF90 (Fig 
5.1B). 
 
5.2.2. Colocalisation of NF90 and APC3 by microscopy 
In order to determine the particular sub-cellular locations of NF90 and the APC/C, I 
performed immunofluorescence microscopy on interphase HeLa cells using anti-NF90 
antibody and the anti-APC3 antibody AF3.1 (Fig 5.2). The results revealed that APC3 
and NF90 partially colocalise in the nucleus, and that these complexes are particularly 
prevalent at the periphery of the nucleus. Furthermore APC3 and NF90 complexes were 
also identified in the cytoplasm (Fig 5.2).      
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5.2.3. APC5 and APC7 bind directly to NF90 in vitro 
As co-IP studies demonstrated the existence of NF90-APC/C complexes in vivo, I 
resolved to establish whether these interactions occur directly, by performing GST-
pulldowns. I therefore subcloned full-length NF90 and NF45 from pcDNA 3.1 into 
pGEX 4T-1. After validation of DNA sequences, BL21 RIL E. coli were transformed 
with the appropriate pGEX constructs and the fusion proteins were expressed and 
purified. In order to determine the binding capacity of GST-NF45 and GST-NF90 for 
APC5 and APC7, L-α-[35S]-methionine-labelled APC5 and APC7 were incubated with 
GST-NF45 and GST-NF90. After GST pulldown with glutathione-agarose, binding 
proteins were specifically eluted with glutathione and resolved by SDS-PAGE. 
Following fluorography and autoradiography it was seen that NF90 binds directly to 
APC5 (Fig 5.3A) and to APC7 in vitro (Fig 5.3B). In contrast NF45 demonstrated a 
very weak affinity for APC5 (Fig 5.3A). These findings suggest that APC5 and APC7 
bind to NF90 preferentially.  
 
5.2.4. Generation of GST-NF90 fusion fragments, and determination of APC/C 
binding sites on NF90 in vitro 
In order to delineate the regions of NF90 that are responsible for binding to APC5 and 
APC7, I generated GST-NF90 fusion fragments (Fig 5.4Aii), which were cloned from 
full length NF90 cDNA and inserted into pGEX 4T-1. Sequences were validated and 
the GST-NF90 fragments were expressed in BL21 RIL E. coli. GST-pulldown, revealed 
that the central (fragment 2) and C-terminal (fragment 3) fragments of NF90, which 
both contain double stranded RNA binding motifs (dsRBMs) interact with APC5 (Fig 
5.4B) and APC7 (Fig 5.4C), whereas the N-terminal fragment of NF90 (fragment1) fails 
to bind to these APC/C components (Fig 5.4B and C). Given that APC5 and APC7 bind  
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to regions of NF90 that both contain dsRBMs it seemed likely that the interaction was 
dependent upon the dsRBMs. Therefore, in order to test this possibility I generated 
GST-dsRBM1 and GST-dsRBM2 fusions that exclusively expressed the dsRBMs of 
NF90 (Fig 5.5A). Following GST pulldown using the GST-dsRBM1 and GST-dsRBM2 
of NF90 it was determined that APC5 (Fig 5.5B) and APC7 (Fig 5.5C) bind directly to 
NF90‟s dsRBM1 and dsRBM2. This observation raised the possibility that the 
interaction between APC/C and NF90 may be regulated by dsRNA. 
 
5.2.5. The in vitro interaction between NF90 and the APC/C is mediated by a 
double dsRNA intermediate  
To assess whether dsRNA regulates the interaction between the dsRBMs of NF90 and 
APC/C components, L-α-[35S]-methionine-labelled APC5 and APC7 were incubated 
with GST-dsRBM1 and GST-dsRBM2. After pulldown with glutathione-Sepharose 
beads, bound proteins were then incubated with RNase buffer alone or with RNase V1, 
which specifically degrades dsRNA. Any unbound proteins were then removed by 
extensive washing. The remaining proteins were specifically eluted with glutathione and 
separated by SDS-PAGE. In order to establish whether proteins had been loaded in 
equal amounts the gel was subjected to Coomassie blue staining (Fig 5.6A). Following 
fluorography and autoradiography it was seen that degradation of dsRNA ablates the 
interaction between the dsRBMs of NF90 and APC7 (Fig 5.6B), therefore suggesting 
that the interaction is bridged by a dsRNA intermediate.  
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5.2.6. TIF1, NF45 and NF90 are not associated with APC/C E3 ubiquitin ligase 
activity 
The ability of TIF1, NF45 and NF90 to interact with components of the APC/C in vivo, 
suggests that these proteins may be associated with APC/C E3 ubiquitin ligase activity. 
In order to investigate this possibility, I took advantage of the observation that 
immunoprecipitated APC/C complexes are capable of poly-ubiquitylating cyclin A and 
cyclin B in the presence of E1 and E2 enzymes in vitro (King, Peters et al. 1995; Geley, 
Kramer et al. 2001). Initially, I performed immunoprecipitations from A549 cells using 
anti-NF45, anti-NF90 and TIF198 polyclonal antibodies, and an anti-APC3 antibody. 
Precipitated immune-complexes were then added to ubiquitin ligase reaction mix 
containing rabbit E1, human E2 enzymes (UBCH10, UBCH5 and UBCH4), and L-α-
[
35
S]-methionine-labelled cyclin A or cyclin B substrates. Samples were then separated 
by SDS-PAGE and subjected to fluorography and autoradiography. As expected, 
complexes that were immunoprecipitated with an anti-APC3 monoclonal antibody were 
capable of polyubiquitylating cyclin A (Fig 5.7A) and cyclin B (Fig 5.7B). In contrast 
immune complexes associated with NF45, NF90 or TIF1 were unable to catalyse 
polyubiquitylation of cyclin A and cyclin B (Fig 5.7A and B), indicating that these 
specific antibodies do not co-IP active APC/C ubiquitin ligase activity. 
 
5.2.7. Determination of NF45 and NF90 as substrates for APC/C mediated 
ubiquitylation 
Analysis of the amino acid sequence of NF45 and NF90 resulted in the identification of 
putative D-boxes (RXXL) suggesting that NF45 and NF90 might be APC/C substrates. 
In order to authenticate these D-boxes I initially cloned NF45 and NF90 into pcDNA  
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3.1 using wild type cDNA. After validating DNA sequences, proteins were expressed 
using wheat germ extract. Active APC/C complexes were then immunoprecipitated with 
an anti-APC3 antibody, and added to a ubiquitin ligase reaction mix containing L-α-
[
35
S]-methionine-labelled cyclin A, cyclin B, NF45 or NF90. As anticipated APC3 and 
its associated APC/C holoenzyme was able to polyubiquitylate cyclin A and cyclin B 
(Fig 5.8A), therefore demonstrating the efficacy of this assay. However I was unable to 
detect APC/C mediated mono or poly-ubiquitylation of NF45 and NF90 (Fig 5.8B) 
following incubation with active APC/C ligase complexes, therefore demonstrating that 
these proteins are not targets for APC/C mediated ubiquitylation. 
 
5.2.8. Exogenous NF90 and NF45 cooperate with exogenous APC/C components to 
potentiate transcription from the IL-2 promoter 
It has previously been determined that NF90/NF45 regulates transcription from the IL-2 
promoter (Corthesy and Kao 1994). In order to investigate whether APC/C components 
can cooperate with NF90/NF45 to regulate the IL-2 promoter, I transfected HCT116 
cells with NF90/NF45 and either APC5 or APC7 in conjunction with a plasmid 
containing the IL-2 promoter upstream of a luciferase reporter gene. The activity of the 
resulting luciferase reporter protein, and hence transcription was measured 24 hours 
later (Fig 5.9). As expected NF90/NF45 expression stimulated luciferase activity 
approximately two fold. Expression of APC5 with NF90/NF45 further enhanced IL-2 
reporter gene expression by approximately 90%, while expression of APC7 with 
NF90/NF45 increased luciferase expression by approximately 50%. Significantly, 
expression of APC5 or APC7 alone had little or no effect on luciferase activity (Fig 
5.9).  
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Results in this section demonstrate that NF90 cooperates with APC5 and APC7 to 
activate transcription from the IL-2 promoter in vitro, suggesting that the entire APC/C 
holoenzyme might also be important for IL-2 transcription. 
 
5.2.9. Dynamic binding of the APC/C and NF90 to the IL-2 promoter in vivo 
Two recent reports demonstrate that NF90 binds to the proximal IL-2 promoter in 
response to stimulation with PMA and ionomycin in vivo, which correlates with the 
ability of NF90 to activate IL-2 transcription in response to PMA and ionomycin 
stimulation in vitro (Shi, Godfrey et al. 2007; Shi, Qiu et al. 2007). The capacity of 
APC5 and APC7 to activate transcription from an IL-2 reporter construct in cooperation 
with NF90/NF45 in vitro, also suggests that the APC/C might also be associated with 
the IL-2 promoter in vivo. In order to test this I replicated a ChIP protocol that was used 
by Shi et al. (2007) to demonstrate inducible binding of NF90 to the IL-2 promoter. In 
short, Jurkat T-cells were either nonstimulated or stimulated with 20ng of PMA and 
2uM ionomycin for 4 hours. Following treatment with 1% formaldehyde and DNA 
shearing, chromatin-DNA complexes were immunoprecipitated with antibodies against 
either NF90, APC5 or APC7. Immunoprecipitated DNA was purified and analysed by 
PCR using oligonucleotide primers that were specific to the IL-2 proximal promoter 
(Fig 5.10). As expected, PMA and ionomycin stimulation induced binding of NF90 to 
the IL-2 promoter. Interestingly, my analysis also revealed that APC5 and APC7 are 
bound to the IL-2 promoter in non-stimulated cells and that their dissociation is induced 
upon treatment with PMA and ionomycin. Given that in unstimulated cells IL-2 
transcription is inhibited, results in this section suggest that the endogenous APC/C 
holoenzyme may function to repress IL-2 transcription in vivo. 
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5.2.10. Exogenous NF90 and NF45 cooperate with exogenous APC/C to potentiate 
transcription from the TNF promoter 
Given that transcription from the TNF promoter is inhibited by CsA (McCaffrey, 
Goldfeld et al. 1994) and that transactivation of the IL-2 promoter by NF90/NF45 is 
also inhibited by CsA (Kao, Chen et al. 1994), it seemed likely that the TNF promoter 
may also be subject to regulation by NF90/NF45 and the APC/C. To test this 
possibility, I transfected HCT116 cells with a plasmid containing the TNF promoter 
upstream of a luciferase reporter gene in combination with NF90/NF45 and either 
APC5 or APC7 (Fig 5.11). As expected NF90/NF45 enhances luciferase activity by 
approximately 130%. Addition of APC5 further increases activity by approximately 
70%, whilst addition of APC7 enhances activity by 100%. Expression of APC5 or 
APC7 alone, had negligible effects on luciferase activity. In conclusion, the results 
presented in this section demonstrate that APC5 and APC7 cooperate with NF90/NF45 
to stimulate transcription from the IL-2 and TNF promoters in vitro 
 
5.2.11. APC7 recruits CBP/p300 to the TNF promoter in order to potentiate 
transcription.  
Work in our laboratory has previously demonstrated an interaction between APC7 and 
CBP/p300, which is important for transactivation of the CDC6 and p21
CIP1
 promoters 
(Turnell, Stewart et al. 2005); other workers have demonstrated that CBP potentiates 
TNF transcription (Falvo, Brinkman et al. 2000). Therefore, in order to investigate 
whether APC7 can regulate the TNF promoter through its interaction with CBP/p300, I 
made use of an APC7 deletion mutant (ΔN-APC7) previously generated in our lab, 
which ablates CBP/p300 binding due to removal of its E1A N-terminal homology 
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domain (Fig 5.12B). Thus HCT116 cells were transfected with a plasmid containing the 
TNF promoter upstream of a luciferase reporter gene in combination with NF90/NF45 
and wt APC7 or ΔN-APC7. The activity of the luciferase reporter gene was assayed 24 
hours post-transfection (Fig 5.12A). As previously demonstrated APC7 and NF90/NF45 
cooperated to enhance transcription from the TNF promoter. Interestingly, ΔN-APC7 
retained substantial ability to activate the TNF promoter in cooperation with 
NF90/NF45, although this difference is not statistically significant is does indicate that 
the ability of APC7 to activate TNF transcription may be partially dependent on 
CBP/p300. 
 
5.2.12. Endogenous APC5 represses the TNF promoter 
Over-expression of exogenous NF90/NF45 and APC/C subunits may result in the 
formation of non-physiological protein interactions, and therefore cause aberrant 
recruitment of proteins to the TNF promoter. In light of this I decided to investigate 
whether endogenous NF90 and APC/C are also capable of regulating TNF transcription. 
Thus 72hours after siRNA mediated knockdown of APC5, APC7 and NF90 (Fig 5.13B) 
I transfected HeLa cells with a TNF-luciferase reporter construct. The resulting 
luciferase activity was quantified 24 hours later (Fig 5.13A). Interestingly, following 
APC5 knockdown transcriptional activity of the TNF promoter was enhanced by 
approximately 450%, while APC7 knockdown increased the rate of transcription by 
approximately 200%, in comparison to the non-silencing control. In contrast there was 
no significant alteration in transcription from the TNF promoter after NF90 knockdown. 
In summary, the data presented in this section establishes that endogenous APC5 and 
APC7 repress transcription from the TNF promoter in the absence of PMA and  
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ionomycin stimulation. Whereas endogenous NF90 has no significant effect on TNF 
transcription in the absence of PMA and ionomycin treatment.  
 
5.2.13. The effect of NF90 and APC5 on TNF transcription in vivo 
Work in this chapter has established that exogenous NF90/NF45 and APC/C subunits 
cooperate with one another to bind and enhance transcription of a synthetic TNF 
promoter (Fig 5.11), while endogenous APC5 and APC7 function to repress a synthetic 
TNF promoter (Fig13A). Taken together, these observations suggest that NF90 and the 
APC/C might function in concert in order to regulate the TNF promoter in vivo. Also, 
given that NF90/NF45 dependent transcription, and TNF transcription are both 
activated after PMA and ionomycin treatment (Hensel, Mannel et al. 1987; Richards, 
Dennert et al. 1989; Corthesy and Kao 1994), it seems likely that the ability of NF90 
and APC/C to regulate  
TNF transcription is influenced by PMA and ionomycin. To examine this possibility, I 
first transfected 16-Human Bronchial epithelial cells (16-HBE) with siRNA against 
NF90, APC5 or a non-silencing siRNA (Fig 5.14B). 5 days post transfection, I either 
mock treated or stimulated cells with 20ng of PMA and 2uM ionomycin for 6 hours, in 
order to activate NF90/NF45 dependent transcription. Cells were then harvested and 
whole cell RNA was extracted with a Qiagen RNeasy kit. Isolated RNA was then 
transcribed into cDNA by RT-PCR and utilized for quantitative realtime-PCR, in order 
to detect TNF gene transcripts, and hence measure levels of TNF transcription (Fig 
5.14A). Prior to PMA and ionomycin stimulation levels of TNF transcription in cells 
treated with APC5 siRNA showed a 100% increase in relative levels of TNF 
transcription when compared to non-silencing control or cells treated with NF90 
siRNA. As expected PMA and ionomycin stimulation of 16-HBE cells resulted in a 
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substantial increase in levels of TNF transcription. Following knockdown of NF90 and 
PMA and ionomycin stimulation there was approximately a 25% decrease in levels of 
TNF transcription when compared to non-silencing controls. In contrast, cells in which 
APC5 had been knocked down showed no significant difference in levels of TNF 
transcription after PMA and ionomycin stimulation when compared to non- silencing 
controls. Results in this section demonstrate that knockdown of APC5 has no effect on 
the ability of PMA and ionomycin to stimulate TNF transcription in vivo. 
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5.3. Discussion   
Co-IPs and GST-pulldowns in this chapter reveal the existence of protein complexes in 
vivo and in vitro that are composed of APC/C components and NF90/NF45 (Figs 5.1, 
5.2 and 5.3), suggesting that NF90/NF45 might bind to the entire APC/C holoenzyme. 
These findings provide confirmation of the interaction between APC7 and NF45 that 
was identified by mass spectrometry in chapter 3. Interestingly, a luciferase-reporter 
assay and ChIP experiment strongly imply that the APC/C regulates IL-2 transcription 
in conjunction with NF90 in vivo and in vitro (Fig 5.9 and 5.10). In addition 
endogenous APC/C components also cooperate with NF90 to modulate transcription of 
the TNF promoter in vivo and in vitro (Fig 5.11-14). It should be noted that the NF90 
antibody and siRNA used in this chapter also target NF110, suggesting that some the 
functions ascribed to NF90 in this study may actually be mediated by NF110. 
A number of observations presented in this chapter and chapter 3 suggest that the 
APC/C holoenzyme or at least an APC/C subcomplex forms part of the ARRE-2 
regulatory complex. For instance APC3 colocalises to a limited extent with NF90 in the 
nucleus (Fig 5.2), while APC5 and APC7 bind directly to NF90 in vitro (Fig 5.3). In 
addition APC5 and APC7 also form a complex with NF90/NF45 in vivo (Fig 5.1), 
although given that the anti-NF90 antibody used in this study also recoginses NF110, 
APC/C components might actually bind to NF110 and not NF90. Also, work from 
chapter 3 demonstrates an interaction between APC7 and the ARRE-2 regulatory 
component Ku70 in vivo (Fig 3.11) (Aoki, Zhao et al. 1998; Ting, Kao et al. 1998; Shi, 
Qiu et al. 2007). Moreover, APC5 and APC7 cooperate with NF90/NF45 to 
transactivate the IL-2 promoter in vitro (Fig 5.9). Lastly, data presented here 
demonstrates dynamic binding of NF90, APC5 and APC7 to the IL-2 promoter 
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following PMA and ionomycin treatment (Fig 5.10). This parallels work by Shi et al. 
(2007), which details the dissociation of Ku70 from the IL-2 promoter, and a 
concomitant induction of NF90 binding in response to PMA and ionomycin stimulation. 
Significantly, the ability of APC/C subunits to bind to the IL-2 promoter in the absence 
of PMA and ionomycin stimulation in a manner analogous to Ku70, correlates with 
reduced IL-2 transcription and therefore suggests that the endogenous APC/C 
holoenzyme may repress IL-2 transcription in vivo (see Fig 5.15 for a model of TNF 
and IL-2 promoter regulation by endogenous NF90/NF45, APC5 and APC7).       
Analysis of TNF transcription by realtime-PCR demonstrates that NF90 functions to 
enhance TNF transcription in response to PMA and ionomycin treatment in vivo (Fig 
5.14A), although given that this was shown using an NF90 siRNA that also targets 
NF110, TNF transcription might actually be dependent on endogenous NF110 . The 
ability of NF90 to transactivate a TNF promoter construct (Fig 5.11) suggests that it 
may regulate TNF transcription in vivo through binding directly to the TNF promoter. 
In contrast to NF90, endogenous APC5 and APC7 repress transcription from a TNF 
promoter construct (Fig 5.13A) while APC5 represses TNF transcription in the absence 
of PMA and ionomycin stimulation in vivo (Fig 5.14A). Indeed APC5 knockdown in 
16HBE cells enhances the levels of TNF mRNA by 100% in vivo (Fig 5.14A). Whereas, 
APC5 knockdown in HeLa cells causes an approximate increase of 450% in 
transcription from a TNF promoter construct (Fig 5.13A). These differences may reflect 
disparity in the level of APC5 knockdown (Fig 5.13B and 5.14B) or differences in 
experimental design. Given that endogenous APC7 represses the TNF promoter in vitro 
(Fig 5.13A) it may be possible to further enhance TNF transcription in vivo by knocking 
down APC7 or additional APC/C subunits in conjunction with APC5. Interestingly, 
knockdown of endogenous NF90 by RNAi in the absence of PMA and ionomycin 
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stimulation has no effect on TNF transcription in vitro or in vivo (Fig 5.13A and 5.14A). 
However, one would expect a reduction in levels of transcription after NF90 
knockdown given that NF90 activates the TNF promoter (Fig 5.11). This could be 
attributed to the inability to achieve sufficient knockdown of NF90 (Fig 5.13B and 
5.14B) or suggests that endogenous NF90 is unable to bind to, and activate the TNF 
promoter in the absence of PMA and ionomycin stimulation, such that a reduction in 
NF90 expression would have no effect upon transcription from the TNF promoter in 
nonstimulated cells.  
Direct association between NF90 and the TNF promoter could be inhibited as a result of 
APC5 and APC7 recruiting repressive complexes to the TNF promoter, thereby 
generating a closed chromatin conformation inaccessible to NF90, indeed the APC/C 
might be able to mediate transcriptional repression through APC8 and APC7, which 
contain a putative binding site for the transcriptional repressors C-terminal binding 
protein 1 (CtBP1) and RB respectively. Alternatively, binding of APC5 and APC7 to 
the TNF promoter might sterically inhibit binding of NF90 to the TNF promoter. A 
model for regulation of the TNF promoter by NF90 and the APC/C may mirror the 
dynamic binding of NF90 and APC/C subunits to the IL-2 promoter, whereby 
repression of the TNF promoter by APC5 in the absence of PMA and ionomycin 
stimulation, correlates with binding of APC5 to the TNF promoter. Upon stimulation 
with PMA and ionomycin, APC5 would be induced to dissociate from the TNF 
promoter allowing NF90 to bind and activate transcription (see Fig 5.15 for a model of 
IL-2 and TNF promoter regulation by endogenous NF90/NF45, APC5 and APC7). If 
this were the case, it would explain why knockdown of APC5 has no significant effect 
on TNF expression after PMA and ionomycin stimulation (Fig 5.14A) as even if APC5 
were expressed to its full extent it would no longer be bound to the TNF promoter.  
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Exogenous APC5 and APC7 cooperate with NF90/NF45 to transactivate the TNF and 
IL-2 promoters in vitro (Fig 5.9 and 5.11). The observation that exogenous APC5 and 
APC7 can‟t activate transcription of the IL-2 and TNF promoters in the absence of 
NF90/NF45 in vitro, suggests that exogenous APC5 and APC7 do not bind directly to 
these promoters and must be recruited by NF90/NF45. In contrast endogenous APC5 
and APC7 inhibit TNF transcription in vitro and in vivo (Fig 5.13A and 5.14A), while 
immunoprecipitation of the IL-2 promoter with APC5 and APC7 (Fig 5.10) indicates 
that these proteins bind directly to the IL-2 promoter and repress it in vivo. The 
differences observed between the roles of exogenous APC/C subunits and endogenous 
APC/C subunits may be attributed to the possibility that nonphysiological over-
expression of APC5 and APC7 after transfection with the corresponding expression 
constructs might titrate out or sequester proteins. This could result in the formation of 
sub-stoichiometric APC/C complexes and cause the aberrant recruitment of 
transcription factors to the TNF and IL-2 promoters. In addition over-expression of 
these subunits may deprive APC5 and APC7 of post-translational modifications that are 
required to induce their binding to the IL-2 and TNF promoters. High levels of APC5 or 
APC7 expression might titrate out factors that mediate post-translational modifications 
of the APC/C or could restrict their activity by altering the cell cycle distribution given 
the importance of the APC/C as a cell cycle regulator.  
Luciferase-reporter assays in this chapter reveal that the APC/C and NF90/NF45 
cooperate to regulate transcription (Figs 5.9, 5.11 and 5.12), it therefore seems likely 
that the interaction between the APC/C and NF90 may be important for regulation of a 
large panel of genes. For instance, NF90 displays a physiological association with the 
myc11 promoter (Shi, Qiu et al. 2007), while NF90 and its related protein NF110 
regulate the PCNA promoter in vitro (Reichman, Parrott et al. 2003). Also, a large panel 
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of cytokine genes, including IL-2 and TNF, are inhibited by CsA (Hess, Tutschka et al. 
1982; Pawelec and Wernet 1983; McCaffrey, Goldfeld et al. 1994), which has been 
demonstrated as a potent inhibitor of NF90/NF45 dependent transcription (Kao, Chen et 
al. 1994). Furthermore, given that PMA and ionomycin stimulation mimics ligation of 
the IL-2R and TNFR, the APC/C may also repress a number of other IL-2 and TNF 
responsive genes.  
IL-2 autocrine signalling induces S phase entry, while activation of the TNFR can also 
stimulate cellular proliferation (Robb, Greene et al. 1984; Stern and Smith 1986). It is 
therefore tempting to speculate that the APC/C could exert a novel method of 
controlling cell cycle progression by inhibiting transcription of TNF and IL-2, therefore 
preventing cellular proliferation in response to autocrine signalling. During G1 the 
APC/C maintains cyclin A instability (Geley, Kramer et al. 2001; Rape, Reddy et al. 
2006), therefore it is plausible that the APC/C may also prevent cyclin A accumulation 
by inhibiting IL-2 transcription, and as a result preventing an increase in levels of cyclin 
A, which is observed in response to IL-2R ligation (Li, Godfrey et al. 2005). If the 
APC/C does inhibit IL-2 transcription it would also provide a mechanism through 
which the APC/C could enforce G1 arrest in response to certain cellular stresses, as IL-
2R ligation also increases transcription of other proteins required for cellular 
proliferation such as c-myc, and cyclin D (Turner 1993; Moon and Nelson 2001). 
Interestingly, IL-2 expression is highly elevated during mitosis in carcinoma cells 
(Reichert, Nagashima et al. 2000), implying that IL-2 autocrine signalling may be 
important for the onset of mitosis in normal cells. In addition elevation of TNF 
expression is associated with up regulation of cyclin A and cyclin B, which are required 
for entry into mitosis (Gaiotti, Chung et al. 2000; McPherson, Kubik et al. 2003). 
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Therefore modulation of TNF or IL-2 expression by the APC/C may be one means by 
which the APC/C is able to regulate the onset of mitosis. 
In addition to their well characterised roles during transcription, NF90/NF45 are also 
known to be involved at many levels of mRNA processing such as splicing (Saunders, 
Perkins et al. 2001; Zhou, Licklider et al. 2002; Leung, Andersen et al. 2003), mRNA 
export, mRNA stabilisation (Shim, Lim et al. 2002; Shi, Zhao et al. 2005) and 
translation (Ting, Kao et al. 1998; Xu and Grabowski 1999), suggesting that the APC/C 
may also cooperate with NF90 to regulate these processes. Significantly, a role for 
APC7 in splicing is further supported by interaction between APC7 and the splicing 
factor TLS, which was identified by mass spectrometry in chapter 3 (Fig 3.12). A 
potential role for the APC/C in translation is strengthened by the observation that APC3 
colocalises with cytoplasmic NF90 (Fig 5.2), which might occur at ribosomes, while 
APC5 has also previously been demonstrated to associate with ribosomes (Koloteva-
Levine, Pinchasi et al. 2004). Indeed work in chapter three shows that APC7 binds the 
translation factor eEF1A (Fig 3.9). Lastly, the observation that the majority of nuclear 
APC3-NF90 complexes occur at the periphery of the nucleus (Fig 5.2), close to the 
nuclear membrane, coupled to the fact that NF90/NF45 are important for nuclear export 
of mRNA (Gwizdek, Ossareh-Nazari et al. 2003), suggests that NF90-APC/C 
complexes may function during mRNA export.  
The inability of anti-NF45 and anti-NF90 antibodies to immunoprecipitate APC/C 
ligase activity (Fig 5.7) suggests that NF45/NF90 may not interact with the entire 
APC/C holoenzyme, but with a sub-complex that is devoid of ligase activity. Although, 
interaction between APC3 and NF90 contradicts this (Fig 5.2), as APC3 is crucial for 
activation of the APC/C‟s ubiquitin ligase activity (Kraft, Herzog et al. 2003; 
Vodermaier, Gieffers et al. 2003). Other work has suggested that NF90 and NF45 are 
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involved in mitotic control as their knockdown results in the appearance of 
multinucleated cells that could possibly arise due to deregulation of the APC/C and 
APC/C ubquitin ligase activity (Guan, Altan-Bonnet et al. 2008). The failure of NF90 to 
immunoprecipitate APC/C ligase activity could be attributed to the possibility that only 
a small fraction of cellular NF90/NF45 may be combined with the APC/C and therefore 
only a small proportion of NF90/NF45 immunoprecipitate will be associated with 
APC/C ligase activity. Alternatively NF90/NF45 may actually inhibit APC/C ligase 
function. If so, the existence of a putative consensus CDK phosphorylation site ((S/T) P 
X (K/R) in NF90, coupled to previously observed M phase specific phosphorylation of 
NF90 (Matsumoto-Taniura, Pirollet et al. 1996), suggests that during G2/M, 
phosphorylation of NF90 by CDK1 could potentially activate APC/C ligase function, as 
a result of a conformational change in NF90. Alternatively phosphorylation of NF90 
could stimulate dissociation of a potentially inhibitory NF90 from the APC/C. 
Interestingly levels of nuclear NF110, which is virtually identical to NF90 in its first 
671 amino acids (Duchange, Pidoux et al. 2000) and therefore may also bind to the 
APC/C, have previously been demonstrated to increase during S phase until the G2/M 
transition (Xu, Leonova et al. 2003), therefore suggesting that NF110 and not NF90 
may be important for APC/C regulation during or prior to mitosis.  
NF90/NF45 are not targets for APC/C mediated ubiquitylation in vitro (Fig 5.8B), 
despite the presence of putative D-boxes. It is possible that other members of the 
ARRE-2 regulatory complex may be substrates for APC/C mediated ubiquitylation, 
indeed Ku80 contains 1 putative D-box, while Ku70 contains 4 putative D-boxes, three 
of which conform to the more extensive RXXLXXXXN/D/E consensus sequence 
(Geley, Kramer et al. 2001).  
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Given the ability of APC5 and APC7 to bind to the dsRBMs of NF90 (Fig 5.5B and C) 
and the conserved nature of dsRBMs in all proteins from this family (Fierro-Monti and 
Mathews 2000), it seems likely that APC5 and APC7 may also bind to other dsRBM-
containing proteins such as PKR (Green and Mathews 1992; Patel and Sen 1992) and 
RNA helicase A (RHA) (Zhang and Grosse 1997). Also, it seems that APC7 can 
interact with the dsRBMs of NF90 via a dsRNA intermediate (Fig 5.6B), indicating that 
APC7 might bind to RNA in vivo, which is consistent with a role for the APC/C in 
splicing, mRNA export and translational control as discussed above. Furthermore, it 
seems likely that the interaction between the dsRBMs of NF90 and APC7 may be a 
target for viral inhibition given that NF90 binds to adenovirus VA RNAII (Liao, 
Kobayashi et al. 1998). For example, binding of VA RNAII to NF90 could interfere 
with APC/C and NF90 dependent transcriptional regulation, and therefore possibly 
prevent activation of IFN inducible genes by NF90 (Krasnoselskaya-Riz, Spruill et al. 
2002; Reichman, Parrott et al. 2003). 
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6.1. Mass spectrometric analysis and future perspectives  
The initial aim of this study was to identify novel APC/C interacting proteins by mass 
spectrometric analysis of APC7 immunoprecipitates. Using this approach I identified a 
number of known APC/C subunits demonstrating the efficacy of this technique and also 
six novel APC7-interacting proteins. The second aim of this study was to validate any 
novel interactions, and study their functional consequences.  
I choose to examine the interaction between APC7 and NF45 due to NF45‟s well 
defined role in transcription (Corthesy and Kao 1994; Kao, Chen et al. 1994; Aoki, 
Zhao et al. 1998; Ting, Kao et al. 1998; Shi, Godfrey et al. 2007; Shi, Qiu et al. 2007). I 
also focused on the interaction between APC7 and TIF1γ as a result of TIF1γ’s 
chromosomal translocation in cancer (Klugbauer and Rabes 1999), indicating that 
TIF1γ functions during cellular proliferation and differentiation. In the future it will be 
important to validate the interactions between APC7 and the additional novel APC7 
interacting proteins identified in this study and go on to investigate their functional 
significance.  
Advances in mass spectrometer technology and sample preparation protocols have 
recently been utilised to analyse APC7 immunoprecipitates. This work yielded 20 
APC7 peptides and 9 NF90 peptides compared to 6 APC7 peptides and 0 NF90 peptides 
from work in chapter 3 (Dr A Turnell, unpublished observation). Given these significant 
improvements it is my intention to identify additional novel APC/C interacting proteins. 
Also, now that I am in possession of a high titre TIF1γ antibody, future work will focus 
on identifying novel TIF1γ interacting proteins, as reports of TIF1γ function are scarce. 
In particular it would interesting to identify putative substrates for TIF1γ mediated 
ubiquitylation, in order to complement findings by Dupont et al (2005), which suggest 
that TIF1γ is a ubiquitin ligase. In addition to this, it will be desirable to detect any 
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components of the ubiquitination machinery that TIF1γ interacts with such E2 ubiquitin 
transferases, DUBs or other ubiquitin ligases. 
 
6.2. A role for TIF1γ in mitotic progression 
At the beginning of this study understanding of TIF1γ was limited to a nonphysiological 
role in transcription and evidence of its chromosomal translocation in cancer 
(Klugbauer and Rabes 1999; Venturini, You et al. 1999), suggesting that TIF1γ 
regulates cellular proliferation and differentiation. In accordance with these findings the 
interaction between APC7 and TIF1γ that was identified in this study also further 
implicated TIF1γ in cell cycle control, as the APC/C has a well defined role in 
regulating proliferation (Peters 2002; Skaar and Pagano 2008). In light of this, one of 
the major aims of this study was to determine the function of the interaction between the 
APC/C and TIF1γ during cell cycle regulation.  
Initial data from chapter 4 demonstrate that TIF1γ knockdown stabilises the APC/C‟s 
mitotic substrates such as cyclin A, cyclin B, and CDC20, suggesting that TIF1γ 
cooperates with the APC/C to regulate APC/C substrate degradation during mitosis. 
Additional evidence from chapter 4 further implicates TIF1γ in mitotic control, as 
TIF1γ band shifts after SAC activation, which is indicative of TIF1γ phosphorylation a 
might be required to inhibit the ability of TIF1γ to promote APC/C substrate 
degradation. Furthermore, TIF1γ expression increases the mitotic index and alters the 
mitotic distribution, by blocking cells in a metaphase-like state. It will be particularly 
important to supplement this TIF1γ knockdown data by attempting to complement the 
observed mitotic defect by expressing exogenous TIF1γ that is refractory to siRNA 
knockdown.  
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Other evidence of a role for TIF1γ during mitosis is provided by an interaction between 
the APC/C‟s early mitotic activator CDC20 and TIF1γ in vivo, suggesting that TIF1γ is 
associated with, and may regulate, the APC/C during mitosis. TIF1γ also interacts with 
the APC/C‟s mitotic substrate cyclin A in vivo, although given that APC/CCDH1 also 
mediates cyclin A degradation during G1 it is entirely possible that TIF1γ interacts with 
the G1 form of cyclin A (Hsu, Reimann et al. 2002; Havens, Ho et al. 2006). However, 
work from our lab has failed to demonstrate an interaction between TIF1γ and the 
APC/C‟s G1 regulator CDH1 (Fang, Yu et al. 1998; Kramer, Gieffers et al. 1998; 
Zachariae, Schwab et al. 1998; Jaspersen, Charles et al. 1999), indicating that TIF1γ is 
most likely exclusively associated with mitotic APC/C
CDC20
 and therefore with cyclin A 
during mitosis. Therefore, the questions of when during the cell cycle TIF1γ interacts 
with cyclin A, and whether ablation of TIF1γ expression results in the unexpected 
presence of cyclin A post-prometaphase or during early G1 should be addressed. 
Despite the failure to demonstrate an interaction between TIF1γ and CDH1 in this study 
it is possible that TIF1γ may still regulate APC/CCDH1 during G1. Indeed if TIF1γ is 
important for APC/C
CDH1 ligase activity during G1 then TIF1γ knockdown could result 
in early accumulation of cyclin A and degradation of p27
KIP1
 promoting premature S 
phase entry that could potentially result in activation of an S phase checkpoint. This 
idea is given credence by evidence from chapter 4, which demonstrates that TIF1γ 
knockdown, like ablation of CDH1 results in an enrichment of cells in S phase (Bashir, 
Dorrello et al. 2004). This is notably consistent with a previous report that details 
inhibition of DNA synthesis following ablation of TIF1γ expression (Dupont, 
Zacchigna et al. 2005), suggesting an S phase block. 
Given that TIF1γ interacts with the APC/C‟s mitotic substrate cyclin A and regulates 
cyclin A degradation it seems likely that TIF1γ might directly target cyclin A for 
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degradation during mitosis, indeed, the mitotic phenotype observed after TIF1γ RNAi 
treatment resembles the mitotic delay observed in cells in which wt cyclin A has been 
over-expressed (den Elzen and Pines 2001), which is akin to APC/C inhibition. 
Therefore, ablation of TIF1γ expression may indirectly stabilise other APC/C substrates 
by slowing passage through mitosis. This is consistent with the observation that TIF1γ 
knockdown promotes the accumulation of cyclin B while evidence from chapter 4 
shows that TIF1γ is unable to interact with cyclin B in vivo.  
Interestingly TIF1γ knockdown impairs APC/C ligase activity in vitro, suggesting that 
TIF1γ is important for this function. In order to further elucidate the role of TIF1γ 
during APC/C substrate ubiquitylation it would be of great interest to examine whether 
the addition of recombinant TIF1γ to an APC/C ligase assay can enhance ubiquitylation 
of specific APC/C substrates. Alternatively, TIF1γ might actually be capable of 
ubiquitylating APC/C substrates in the absence of the APC/C. To complement this 
future work should also focus on determining if TIF1γ is capable of direct binding to 
APC/C substrates and if other TIF1γ antibodies or tagged TIF1γ can precipitate APC/C 
ligase activity, and whether TIF1γ precipitates have a preference for specific substrates.  
A large amount of the data in this study was obtained by the use of TIF1γ siRNAs, 
therefore it will be important to corroborate a role for TIF1γ in mitosis by other means. 
For instance, it will necessary to determine if TIF1γ localises to mitotic structures or 
undergoes posttranslational modification during mitosis. Indeed the TIF1γ band shift 
observed after treatment with nocodazole may indicate mitotic phosphorylation by 
either BUBRI in response to SAC activation or cyclin A-CDK complexes upon entry 
into mitosis.  
Many APC/C regulatory molecules such as cyclin B and CDC20 are actually directly 
targeted for degradation by the APC/C (Dawson, Roth et al. 1995; Sigrist, Jacobs et al. 
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1995; Sudakin, Ganoth et al. 1995; Prinz, Hwang et al. 1998; Shirayama, Zachariae et 
al. 1998). However work in this study suggests that the APC/C doesn‟t directly target 
TIF1γ for degradation, as I was unable to ubiquitylate TIF1γ with APC3 
immunoprecipitates in vitro while ablation of CDH1 expression causes a reduction in 
TIF1γ expression. Consequently it will be important to determine if APC/CCDH1 is 
capable of indirectly controlling TIF1γ stability by regulating the stability of a putative 
TIF1γ ubiquitin ligase, a particularly attractive candidate is SKP2, which is targeted for 
degradation by the APC/C
CDH1 
during G1 (Bashir, Dorrello et al. 2004; Wei, Ayad et al. 
2004). Alternatively the observed reduction in TIF1γ levels after CDH1 knockdown 
may be due to cell cycle effects, as loss of CDH1 expression has previously been shown 
to induce premature S phase (Bashir, Dorrello et al. 2004). It would also be interesting 
to determine whether TIF1γ is capable of postranslationally modifying the APC/C, 
which is suggested by the presence of a RING domain in the N-terminus of TIF1γ that 
is thought to confer TIF1γ with ubiquitin ligase activity and may be also be capable of 
mediating SUMOylation (Dupont, Zacchigna et al. 2005; Quimby, Yong-Gonzalez et 
al. 2006).  
Lastly it will be important to identify gene promoters that are regulated by TIF1γ, and 
whether the APC/C and TIF1γ cooperate during transcriptional control. Also given that 
TIF1γ and the APC/C regulate the activity of a number of transcription factors in 
response to TGF-β signalling it will be interesting to investigate possible cross talk 
between TIF1γ and the APC/C in this pathway (Wan, Liu et al. 2001; Dupont, 
Zacchigna et al. 2005; He, Dorn et al. 2006).  
 
190 
 
6.3. The APC/C regulates cytokine transcription  
A previous report from our lab demonstrates that the APC/C regulates transcription 
(Turnell, Stewart et al. 2005), which taken together with the interaction between APC7 
and NF90/NF45 from chapter 5, suggested that the APC/C may regulate IL-2 
transcription in conjunction NF90/NF45. I therefore undertook work to elucidate the 
function of the APC/C during IL-2 transcription 
Initial investigation concerning the function of the interaction between NF90/NF45 and 
the APC/C revealed that NF90/NF45 is not ubiquitylated by the APC/C or associated 
with active APC/C ubiquitin ligase activity. Subsequent luciferase reporter assays 
revealed that when over-expressed NF90/NF45 and APC/C components cooperate with 
one another to activate transcription from the IL-2 and the TNF promoters. In contrast it 
appears that endogenous APC/C proteins actually function to repress transcription of 
promoters that are regulated by NF90/NF45, as APC/C subunits repress a synthetic TNF 
promoter in vitro and TNF mRNA production in vivo. In addition APC/C subunits also 
associate with the IL-2 promoter in the absence of PMA and ionomycin stimulation, 
which suggests that APC/C subunits constitutively repress the IL-2 promoter. Protein 
over-expression could result in aberrant protein function through incorrect protein 
localisation, nonphysiological protein interactions or by titrating out interacting 
proteins. Therefore, my tendency is to lean towards the observation that the endogenous 
APC/C appears to repress cytokine transcription. Together with binding data this 
suggests the existence of complex consisting of the APC/C and NF90/NF45, which 
regulates cytokine transcription through direct dynamic binding of its constituents to the 
promoter (see Fig 5.15 for a model of TNF and IL-2 promoter regulation by endogenous 
NF90/NF45, APC5 and APC7). It may be possible to alter the function of exogenously 
introduced APC/C subunits by carefully titrating the proteins levels down. Also it 
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should be determined what effect over-expression and knockdown of APC/C subunits 
has on the cell cycle distribution and therefore the promoter activity of cytokine genes. 
A number of studies indicate that TNF and IL-2 regulate the cell cycle both by autocrine 
and paracrine signalling. For instance, IL-2 stimulates progression through G1 and is 
elevated during mitosis in cancer cells while TNF promotes accumulation of mitotic 
cyclins (Gaiotti, Chung et al. 2000; Reichert, Nagashima et al. 2000; Moon and Nelson 
2001; McPherson, Kubik et al. 2003). Given that the APC/C is thought to control the 
cell cycle by potentiating transcription of p21
CIP1
 and CDC6 it is tempting to speculate 
that the APC/C can also regulate proliferation by modulating TNF and IL-2 
transcription (Turnell, Stewart et al. 2005). Therefore it would be interesting to 
determine if APC/C knockdown can enhance proliferation through up regulation of IL-2 
and TNF signalling. To complement this work it may be possible to demonstrate the cell 
cycle dependent association and repression of the IL-2 and TNF promoters by the 
APC/C. It is also possible that association of the APC/C with cytokine promoters may 
be altered during stress responses. For instance, expression of TNF is elevated 
following exposure to IR (Rube, Wilfert et al. 2002), therefore it is possible that the 
APC/C may be induced to dissociate from the TNF promoter following IR treatment 
enhancing TNF transcription. Alternatively, the APC/C might be recruited to IL-2 and 
TNF promoters following cytostatic stresses such as nutrient starvation in order to 
inhibit cellular proliferation. 
A recent report suggests that NF90/NF45 may regulate the cell cycle, as their 
knockdown inhibits DNA synthesis, and results in aberrant mitosis (Guan, Altan-
Bonnet et al. 2008); mitotic phosphorylation of NF90 also suggests a role for NF90 in 
mitotic control (Matsumoto-Taniura, Pirollet et al. 1996). These findings indicate that 
NF90/NF45 may cooperate with the APC/C to regulate DNA synthesis or mitosis by 
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regulating APC/C ligase activity. It will be important to address this notion in the 
future. 
An isolated report details the presence of APC5 at ribosomes (Koloteva-Levine, 
Pinchasi et al. 2004), suggesting that the APC/C is important during translation. This 
notion is further supported by the ability of NF90 to regulate translation and the fact that 
work in chapter 5 shows colocalisation between NF90 and APC3 in the cytoplasm(Ting, 
Kao et al. 1998; Xu and Grabowski 1999; Vumbaca, Phoenix et al. 2008), suggesting 
that they cooperate in translational control. In addition it appears that the APC/C may be 
involved in regulating NF90‟s role during mRNA processing such as splicing and 
nuclear export(Shim, Lim et al. 2002; Zhou, Licklider et al. 2002; Leung, Andersen et 
al. 2003). This is suggested by work in chapter 5, which indicates that APC3 and NF90 
may function together in mRNA nuclear export, due to the fact that they colocalise at 
the periphery of the nucleus. Interaction between the splicing factor TLS and APC7 as 
identified by mass spectrometry in chapter 3 also supports the notion that the APC/C 
functions in concert with NF90/NF45 to control splicing. In light of these factors, future 
work should focus on elucidating the role that APC/C-NF90/NF45 complexes play 
during mRNA processing. 
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